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HIV-1 rapid escape from immune surveillance can be detrimental to the host. However, if 
these escape mutations are located in functionally important regions of the viral genome, 
they can attenuate viral replication and provide some benefit to the host. Understanding the 
dynamics of viral evolution in early infection and events associated with control of 
infection will inform vaccine design. This study investigated the frequency and timing of 
cytotoxic T-lympthocyte (CTL) escape and its pathogenic consequences on HIV-1 subtype 
C disease progression.  
Samples were obtained from 58 individuals recruited within three months of HIV-1 
infection into the CAPRISA 002 acute infection cohort. Full-length gag (n=365) and nef
(n=289) sequences were generated from enrolment 0 (median 1.4 months [IQR=1-2]), 3, 6, 
12 and 24 months post infection. Additional sequences (n=120) were generated to 
investigate the fixation of escape mutations. Putative escape was defined as non-
synonymous changes within or flanking known epitopes restricted by the participants HLA.
Timing of escape was defined as either acute (< 3 months), early (>3 to ≤6 months) or late
(>6 to 12 month). For the newly identified mutation, replication of wild-type and mutant
viruses in PBMCs was compared.
All individuals were infected with subtype C viruses: 51 had single infections and seven
individuals were dually infected with two phylogenetically distinct strains. Of these seven,
four were co-infected at or close to transmission, and three were superinfected. CTL escape
was detected in individuals with single infection and identified in 69% (35/51) of
individuals. It was more frequently observed in the acute than early/late infection phases 
(3.8 versus 1.1 escape/month/100 amino acid; p=0.0231). Participants with viruses
escaping CTL responses in Gag and/or Nef had significantly higher CD4+T-cell counts at 3
and 6 months post-infection (PI) compared to those whose virus never escaped (p=0.0018
and 0.0542, respectively). Furthermore, although the decline in CD4+ counts was similar
after 3 months, the initial preservation of the CD4+ cells in early infection resulted in an 











viruses escaped in acute infection, compared to those that never escaped over this time 
period (p=0.0274). Moreover, HLA-B alleles selected a significantly higher number of viral 
escape mutations (72.4%, 42/58) compared to HLA-A alleles (17.2%, 10/58) (p=0.0134).  
In the second part of this work, the timing and impact of mutations in the TL9 epitope on
disease progression in five B*81:01- and two B*39:10-positive subtype C infected
individuals was investigated. While cytotoxic T-lymphocyte (CTL) mediated escape
mutations in this epitope have been associated with an in vitro fitness cost to the virus, the
impact on disease progression in vivo had never been investigated. Whereas both B*39:10
participants sampled at two months post-infection had viruses with mutations in the TL9
epitope, in three of the five (3/5) B*81:01 participants, TL9 escape mutations were only
detected 10 months after infection, taking an additional 10 to 15 months to reach fixation.
In the two remaining B*81:01 individuals, one carried a TL9 escape variant at 2 weeks
post-infection, whereas no escape mutations were detected in the virus from the other
participant up to 33 months post-infection, despite CTL targeting of the epitope. In all
participants, escape mutations in TL9 were linked to co-evolving residues in the region of
Gag known to be associated with host tropism. Late escape in TL9, together with co-
evolution of putative compensatory mutations, coincided with spontaneous increase in viral
loads in two individuals who were otherwise controlling infection. 
Finally, in an attempt to resolve the conflict in the field over the impact of transmitted CTL
escape mutations on disease progression, viral loads and CD4+ counts were compared in
participants infected with viruses carrying polymorphisms associated with beneficial HLA-
B*57/58:01 and B7 supertype (B*39:10/81:01) allelic selective pressure in HLA 
mismatched participants. In HLA-B*57/58:01-negative participants, 51% (25/49) were
infected with viruses carrying at least one of the B*57/58:01 attenuating escape mutations
in ISW9 (A146P:19/49), KF11 (A163G: 10/49) or TW10 (T242N/S: 11/49) epitope. In
HLA-B7 negative participants, only 9.4% (3/32) had viruses carrying mutations in the 
HLA-B7 immunodominant TL9 epitope. A novel mutation in Gag p17, Q65H, was 
identified which, in PBMCs assays, reduced replication by 22% compared to wild-type.











B7 and A*30 negative participants. Unlike a previous study in this cohort, which analysed 
a subset of 21 individuals, infection with viruses carrying mutations in HLA-B*57/58:01 
restricted epitopes alone did not impact on viral load setpoint in HLA-mismatched 
participants, although CD4 counts at 3 months post infection were higher in participants 
infected with viruses carrying greater than any 2 of these mutations (p=0.031). However, 
HLA-mismatched participants infected with viruses carrying 3 or more of any of the 
B*57/58:01 or B*39:10/81:01 attenuating escape mutations had significantly lower viral 
load and higher CD4 counts at 3 months (p=0.017 and p=0.041) and at 12 months (p=0.008 
and 0.091) post-infection, respectively.  
Overall, this study demonstrates a high frequency of CTL escape in early infection 
compared to later, and that immune responses selecting escape mutations in acute infection
provide benefit within the first year of infection. Furthermore, this study suggests that 
multiple mutations generated when viruses are passaged through individuals with beneficial 
HLAs are needed to attenuate the virus. However, B*81:01 mediated viral evolution in 
chronic infection, in a single Gag p24 epitope, had a detrimental impact on the control of
viraemia. Despite this, the overall benefit of escape in acute infection on survival in the first 
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1.0. Background  
Human immunodeficiency viruses (HIV) belong to the lentivirus genus of the family
Retroviridae (van Regenmortel et al., 2000). As the causative agent of the global AIDS
epidemic, the impact of HIV type 1 (HIV-1) on humanity has been immense. At least 25
million people have died of HIV-1-related causes since the beginning of the epidemic, while it 
is estimated that approximately 34 million people were living with the virus by the end of 
2010 (UNAIDS World AIDS Day Report, 2011). South Africa is the country with the largest 
number of people infected with HIV globally (UNAIDS World AIDS Day Report, 2011). In
2010, approximately 5.6 million people in South Africa were living with HIV, while 390 000 
individuals were newly infected in 2010 alone (UNAIDS World AIDS Day Report, 2011)
Increased access to antiretroviral therapy is having a significant impact on HIV mortality rate;
however, the only way to effectively control the HIV-1 epidemic is with an effective vaccine.
In 2009, the first HIV vaccine trial to show efficacy was the RV144 trial in Thailand. This 
trial, which tested a canary pox vector expressing the gp120/gag/protease genes, followed by
a gp120 protein boost, was shown to result in a 31.2% reduction in incidence of HIV infection 
(Rerks-Ngarm et al., 2009). Two correlates of risk were identified: vaccinated volunteers with 
high levels of plasma IgG binding antibodies to V1/V2 had a 41% reduction in infection, with
those with medium to high levels of these antibodies having a 75% reduction in HIV infection 
rate. However high level of plasma IgA antibody responses had the opposite effect with
individuals with these responses having a 54% increased HIV infection rate. The infection
rate in the placebo was the same as the IgA responder group suggesting that these IgA
antibodies interfered with protection rather than enhancing HIV infection (Haynes et al., 
2012).
While the RV144 trial provided some insights, the protection was modest and the precise 
responses needed to effectively block infection remain unclear. Furthermore, as HIV-infected 
people are unable to eradicate the virus, it is impossible to use natural immunity to help 
elucidate these correlates of protection. However, it is still generally accepted that an effective 











(CTL) responses (Koup et al., 2011; Richman et al., 2009; Richman et al., 2003). Major
challenges in the vaccine development are, firstly, the design of immunogens that would elicit
broadly cross-neutralizing antibodies that would be effective against the diversity of viral
envelope glycoproteins; and secondly, the quality and breadth of cellular immune responses 
that correlate with protection are unknown (Burton et al., 2004; Haynes et al., 2012; McElrath
and Haynes, 2010; Moore, 1997; Moore et al., 200; Taylor et al., 2008; van Regenmortel,
2011). This thesis will focus on understanding cellular immune responses associated with 
control of viral replication. Characterisation of how the virus adapts provides a sensitive tool
to elucidating immune pressure and is one approach to identifying responses associated with
control of infection that may be important for a vaccine to elicit. In this project, in a well-
characterised subtype C cohort recruited from very early in infection, we perform a detailed 
characterisation of viral sequences to better understand early CTL pressure exerted on the
virus, and to identify relevant epitopes for inclusion into vaccine immunogens. 
This study focused on the Gag and Nef proteins of the virus as these are consistently shown to 
be the most immunodominant proteins (Gray et al., 2009a; Kiepiela et al., 2007) and as Gag is
recognised earlier than any other protein (Payne et al., 2010; Sacha et al., 2007). Furthermore,
targeting of Gag has been associated with better disease outcome (Kiepiela et al., 2007; Miura
et al., 2009; Rolland et al., 2008), although a study of Gray et al. (2009) found that Gag
responses (as measured with IFN-γ ELISpot assay) in acute infection (<3 months post-
infection) did not predict the subsequent course of HIV-1 subtype C infection.  
This chapter will overview the genetic diversity of the global pandemic, the structure and 
function of Gag and Nef proteins, the natural history of disease, and finally the role of CTL 













1.1 Genetic Diversity  
 
Extensive and dynamic genetic diversity is a hallmark of HIV due to the error prone nature of 
the reverse transcriptase enzyme (Ho et al., 1995; Keulen et al., 1997; Op de Coul et al., 
2001; Roberts et al., 1988), the genomic recombination capacity (Temin, 1993) and the high 
viral turnover (Ho et al., 1995). A number of factors drive this diversity including the 
prolonged host immune selective pressure on the virus (Lemey et al., 2007; Michael, 1999). 
This high genetic diversity impacts on diagnostic efforts, as well as on vaccine and drug 
development (Buonaguro et al., 2007; Lal et al., 2005; Peeters et al., 2003). It also challenges 
our understanding of viral transmission and pathogenesis.    
 
HIV has been classified into two types, HIV-1 and HIV-2 but this review will focus on HIV-1 
only.  HIV-1 strains identified throughout the world have been classified into four major 
phylogenetic groups, which are M (Major), O (Outlier), N (non-M, non-O) (Peeters and 
Sharp, 2000; Simon et al., 1998) and a newly identified HIV-1 group P consisting of an O-
like variant that is more closely related to SIV-gorilla than to group O (Plantier et al., 2009; 
Vallari et al., 2011). Group M viruses are responsible for the global pandemic and have been 
further subdivided into 9 distinct phylogenetic subtypes, namely A, B, C, D, F, G, H, J and K. 
Subtypes A and F have been classified into sub-subtypes (A1–A2, F1–F2), and there are over 
48 circulating recombinant forms (CRFs) (www.hiv.lanl.gov) identified. Recombinant forms 
are generated when a person is infected with two or more subtypes, which recombine such 
that the viral genomes comprise of segments originating from different subtypes and are 













Figure 1.1 An overview map of global distribution of HIV-1 subtypes and recombinants
(from Woodman and Williamson, 2009). The colours illustrate the dominant subtypes or
recombinant forms circulating in these regions. 
Within the group M, the average inter-subtype genetic variability for the gag gene is 15%,
whereas it is 25-30% for the env gene (Janssens et al., 1994; Kuiken et al., 2000). While at the
moment all the known HIV-1 subtypes are present in sub-Saharan Africa, their distribution in 
the region vary remarkably: subtype A and its recombinants predominating in west Africa;
subtype A and D in East African countries; and subtype C in the southern and south eastern 
region of Africa, as well as Ethiopia (Hemelaar et al., 2011). Subtype A is also distributed 
across Eastern Europe and Central Asia. Subtype B is found in America, Western Europe and
East Asia, while Subtype D is most prevalent in North Africa and the Middle East. Subtype G 












In southern Africa, Ethiopia and India, the epidemics are nearly exclusively caused by 
subtype C (Abebe et al., 1997; Hemelaar et al., 2011; Hussein et al., 2000). Further, the BC 
CRFs_07 and _08 have become dominant in China. According to a report of Hemelaar et al.
(2011), subtype C represents the largest number of HIV-1 infections worldwide accounting 
for nearly a half (48%) of the global infections.  
1.2. Organisation of the HIV Genome 
The integrated form of HIV-1 or the provirus is about 9.8kb in length (Muesing et al., 1985)
(Figure 1.2). A repeated sequence known as the long terminal repeats (LTRs) flank the central
region of the proviral DNA that carries the genes encoding nine proteins (Gallo et al., 1988).
The HIV proteins can be divided into three classes, which are the major structural proteins,
Gag, Pol, and Env; the regulatory proteins Tat and Rev; and the accessory proteins, Vpu, Vpr,
Vif, and Nef. This thesis focuses on HIV-1 escape of cytotoxic lymphocytes (CTL) in Gag 
and Nef, and since escape has been shown to affect HIV-1 replication capacity (Boutwell et 
al., 2009; Martinez-Picado et al., 2006; Peyerl et al., 2004; Rolland et al., 2008; Wright et al., 
2010; Wright et al., 2011), it has been important to have an understanding of the functional 
domains of these two proteins. 
1.2.1 Structural protein – Gag
The viral Gag protein serves as the major structural component of the HIV-1 virion (Hunter,
1994). The gag gene is initially translated as a Gag polyprotein precursor (Pr55gag), a gene
product of 55-kilodaltons (kD) (Goff, 2007a). This polyprotein is cleaved post-translationally
into matrix (MA or p17), capsid (CA or p24), nucleocapsid (NC) (Morellet et al., 1992) and 
p6 - and two spacer peptides, SP1 (p2) and SP2 (p1) that separate the CA from NC and p6 
respectively (Freed, 1998; Gelderblom, 1991; Gottlinger et al., 1989; Kaplan et al., 1994). In 
the 55 kDa Gag precursor, these proteins are arranged in the order of MA-CA-SP1/p2-NC-















Figure 1.2 Organisation of the HIV genome with the gag open reading frame enlarged (from 
Freed, 1998) and the matrix (MA), capsid (CA), p2, nucleocapsid (NC), p1 and p6 proteins 
shown.   
 
1.2.2 The Matrix protein (p17 or MA) and its role in the viral life cycle 
 
The MA protein consists of about 132-amino acid residues and is post-translationally 
myristoylated at the N-terminus (Bryant and Ratner, 1990; Gottlinger et al., 1989). The two 
major roles of this protein are in viral assembly and stabilization of the lipid envelope.   
 
The role of MA in viral assembly is largely due to its membrane binding properties. Targeting 
to the plasma membrane depends upon the myristoylation of the MA domain of the Gag 
precursor at the N terminus (Pal et al., 1990). The membrane-binding (membranotropic) 
signal is found in the first six amino acids of the protein (Figure 1.3) (Bryant and Ratner, 
1990; Freed et al., 1994; Spearman et al., 1994). This portion regulates intracellular 
localization that targets Pr55gag to the plasma membrane where viral assembly and budding 
take place (Dong et al., 2005; Jouvenet et al., 2006; Lindwasser and Resh, 2004). This 
membrane-binding signal works together with a highly basic patch (residues 6–8) and the 
polybasic region (residues 26 and 32) (KKKYKLK) to promote tight Gag membrane binding 
(Ono et al., 2000; Ono and Freed, 1999; Paillart and Gottlinger, 1999).   
 
The central region of the MA (residues 41 to 78) has been shown to be essential for viral 
assembly, with single-amino-acid changes that prevent dimerization and viral like particle 













alpha helix 4 (residues 54 to 68), which forms part of a finger-like projection from one side of 
the molecule. Furthermore, the MA protein is essential for envelop incorporation into virions 
through association with the gp41 cytoplasmic tail (Bhattacharya et al., 2006; Dorfman et al., 
1994; Murakami and Freed, 2000). Although the mechanism involved in envelope 
incorporation during viral assembly is not clearly defined, the following multiple mutations in 
the two groups, (R18G, K20I, R22A) and (K32I, H33L) in the N-terminal globular head 
region, and L49D were shown to affect Env incorporation (Bhatia et al., 2007; Casella et al., 
1997; Davis et al., 2006; Hill et al., 1996). Furthermore, a study recently demonstrated that 
the MA E99V mutant viruses can also affect Env-incorporation and substitution in MA 
residue 84 were identified to restore (compensate for) defects due to E99V, suggesting a key 
role in HIV-1 Env incorporation of the C-terminal hydrophobic pocket of MA (Brandano and 
Stevenson, 2012).    
 
Unlike other retroviruses, HIV is able to infect non-dividing cells due to the karyophilic signal 
properties of the MA, which the cellular nuclear import machinery recognizes (Bukrinsky et 
al., 1993; Lewis et al., 1992). The MA nuclear localization signal (NLS) has been mapped to 
the exposed basic patch (residues 24–31) on the globular head (Bukrinsky et al., 1993; Zhou 
et al., 1994). There are two NLS, encompassing residues 24–31 (KKKYKLK) and 110–114, 
(KSKKK), both of which consist of basic amino acids that introduce positive charge 
properties, crucial for the nuclear targeting (Bukrinsky et al., 1993; Haffar et al., 2000; von 
Schwedler et al., 1994). The MA interacts with different nuclear transport receptors (cellular 
importins) and together with Vpr, integrase and NC, it regulates and contributes to nuclear 
import of the preintegration complex (PIC) (Bukrinsky, 2004; Butterfield-Gerson et al., 
2006). Furthermore, mutations in its nuclear localization signal affect postchromatin-binding 
events and impair viral infectivity without significantly changing the nuclear transport of PIC, 
suggesting that MA is involved in viral DNA integration into the host cell chromosome 













Figure 1.3: Schematic presentation of the MA and known functional sites (from Fiorentini et 
al., 2010). The N-terminal myristoylation site (N-Myr), nuclear export signal (NES), and
nuclear localization sequences (NLS) and Env uptake region are also shown. Interfaces 
thought to be involved in trimerisation of p17 are shown. 
On the other hand however, to ensure that components required for virion assembly are
available in the cytoplasm, a nuclear export signal (NES) is present which targets the Gag–
RNA complex to the cytosol and is required to counteract the NLS (Dupont et al., 1999).
Mutations in MA, K18, K20 and R22 that block its NES result in the abnormal accumulation 
of Gag and viral genomic RNA in the nucleus (Dupont et al., 1999). 
1.2.3 The Capsid protein (p24) 
The HIV-1 capsid (CA) forms a shell or a distinctive conical core surrounding the viral RNA
genome and core-associated proteins in the mature virion (Briggs et al., 2004; Carlson et al., 
2008; Tang et al., 2001). During viral assembly and budding, the CA incorporates the Gag-
Pol precursor into capsid of virions (Chien et al., 2006; Smith et al., 1993), which is an 
important event for the recruitment of reverse transcriptase, integrase and protease into viral 
particles. The N-terminal region of the CA functions in virion maturation and incorporation of

















Figure 1.4 Schematic representation of the Capsid protein (CA), showing the position of 
cyclophilin A binding loop (Yoo et al., 1997) and the major homology region (Chang et al., 
2007) (re-drawn from Adamson and Freed, 2007). The N-terminal domain (NTD) and C-
terminal domain (CTD) are illustrated. Numbers are Gag amino acid residues, HXB2 
positions.  
 
The CA protein consists of two interdependently folded domains, an N-terminal domain 
(NTD) or the ‘‘core’’ domain (Gag residues 133-278) that mediates hexamer formation and a 
C-terminal domain (CTD) (Gag residues 279-363) or the ‘‘dimerization’’ domain (Briggs et 
al., 2003; Gamble et al., 1997; Gitti et al., 1996; Li et al., 2000). Studies by NMR 
spectroscopy (Gitti et al., 1996) and X-ray crystallography (Gamble et al., 1996; Momany et 
al., 1996; Mortuza et al., 2004) show that the core domain is highly helical and consists of 
seven α-helices, a short two stranded β-hairpin, and an exposed loop that serves as the binding 
site for CypA (Figure 7). The β-hairpin (Gag residues 133-145) conformation is thought to be 
stabilized by a salt bridge between the N-terminal CA amine of P133 and D183 in helix 3 
(Fitzon et al., 2000; Gitti et al., 1996; Kelly et al., 2006; Tang et al., 2002; von Schwedler et 
al., 1998). NMR studies of Gitti et al. (1996) suggested that residues P133–N137 in the N-
terminal of the mature CA pair with residues Q141–Q145 to form the antiparallel strands of a 
β-hairpin that packs against helix 6 (Figure 1.5). Furthermore, although differences exist, in 
both the mature and immature CA, residues H144–I147 interact with the globular portion of 
the N-terminal CA domain, T180 (helix 3), I243, I247 and M250 in Helix 6 (Tang et al., 
2002). Additional interactions between the β-hairpin and the rest of N-terminal domain of the 
CA include hydrogen bond between the backbone N-H of I134 and the carbonyl of G178. 
These bonds are further supported by the hydrophobic packing between the side chains of the 















Figure 1.5:  Structural model for the HIV-1 CA protein based upon crystal structures of the 
protein’s NTD and CTD (von Schwedler et al., 2003). Residues forming the seven a-helices 
are S148–K162, S165–S176, T180–V191, H194–H216, R232–A237, T242–T251 and V258–
S278 respectively, and are packed together in a flat and triangular shape, while residues 
P217–P231, which include the CypA-binding site, form a conformationally flexible loop 
(Tang et al., 2002). Residues forming the CTD α-helices (8 – 11) are P292-L304, S310-V323, 
N327-L334, and A341-A349. Numbers are Gag amino acid residues, HXB2 positions.  
 
1.2.3.1 The Capsid and cyclophilin A (CypA) binding 
 
The earliest studies on murine leukemia virus (MLV) demonstrated that a host antiretroviral 
factor, Fvl, restricted the incoming (post-entry) viral capsid and prevented infection of mouse 
cells in a CA-dependent manner or dependent on mouse background (Best et al., 1996; 
Friend, 1957; Hilditch et al., 2011; Schindler et al., 1981). Replication of HIV in humans, but 
not in non-human primates, suggested that similar factors could be involved in restricting 
lentiviral infections in a CA-dependent manner (Besnier et al., 2002; Cowan et al., 2002; 
Hatziioannou et al., 2005; Hofmann et al., 1999; Munk et al., 2002; Towers et al., 2003). 
Studies subsequently elucidated the lentiviral restriction factor in non-human primates as 
TRIM5 (a member of tripartite motif family of proteins) related genes (Nisole et al., 2004; 













HIV infectivity in the Old World monkey (OWM) cells by interacting with a host restriction 
factor, TRIM5α (Berthoux et al., 2005; Keckesova et al., 2006; Stremlau et al., 2006a).   
 
CypA is a cytosolic protein that catalyzes the cis–trans isomerization of proline residues 
(Fischer et al., 1989). Virions incorporate CypA via interactions with a proline-rich stretch in 
the NTD of the capsid (Braaten et al., 1997). Although the proline rich loop in the viral capsid 
domain directly binds to the hydrophobic binding pocket of CypA (Braaten et al., 1997; 
Endrich et al., 1999), residues that are critical for CypA binding in the NTD of the CA are 
Gag - G221 and P222 (Braaten et al., 1996; Gamble et al., 1997). In humans, CypA is 
required for maximum viral infectivity and virions deficient in CypA show defects early in 
postinfection events (Braaten et al., 1996; Luban, 2007; Steinkasserer et al., 1995). The 
observation that CA point mutants close to the CypA binding site such as CA A224E or 
G226D appear to lead to restriction of HIV-1 in human cells further supports the idea that 
CypA is required for viral infectivity (Sokolskaja et al., 2004). Cyclophilin has been 
implicated in promoting the uncoating stage of the CA (Briones et al., 2010; Saphire et al., 
2002). A more recent study has demonstrated that HIV-1 capsid-cyclophilin interactions is 
required for the nuclear import pathway, integration targeting and in replication maximization 
(Schaller et al., 2011). 
 
Human TRIM5α_h is substantially less potent than TRIM5α_rh from the old world monkeys 
although it has been shown to have some in vitro anti-HIV activity (Kaumanns et al., 2006; 
Stremlau et al., 2004; Yap et al., 2004). It has been shown that TRIM5α_h inactivates 
cyclophilin binding to the incoming retroviral capsid and accelerates viral uncoating, which 
inhibits reverse transcription and transportation of the viral genome to the nucleus (Sebastian 
and Luban, 2005; Stremlau et al., 2004; Stremlau et al., 2006a; Ulm et al., 2007). Several 
studies have also shown that the interaction between host cyclophilin and HIV-1 CA within 
the host cell modulates the binding of host restriction factors like TRIM5α (Berthoux et al., 
2005; Hatziioannou et al., 2005; Sokolskaja et al., 2004). However, preventing the interaction 
of HIV-1 incoming cores with CypA reduces viral infectivity independently of TRIM5 













shown that TRIM5α_h does not recognise HIV-1; but HIV-1 becomes restricted by something 
else in the absence of CypA activity (Keckesova et al., 2006; Sokolskaja et al., 2004).  
 
CypA also interacts with both p6 and Vpr but the biological significance of this interaction in 
the HIV life cycle is still not completely understood, although it is thought that CypA 
modulates host activities to favour viral replication (Solbak et al., 2010)  
 
1.2.4. The Major homology region  
 
The HIV-1 major homology region (MHR) – (CA 153–172) or (Gag 285 – 304) is located 
near the end of the N-terminus of the capsid or C domain and consists of a stretch of 20 
residues (Figure 1.6), that are highly conserved across retroviral genera (Gamble et al., 1997). 
The most highly conserved residues Q287, G288, E291, and R299 were shown to form a 
network of hydrogen-bonds that stabilize a conformation required for the Gag–Gag 
interactions for Gag particle assembly (Campos-Olivas et al., 2000; Gamble et al., 1997). 
Furthermore, other conserved hydrophobic residues, 293F, 296Y, 297V, 301Y, and 304L lie 
on one face of helix 1 (Clish et al., 1996), where they contribute to the hydrophobic core of 
the protein (Gamble et al., 1997). Mutations in Q287 and E291 block HIV replication 
(Mammano et al., 1994). Mutations in residues K290 and Y296 respectively blocked virus 
assembly or production of virus-like particle (VLP) in vitro (Mammano et al., 1994; von 
Schwedler et al., 2003), while substitutions at K290, F300 or E307 significantly diminished 




Figure 1.6: Schematic representations of HIV-1 Capsid with MHR, HIV-1 subtype C, 2004 
consensus sequence within the CA (20 residues) (Drawn based on Gamble et al. 1997). The 













conserved hydrophobic residues (293F, 296Y, 297V, 301Y, and 304L) are shown in blue. 
Numbers are Gag - HXB2 amino acid positions.  
 
1.2.5. The Nucleocapsid  
 
The 7kDa HIV Nucleocapsid (NC) is a highly basic protein that is characterized by the 
presence of two zinc-finger motifs, Cys-X2-Cys-X4-His-X4-Cys (CCHC, X = variable HIV-1 
amino acid), which are critical to its functions (Bess et al., 1992; South and Summers, 1993; 
Summers et al., 1990). NC is found tightly associated with the viral RNA in the mature virion 
(Meric et al., 1984). Mutations that disrupt the NC zinc fingers affect genomic RNA 
encapsidation and virus infectivity (Gorelick et al., 1988; Gorelick et al., 1990). These two 
major mutations in the NC are H23C and H44C (Figure 1.7).  
 
The NC binds, encapsulates and protects viral RNA. However, it is also thought to be 
involved in RNA dimerization, Gag interactions, membrane binding, reverse transcription and 
preintergration complex stability (Freed, 1998). Furthermore, the NC employs its nucleic acid 
chaperone activity to anneal the aminoacyl tRNA Synthetase (tRNALys, 3) primer to the viral 
genome during reverse transcription (Kleiman et al., 2004; Rein et al., 1998). 
 
 
Figure 1.7: Primary sequence of HIV-1 NC - NL4-3 isolate – showing (in grey) the Cysteine 
and Histidine residues that chelate zinc (Levin et al., 2005) 
 
1.2.6 The viral late domain (HIV-1) – p6  
 
In HIV-1, a highly conserved motif, Pro-[Thr/Ser]-Ala-Pro (PSAP)/(PTAP) and a  conserved 
leucine motif LYPXnL (n = 1-3 variable residues) located near the N and C terminus of p6, 
respectively were identified to be critical in releasing virus particles after budding from the 













motif in viral budding is to interact with cellular endosomal sorting complexes required for 
transport (Carlson et al., 2008), a machinery that catalyze the scission of membrane necks 
(Wollert et al., 2009) in the biogenesis of multivesicular bodies (MVBs) (Hurley, 2008) and a 
key step in virus release (von Schwedler et al., 2003). The ESCRT machinery consists of four 
protein complexes, ESCRT-0,-I,-II and III (Hurley, 2008; Saksena et al., 2007) that are 
involved in the recognition and sorting of membrane proteins to the internal vesicles of 
MVBs/late endosomes that are subsequently degraded in lysosomes (Bieniasz, 2009; Goff, 
2007b; Malim and Emerman, 2008). Budding involves a sequential recruitment of these 
multiprotein ESCRT to endosomal membranes, which leads to release of endosomal vesicles 
into multivesicular bodies (MVBs) and incorporation of ubiquitinylated membrane protein 
cargoes into the inwardly budding vesicles (Bieniasz, 2009; Goff, 2007b; Raiborg and 
Stenmark, 2009). The process is initiated by HRS, a component protein of ESCRT-0 that links 
the ubiquitinylated membrane protein cargoes with the ESCRT-I components Tsg101 (tumor 
susceptibility gene) (Raiborg and Stenmark, 2009). In HIV budding, the p6 PTAP motif 
mimics the PSAP motif in HRS and thus binds with the Tsg101 component while the second 
p6 late domain motif LYPXnL binds with ALIX, a component protein in ESCRT- III (Garrus 
et al., 2001; Pornillos et al., 2003; Strack et al., 2003). A cellular restriction factor BST-
2/tetherin has been shown to hamper HIV-1 release by physically tethering fully formed 
mature particles to the plasma membrane of infected cells (Mangeat et al., 2009; Neil et al., 
2008; Perez-Caballero et al., 2009). A study has recently shown that the ESCRT-0 component 
HRS interacts with HIV accessory protein Vpu to downregulate the cellular host restriction 
factor BST-2/tetherin (Janvier et al., 2011). 
 
1.2.7 Structural and Biochemical Characteristics of Nef 
 
HIV-1 Nef is a myristoylated accessory protein, about 27 kDa and 206 to 210 amino acid 
residues in length (Allan et al., 1985; Niederman et al., 1993). The N-terminal contains a 
hydrophobic myristoylation motif (MGxxxS), which promote its association with cellular 
membranes. Structural studies have revealed that Nef has three major elements: a flexible N-
terminal region (residues 1-80), consisting of acidic region (residues 62- 65) and a type II 













and an exposed, flexible loop (residues 148-180) centred around a dileucine motif (residues 
160-165) bounded by negatively charged di-glutamic acid (residues 154-155) and di-aspartic 
acid (residues 174-175) regions (Arold et al., 1997; Lee et al., 1996). 
  
1.2.8 Major roles of HIV-1 Nef in disease progression   
 
The nef gene is unique to primate lentiviruses and absent in the other retroviruses (Piguet and 
Trono, 1999). The protein Nef was originally thought to be a negative factor that inhibited 
viral replication (Cheng-Mayer et al., 1989; Luciw et al., 1987). However, later studies 
demonstrated the importance of Nef for efficient viral replication and pathogenesis in vivo. In 
rhesus macaques, nef-deleted SIVmac239 displays attenuated viral replication and 
pathogenicity (Kestler et al., 1991; Khan et al., 1998). Virus isolates from several long-term 
non-progressors of HIV-1 infection were found to possess mutations and deletions in nef 
(Deacon et al., 1995; Kestler et al., 1991; Kirchhoff et al., 1995). Nef is incorporated into 
virions and associates with the viral core (Bukovsky et al., 1997; Forshey and Aiken, 2003; 
Kotov et al., 1999; Simmons et al., 2001) and enhances infectivity (Qi and Aiken, 2008). Nef 
is required for maintenance of high viral loads but although macaques infected with nef-
deleted SIV have attenuated infection, these viruses do finally induce AIDS symptoms 
(Desrosiers, 1999; Sawai et al., 2000; Sugimoto et al., 2003). Studies have demonstrated in 
vitro that Nef is a multi-functional protein and is involved in three major activities:  
 
a) Downregulation of cell surface molecules such as CD4 
b) Downregulation of major histocompatibility complex class I (MHC-1)  
c) Modulation of T cell activation state 
 
1.2.8.1 CD4 Downregulation 
 
Nef downregulates CD4 expression by firstly, redirecting CD4 molecules from the trans-
Golgi network (TGN) to the endosomal compartment, where they are targeted to the lysosome 
for degradation; and secondly, by accelerating the internalization of CD4 molecules that have 













1999). The binding of the CD4 cytosolic tail requires a di-leucine motif (residues 413-414) 
and a surface pocket in Nef (residues 57-58) that contains a tryptophan-leucine (WL) motif 
(Aiken et al., 1994; Bonifacino and Traub, 2003; Mangasarian and Trono, 1997). Binding 
between Nef and CD4 appears to be driven, in part, by myristoylation of the Nef protein, 
which targets and concentrates Nef to membranes, the primary site of its action (Bentham et 
al., 2003; Bentham et al., 2006; Harris and Neil, 1994), where it is brought in closer proximity 
to CD4. The presence of basic residues near the N-terminus of Nef supports this subcellular 
localization, as it may serve to anchor the protein among acidic phospholipids common to 
cellular membranes (Dennis et al., 2005).  
 
HIV-1 Nef interacts with the adaptor protein complex (AP) of clathrin coated pits (CCP/AP) 
via a dileucine-based motif (LL165) in the C-terminal region f the viral protein (Bresnahan 
et al., 1998; Craig et al., 1998; Piguet et al., 1998). Adaptor protein complexes are a family of 
heterotetramers that recognize cytoplasmic sorting motifs in transmembrane proteins for 
packaging into clathrin-coated vesicles for intracellular transport (Ohno, 2006; Traub, 2009). 
Nef mutants defective for AP binding are not able to accelerate CD4 internalization, which 
demonstrates that adaptor complexes are a major downstream partner of Nef for CD4 
endocytosis (Piguet et al., 1999). It also interacts with a subunit of the V-ATPase that could 
facilitate its association with the endocytic apparatus (Geyer et al., 2002; Lu et al., 1998).  
 
Another downstream cellular partner of Nef in the down regulation of CD4 is Coatomer (or 
COP I). COP I is a large cytosolic protein complex which forms a coat around vesicles 
budding from the Golgi apparatus (Cosson et al., 1996; Orci et al., 1986). The COP I 
coatomer is involved in the ER-Golgi transport, and Nef accomplishes the down regulation of 
CD4 by connecting the receptor via its acidic dipeptide (Nef, 154-EE-155) to the β-COP 
subunit of COP I coatomer and prevents the cell surface recycling of CD4 that is instead 
targeted to a degradation pathway in endosomes (Oldridge and Marsh, 1998; Piguet et al., 

















1.2.8.2 MHC class I downregulation 
 
Nef downregulates MHC-1 through a pathway different from that of CD4 
(Blagoveshchenskaya et al., 2002; Mangasarian et al., 1999), although the mechanisms 
involved in MHC-I down-regulation are still controversial. Nef attenuates MHC-I cell surface 
expression by accelerating endocytosis of class I molecules from the plasma membrane to the 
trans-Golgi network (TGN). MHC class I is internalized via a clathrin-independent 
mechanism and is sequestered in the trans-Golgi network (TGN), and eventually degraded 
(Greenberg et al., 1998; Le Gall et al., 2000). MHC-I downregulation induced by Nef 
depends on a sorting protein, PACS-1 (phosphofurin acidic cluster sorting protein-1) 
(Blagoveshchenskaya et al., 2002; Hung et al., 2007; Piguet et al., 2000). In this model, 
initiation of MHC-1 downregulation occurs when PACS-1 or AP-1 binds to the Nef 62-
EEEE-65 acidic cluster, which sorts Nef to the Trans Golgi Network (TGN) (Crump et al., 
2001; Piguet et al., 2000). PACS-1 protein is a binding partner for furin, an enzyme that 
cycles between the TGN and endosomes (Wan et al., 1998). Through its highly conserved 
proline motif (72PxxP75 [X= any amino acid]), Nef recruits the TGN-localized Src family 
tyrosine kinase (SFK) which activates a phosphatidyl inositol 3-kinase (Hung et al., 2007) 
that promotes the assembly of a Nef-SFK-ZAP-70/Syk-PI3Kcomplex (Hung et al., 2007). 
This complex is translocated by PACS-1 from early endosomes to the plasma membrane 
where PI3K generates PIP3-containing lipids (Atkins et al., 2008; Peterlin and Trono, 2003; 
Piguet et al., 2000). PIP3-containing lipids recruits the ARNO guanine nucleotide exchange 
factor (GEF) to the plasma membrane which activates ARF6 that finally leads to accelerated 
MHC-I endocytosis through an AP-2/clathrin independent mechanism (Mangasarian et al., 
1999; Padron et al., 2003). However, Larsen et al. (2004) found no effect on the down-
modulation of MHC class I due to mutations that provide more specific perturbations in the 
GDP-GTP cycling of ARF6 (Larsen et al., 2004). Furthermore, another study found that 
inhibiting PACS-1 had no effect on the down-regulation of HLA-A2 and the localization of 














Other models have suggested that Nef connects the MHC-I cytoplasmic tail through the di-
leucine (164-LL-165) motif to subunits of the clathrin adaptor protein complex 1 (AP-1 
complex) (Roeth et al., 2004; Williams et al., 2002). However, mutation of this motif does not 
impair MHC-I down-regulation, which suggests that AP-1 recruitment is a cooperative 
process, involving determinants present in both Nef and MHC-I cytoplasmic tail (Noviello et 
al., 2008; Roeth et al., 2004). The structural formation of the Nef–MHC-I–AP1 complex has 
been recently confirmed by a study of Jia et al. (2012) and supports the idea that AP-1 
recruitment is a cooperative process, involving determinants present in both Nef and MHC-I 
cytoplasmic domain. In this model, HIV-Nef down-regulation of MHC-1 requires the first α-
helix (aa 17 – 26) containing M-20, an acidic cluster (62-EEEE-65), a proline-rich (PxxP)3 
repeat at the junction of the N-terminal loop and the folded core, and residue Asp123 (Atkins 
et al., 2008; Blagoveshchenskaya et al., 2002; Greenberg et al., 1998; Hung et al., 2007; 
Mangasarian  et al., 1999; Noviello et al., 2008; Roeth et al., 2004). Nef interacts with the 
MHC-1 cytoplasmic domain through the µ1 subunit of AP-1 that encompasses the cargo-
recognition site of µ1 and the proline-rich strand of Nef (Jia et al., 2012).  
 
1.2.8.3 Modulation of T cell activation state 
 
Quiescent T cells do not support optimal reverse transcription, integration, and expression of 
the HIV-1 genome due to low levels of nucleotides, ATP, and nuclear transcription activators 
(Coiras et al., 2009; Stevenson, 2003). Several studies suggest that Nef binding to T cell 
receptor (TCR) induces an up-regulation of FAS ligand, resulting in death of cytotoxic T cells 
that come in contact with virus-infected cells (Piguet and Trono, 2001; Xu et al., 1997). 
Moreover, Nef promotes the production of chemokines like the macrophage inflammatory 
proteins (MIP) 1α and 1β, and other mediators of T cell activation, which induce the 
chemotaxis and activation of nearby resting T lymphocytes, facilitating rapid infection (Dai 















Figure 1.8 HIV-1 and SIV Nef-sequence alignment and protein-protein interaction domains 
(from Roeth and Collins, 2006). Boxes indicate protein motifs and their putative cellular 
binding partners (in parentheses). Residues important for protein interactions are underlined. 
The asterisks indicate residues in SIVmac239 Nef that are homologous to important residues in 
HIVNL4-3 Nef that are yet to be tested for functional homology. 
  
1.3 HIV-1 Life Cycle 
 
The HIV virion is enclosed in a roughly spherical outer lipid bilayer membrane 120–200 nm 
in diameter (Briggs et al., 2003), which is studded with trimeric clusters of the transmembrane 
Envelope (Env) gp41 and the surface Env glycoprotein gp120. The core consists of two 
single-stranded genomic RNA in complex with the nucleocapsid (NC) protein, viral protein R 
(Vpr) and the viral enzymes, reverse transcriptase (RT) and integrase (IN) enclosed in a 
capsid shell protein (Adamson and Freed, 2007; Ganser-Pornillos et al., 2008).  
 
During infection, HIV-1 surface envelope (Env) glycoprotein gp120 binds to the cellular 
receptor CD4 and subsequently interacts with a chemokine coreceptor, usually CCR5 or 













changes in both gp120 and the transmembrane envelope gp41, which causes fusion and the 
liberation of the viral core into the cytoplasm of the target cell (Doms, 2000; Melikyan, 2008).  
 
During the uncoating of the viral core, CA is lost, while at least some MA, as well as NC, the 
pol-encoded enzymes and the viral protein R (Vpr) are thought to be retained as part of a 
high-molecular weight complex (Freed, 1998). The RNA genome is reverse transcribed into a 
double-stranded DNA copy that is transported as the high-molecular-weight complex, now 
known as the preintegration complex, into the nucleus where the enzyme IN facilitates the 
stable integration into the host cell genome (Delelis et al., 2008; Harrich and Hooker, 2002; 
Suzuki and Craigie, 2007; Vandegraaff and Engelman, 2007). The integrated viral DNA, 
known as the provirus, serves as the template for the generation of full-length progeny viral 
RNA and a number of spliced mRNA transcripts that are translated in the cytoplasm to yield 
several major structural proteins: the Gag polyprotein precursor, the Gag-Pol polyprotein 
precursor and the Env glycoprotein precursor, gp160 (Freed, 2001). The env gene product, the 
precursor protein, (gp160) is glycosylated within the endoplasmic reticulum. These protein 
components, together with full-length viral genomic RNA, are each transported to the site of 
virus particle assembly at the plasma membrane (Adamson and Freed, 2007).  
 
During or shortly after reaching the plasma membrane, the Gag precursor directs the assembly 
by recruiting two copies of the single-stranded viral genomic RNA and interacting with the 
Gag-pol precursor into structures (Briggs et al., 2003; Derdowski et al., 2004; Sandefur et al., 
2000). This assembly of Gag protein complex causes membrane curvature, which eventually 
buds off as immature virions (Gould et al., 2003; Ono and Freed, 2001). During budding, the 
viral Env glycoproteins are incorporated into the nascent particles. Other associates in these 
structures are viral enzymes [(reverse transcriptase (RT), integrase (IN), and protease (PR)], 
which are incorporated within the nascent virion as part of the precursor gag-pol polyprotein 
(Smith et al., 1993), the cellular tRNAlys3 primer and cellular compounds (De Guzman et al., 
1998; Greene and Peterlin, 2002; Kleiman and Cen, 2004; Zimmerman et al., 2002). 
 
The genomic viral RNA and Vpr are encapsidated through noncovalent interactions with Pr55 













et al., 1995; Lavallee et al., 1994; Sakaguchi et al., 1993). In the process of, or shortly after 
budding, the viral protease (PR) is activated to cleave the Gag and Gag-pol polyprotein 
precursors to the mature Gag and Pol proteins (Briggs et al., 2003). The enzymatic cleavage 
leads to core condensation and the generation of mature, infectious virions which are now 
capable of initiating a new round of infection.  
 
Figure 1.9 Schematic representation of the HIV-1 replication cycle (Ganser-Pornillos et al., 
2008).  
 
1.4 Natural History of HIV Infection 
 
Immediately following HIV-1 exposure and transmission, there is a period of about 7 to 21 
days, known as the eclipse phase, when viral RNA is not detectable in the plasma (Fiebig et 
al., 2003; Kleinman et al., 2009; Zhu et al., 2003). When HIV-1 RNA reaches a concentration 
of 1 to 5 copies per millilitre in plasma, the virus can be detected with quantitative nucleic 
acid amplification (Palmer et al., 2003) and there is generally a uniform and orderly timing of 
the appearance of viral and host markers of infection (Fiebig et al., 2003). The chronologic 
order of appearance in serum of these markers is viral RNA, p24 antigen, and anti-HIV 













length and definition of acute infection varies in individuals but for the purpose of this thesis 
will be defined as the 3-month (100 days) period following HIV infection during which time 
individuals will have undergone complete seroconversion (Kassutto and Rosenberg, 2004; 
Lyles et al., 2000; McMichael et al., 2010). Events in this phase are thought to play an 
important role in subsequent disease progression and clinical outcome (Kelley et al., 2007; 
Piatak et al., 1993). Studies in non-human primates have shown that following transmission, 
the virus crosses the mucosal barrier within hours (Hu et al., 2000) and expands locally at the 
foci of infection. Within a few days to a week after infection, the virus is disseminated 
throughout the body and lymphoid tissue, seeding even the central nervous system (Daar, 
1998; Haase, 2010; Miller et al., 2005). In the lymphocyte-rich compartments throughout the 
body, particularly the spleen and the gut-associated lymphoid tissue (GALT), the virus 
encounters high densities of primary target CD4+ T cells causing a massive burst of viral 
replication. These events result in irreversible and severe depletion of memory CD4+ T cells 
in all tissues, predominantly from the mucosal surfaces (Brenchley et al., 2004; Guadalupe et 
al., 2003; Mattapallil et al., 2005; Veazey et al., 1998). Additionally, viral latency or the silent 
integration of HIV-1 DNA into the genomes of resting CD4 T cells is established (Chun et al., 
1998). The virus load rises rapidly to peak levels in 21–28 days after infection and coincides 
with the release of inflammatory cytokines, the major ones being interferon-α and interleukin-
15 (Stacey et al., 2009). A crucial period in acute infection occurs between transmission and 
peak viremia, just before the occurrence of massive destruction of CD4+ T cell and the 
establishment of viral reservoirs. This has been referred to as the window of opportunity for 
an HIV-1 vaccine where it could potentially control viral replication and prevent extensive 
CD4+ T cell depletion and limit generalized immune activation (McMichael et al., 2010).  
 
Following infection, the peak viremia declines to a much lower steady state known as the viral 
set point (Fiebig et al., 2003; Kaufmann et al., 1998; Lindback et al., 2000; Lyles et al., 2000; 
Mellors et al., 1996). Viral set-point is one prognostic marker of disease progression with 
measurements around 12 months shown to be the most reliable predictor (Lyles et al., 2000).   
 
Around peak viremia, some patients may experience symptoms (Lindback et al., 2000). 













progression (Kelley et al., 2007; Piatak et al., 1993; Vanhems et al., 2000). In subtype B 
infection, the peak HIV-1 viral load has ranged from 105 - 108 RNA copies/ml, lasting for 
about 2 to 3 weeks and finally dropping to set-point in 4-6 month post infection (Daar et al., 
1991; Fiebig et al., 2003; Kaufmann et al., 1998; Little et al., 1999; Lyles et al., 2000). 
Similar observations on the dynamics of primary infection in non–subtype B epidemics in 
African studies including subtype A in Kenya, and C in southern Africa, have been reported. 
Subtype differences in peak viral RNA level in the early stage in HIV-1 infection has been 
reported in Senegal in which CRF02_AG is associated with lower peak viremia  than in HIV-
1 subtype A and G infections (Sarr et al., 2005).    
 
High viral loads have been associated with risk of transmission suggesting that people with 
acute infection are more likely to transmit the virus (Dyer et al., 1998; Granich et al., 2009; 
Hollingsworth et al., 2008; Tovanabutra et al., 2002; Wawer et al., 1999). This also suggests 
that reducing viral loads in acute infection, by either vaccination or treatment would reduce 
the rate of new infections.  
 
HIV-1 primary infection is followed by a chronic phase during which viral load remains 
relatively stable at patient-specific levels with very slow increase until the onset of AIDS 
(Douek, 2003; Sabin et al., 2000). However, although the individual may be asymptomatic, 
the chronic phase is accompanied by persistent viral replication in lymph nodes and rapid 
turnover of plasma virions, together with a steady decline of the main target-cell population, 














Figure 1.10 A typical natural course of HIV infection (An and Winkler, 2010). 
 
The virus load in chronic infection reflects the equilibrium achieved between high rates of 
virus production and clearance; perhaps due to CTL and neutralising antibody responses (Ho 
et al., 1995; Hogan and Hammer, 2001). This period has been described as clinically latent; 
however, the continuous decline in the number of CD4+ T lymphocytes results in the 
individual’s immune system being unable to control opportunistic pathogens culminating in 
life-threatening AIDS-defining diseases (Pantaleo et al., 1993; Sierra et al., 2005). CD4+ T-
cell count is the strongest predictor of clinical progression. Since 2005 in South Africa, 
initiation of anti-retroviral therapy was recommended for individuals with CD4 counts < 200 
cells/ul or AIDS defining illness, however, the recommendations changed in 2008 and 
currently treatment may be initiated when individuals reach CD4 counts ≤ 350 cells/μL 
(www.sahivsoc.org).   
 
1.5 Host factors influencing infection and disease progression 
 
An early population study defined a small percentage of not more than 5% of individuals with 













signs of disease progression for several years following infection as long-term nonprogressors' 
(LTNPs) (Sheppard et al., 1993). LTNPs were, however, further divided in terms of viremia 
into HIV controllers (HIC) (viral load ≤2000 copies/ml) or elite suppressors/controllers 
(ES/EC) (viral load <50 copies/ml) (Deeks and Walker, 2007; Lambotte et al., 2005). The rate 
of HIV-1 disease progression has been shown to depend on a number of host factors. 
Genome-wide association studies (GWAS) have shown that the major determinant of HIV-1 
viral control lies in the major histocompatibility complex (MHC) (Fellay et al., 2007; Pereyra 
et al., 2010) that encode for the human leukocyte antigen (HLA class I). HLA is also a ligand 
for the killer cell immunoglobulin-like receptors (KIR), a polymorphic set of molecules that 
modulate natural killer (NK) cell activity. Polymorphisms in KIR3DS1 (KIR-three domains, 
short cytoplasmic tail) is associated with HIV disease progression (Carrington et al., 2008). 
However, among many other host genetic factors that have been shown to affect disease 
progression are polymorphisms in the HIV-1 co-receptors CCR5 and CCR2 (Dean et al., 
1996), the cytokines IL10 (Naicker et al., 2012; Shin et al., 2000) and IFN gamma (An et al., 
2003), host HIV-restriction factors like APOBEC3G  (apolipoprotein B mRNA-editing 
enzyme-cytidine deaminase enzymes) (An et al., 2004; Reddy et al., 2010) and TRIM5 
(Singh et al., 2011; Stremlau et al., 2004). In the CAPRISA acute infection cohort, which is 
the focus of this study, the following host genetic factors have been shown to affect 
susceptibility to infection: APOBEC3G (Reddy et al., 2010), IL-10 polymorphisms (Naicker 
et al., 2012) and Trim22 (Singh et al., 2011).   
 
1.5.1 The major histocompatibility complex (MHC) 
 
MHC class 1 molecules are membrane-associated proteins that specifically bind and present 
processed pathogen-derived peptides on the cell surface and, in humans, are termed human 
leukocyte antigen or HLA (Hewitt, 2003). MHC class II molecules present foreign exogenous 
peptides to CD4+ T-lymphocytes, while MHC class I molecules present foreign endogenous 
peptides to CD8+ T lymphocytes (Unanue and Cerottini, 1989). A study of Fellay et al. 
(2007) using genome-wide approach identified the most significant polymorphism associated 
with differential set point viral load that were located in the HLA-complex P5 (HCP5) gene 













numbers, rs2395029 and rs9264942, respectively. The SNP database numbers rs2395029 is 
known to be in high linkage disequilibrium (LD) with the HLA-B*57 (Fellay et al., 2007; 
Pereyra et al., 2010), an allele with the strongest impact on HIV-1 disease progression 
(Altfeld et al., 2003; Migueles et al., 2000). In addition, significant associations of differential 
HIV-1 disease progression have been detected with polymorphisms in or close to the the zinc 
ribbon domain–containing 1 (ZNRD1) gene in the HLA locus, which encodes an RNA 
polymerase I subunit (Ballana et al., 2010; Fellay et al., 2007; Limou et al., 2009).  
 
Furthermore, studies with HIV-1 LTNPs in European and North American cohorts show 
increased frequencies of certain specific HLA class I (HLA-A1, HLA-A2, HLA-B13, HLA-
B14, HLA-B17, HLA-B27, HLA-51) and HLA class II (HLA-DR5, HLA-DR6) alleles 
(Carrington and O'Brien, 2003; Magierowska et al., 1999; McMichael, 2007). In southern 
African cohorts, HLAs associated with lower viral loads in chronic infection include B*81:01, 
B*58:01/57 and B*39:10 (Kiepiela et al., 2004; Leslie et al., 2010). Furthermore, HLA-B 
alleles appear to have a greater impact on markers of disease progression compared to HLA-A 
and HLA-Cw alleles (Kiepiela et al., 2004). However, combinations of HLAs have been 
found to have an additive effect, for example Cw*0401-B*8101, HLA-Cw*1203-B*3910, 
and HLA-A*7401-B*5703 haplotypes (Leslie et al., 2010).  
 
In contrast, the presence of HLA-B35, HLA-DR3, and HLA-DQ1 was shown to be more 
frequent in individuals with rapid disease progression (Carrington and O'Brien, 2003; 
MacDonald et al., 2000; Magierowska et al., 1999), while HLA-B*5802 and B*18 were 
found to be associated with high viral loads and lower CD4 counts in southern African 
cohorts (Kiepiela et al., 2004; Leslie et al., 2010). Homozygosity at HLA-A and B has also 
been shown to be disadvantageous for HIV-1 infected individuals probably due to a narrower 
array of HIV-1 derived peptides and as a consequence, a less diverse HIV-1 specific CTL 
repertoire (Carrington et al., 1999; Martin and Carrington, 2005).  
 
Nevertheless, HLA does not always predict disease progression (Emu et al., 2008) and 













influences disease progression, remains a central question in HIV research and optimal 
vaccine immunogen design (McMichael and McCutchan, 2010).  
 
1.6. Kinetics and impact of immune responses on disease progression  
 
HIV-1 induces vigorous humoral and cellular immune responses. The first CD8+ T cell 
(CTL) responses arise around the time when viremia is at its’ highest point and these 
responses peak one to two weeks later, as viremia declines (Borrow et al., 1994; Goonetilleke 
et al., 2009; Koup et al., 1994; Wilson et al., 2000), while neutralizing antibody responses 
occur only long after viremia has been controlled (Goonetilleke et al., 2009; Gray et al., 2011; 
Tomaras et al., 2008). The clinical course of HIV-1 disease is likely to be influenced by the 
nature of the earliest immune response to the virus and the sooner the virus-infected cells can 
be eliminated - before the virus spreads widely and integrates to generate long-lasting and 
non-eradicable reservoirs of latent virus - the faster can the HIV-1 infection be controlled 
(McMichael and McCutchan, 2010). 
 
 
Figure 1.11 An alignment of the earliest innate and adaptive immune responses detected 
















1.6.1 HIV-1 antibody responses 
  
Numerous studies have found no correlation of early Env binding antibody responses with 
disease progression (Cecilia et al., 1999; Frost et al., 2005; Loomis-Price et al., 1998; 
Tomaras et al., 2008). Furthermore neutralizing antibodies are not associated with control of 
HIV replication in chronic infection and do not mediate HIV-1 suppression in elite controllers 
(Bailey et al., 2006; Tomaras et al., 2008). Early neutralizing antibodies develop against the 
autologous “infecting” virus and generally are not able to neutralize the contemporaneous 
virus due to rapid escape (Gray et al., 2011; Gray et al., 2007; Rong et al., 2007; Wei et al., 
2003). Broadly neutralizing antibodies, which develop in only approximately 25% of 
individuals, occur after a number of years of infection and are able to neutralize a diversity of 
viruses (Gray et al., 2009b; Richman et al., 2003; Stamatatos et al., 2009; Wei et al., 2003). 
However, they do not impact on viral replication – possibly because they occur too late in 
infection to influence the course of disease (Cohen et al., 2011; Gray et al., 2011).  
 
 
1.6.2 CD4 T-cell responses 
 
The CD4+ T cell response is needed in orchestrating antibody production and primary 
expansion of CD8+ T cells and their differentiation into cytotoxic effectors (Janssen et al., 
2005; Keene and Forman, 1982). HIV-specific CD4+ T cell responses have been shown to 
expand in acute HIV-1 infection, although there is rapid decline of the responses (Gloster et 
al., 2004; Oxenius et al., 2001). However, as HIV-1 preferentially target HIV-specific CD4+ 
T cells, this results in the disruption of central process required for the successful coordination 
of the antiviral immune response (Dalgleish et al., 1984; Douek et al., 2002; Hel et al., 2006). 
HIV infected individuals have impaired T helper-cell function which has been linked to the 
loss of central memory CD4+ T cells in HIV-I infection (Li et al., 2005; Mattapallil et al., 
2005; Okoye et al., 2012; Younes et al., 2003).    
 
In addition to their helper function, CD4+ T cells can also directly recognize and kill virally 













recent study has shown that in vivo, HIV-specific granzyme A+ (GrzA+) CD4 T cells at 
baseline is significantly enriched in individuals who subsequently control viremia (Soghoian 
et al., 2012), suggesting that cytolytic ''killer'' CD4 T cells are involved in early control of 
HIV-1 infection.  
 
1.6.3 CD8+ T-cell responses  
 
Studies of single-genome amplification and sequencing of the first detectable virus, have 
shown that infection is initiated by a single virus in about 80% of heterosexual transmission of 
HIV-1 clade B and C infections, 60% in men who have sex with men and 40% in injection-
drug users (Abrahams et al., 2009; Keele et al., 2008; Keele et al., 2009; Li et al., 2010; 
Salazar-Gonzalez et al., 2009). The difference in the severity of the genetic bottleneck is 
consistent with the presence or absence of a mucosal barrier to transmission (Cohen et al., 
2011; Haaland et al., 2009).  Following transmission viral diversification is in part due to 
immune selection pressure in the host (Bernardin et al., 2005; Henn et al., 2012; McMichael 
et al., 2010; Salazar-Gonzalez et al., 2009). Studies have shown that most amino acid changes 
in the early virus were a consequence of rapid and sequential selection by mutations by CTL 
responses that recognize epitopes expressed by the founder virus (Goonetilleke et al., 2009). 
Of the few mutations that were not associated with CTL selection, some were reversions 
towards the consensus sequence. Reversions following transmission occur if mutations that 
may have been advantageous to the virus in the previous host return to consensus amino acids. 
Other early changes in viral sequence might have been selected by antibody dependent cell-
mediated virus inhibition or by NK cells (Goonetilleke et al., 2009).  
 
Emergence of CTL responses coincide with clearance of virus during primary HIV-1 in 
humans and simian immunodeficiency virus infection in rhesus monkeys (Borrow et al., 
1997; Goonetilleke et al., 2009; Henn et al., 2012; Koup et al., 1994; Kuroda et al., 1999). 
Interestingly, a recent study in five participants demonstrated that potent CTL antiviral 
responses against heterologous founder viruses occurring during acute infection (Fiebig stages 
1/2 to 5) decline concurrently with the resolution of viremia (Freel et al., 2012). Moreover, 













prevents the reduction in the early viral load (Jin et al., 1999; Matano et al., 1998; Schmitz et 
al., 1999). Furthermore, the role of early CD8+ T cell responses in controlling HIV-1 
replication is strongly supported by the association between particular HLA class I alleles and 
improved course of HIV-1 infection (Carrington and O'Brien, 2003; Pereyra et al., 2010).  
 
However, the quality and breadth of CTL responses needed to controls the HIV-1 replication 
have not been fully elucidated. Some studies have found no correlation between breadth or 
magnitude of either total HIV-1 or protein-specific CD8+-T-cell responses and plasma viral 
load (Addo et al., 2003; Cao et al., 2003; Gea-Banacloche et al., 2000; Peretz et al., 2005), 
while others have found correlations with specific proteins (Jia et al., 2012; Kiepiela et al., 
2007; Masemola et al., 2004). CTL responses in the first 3 months post infection commonly 
target HIV-1 proteins Nef and Gag (Gray et al., 2009a; Lichterfeld et al., 2004) and there 
have been several studies showing that responses targeting Gag, in particular p24, associate 
negatively with plasma viral load (Edwards et al., 2002; Jia et al., 2012; Kiepiela et al., 2007; 
Luo et al., 2012; Masemola et al., 2004; Novitsky et al., 2002; Rolland et al., 2008; Rousseau 
et al., 2008; Saez-Cirion et al., 2009; Zuniga et al., 2006). In contrast, total HIV-1 Env- or 
Nef-specific CD8+ T-cell responses have been found to associate positively with plasma viral 
load (Jia et al., 2012; Masemola et al., 2004; Novitsky et al., 2002). However, some studies 
found no correlation between viral load and Gag-specific CD8+/CD4+ T-cell responses (Betts 
et al., 2001; Peretz et al., 2005), while other studies found no correlation between plasma viral 
load and total HIV-1 Env- or Nef-specific CD8+ /CD4+ T-cell responses (Dalod et al., 1999; 
Edwards et al., 2002; Peretz et al., 2005).  
 
Nonetheless, the majority of these studies were cross-sectional and were done in either 
subtype B setting or chronic HIV-1 infections. There are a few studies examining the timing 
and impact of CTL targeting in acute infection in subtype C infected African populations 
(Gray et al., 2009a; Masemola et al., 2004; Radebe et al., 2011), which would differ in HLA 
background to subtype B infected Caucasian populations (Goulder et al., 2000). Although 
events in acute infection are thought to influence subsequent disease progression, a study 
employing longitudinal samples of the CAPRISA acute infection cohort, found that 













IFN-gamma EliSpot assay did not predict set-point viral load at 12 months post-infection 
(Gray et al., 2009a). This study on the CAPRISA 002 cohort found that Gag and Nef 
responses were the most immunodominant with Nef responses significantly more dominant 
than any other protein. However this study did find, similar to other studies, that 
contemporaneous CD8+ T-cell responses at 12 months post infection, to Env- and Gag 
proteins were positively and negatively correlated with plasma viral load, respectively, while 
there were no correlation with Nef- and Pol-specific CD8+ T-cell responses with viremia 
(Mlotshwa et al., 2010).    
 
The discrepancies observed in studies correlating CTL responses and disease markers may be 
attributed, at least in part, to the differences in methodologies, disease stages and diverse 
population groups studied. However, most studies suggest that individuals progressing slowly 
to infection have strong virus-specific CTL and robust CD4+ T-cell proliferative responses to 
Gag, with Gag and Nef being most immunodominant in primary infection, irrespective of 
other factors (Berger et al., 2011; Kiepiela et al., 2007; Kim et al., 2010; Klein et al., 1995; 
Rolland et al., 2008).  
 
1.7 CTL responses associated with control of viral replication 
 
The association between some HLAs with slow disease progression is likely due to their 
capacity to present epitopes in Gag p24 (Berger et al., 2011; Borghans et al., 2007; Matthews 
et al., 2008; Wang et al., 2009). Beneficial HLAs like B*57/58:01 and B*27 present epitopes 
in the conserved Gag p24, while non-protective HLAs like B*58:02/B*35:02/B*18 present 
no/few p24 epitopes in acute/early infection (Borghans et al., 2007; Brockman et al., 2010; 
Dahirel et al., 2011; Matthews et al., 2008; Wang et al., 2009). Furthermore, increased 
breadth of Gag specific responses has been shown in several distinct population studies to 
associate negatively with viral load (Edwards et al., 2002; Jia et al., 2012; Kiepiela et al., 
2007; Zuniga et al., 2006).  
 
Studies have also shown that CTL recognition of HIV-infected cells early in the viral life 













Sacha et al., 2007). In vitro studies have demonstrated that Gag epitopes can be processed and 
presented directly from the incoming virion in as little as 2h following infection, unlike other 
viral proteins that need about 12 h for expression and recognition (Payne et al., 2010; Sacha et 
al., 2007). It is thought that this early processing of Gag epitopes enables the CTL targeting 
Gag to recognise and kill infected cells before new virions are released and Nef 
downregulation of MHC I (Collins et al., 1998; Payne et al., 2010; Sacha et al., 2007).   
 
Furthermore, some studies have shown that T cells with high functional avidity may recognize 
virally infected cells at lower surface antigen densities than those with low-avidity (Belyakov 
et al., 2007; Bennett et al., 2007; Betts et al., 2004; Mothe et al., 2012). Unlike non- 
functionally avid responses, functionally avid CTL responses select for mutations with a 
fitness cost to the virus and appear to distinguish controllers from progressors (Allen and 
Altfeld, 2008; Frater et al., 2007; Mothe et al., 2009; O'Connor et al., 2002). A recent study 
has further shown that irrespective of the allele, HLA-B alleles restricting Gag specific 
responses exhibited significantly higher functional avidities than responses restricted by HLA-
A or HLA-C molecules or targeting epitopes outside Gag (Berger et al., 2011). 
 
However, the hallmarks of a truly protective immune response remain unclear since 
individuals with HIV infection cannot clear infection and finally progress to AIDS. Numerous 
factors responsible for immune failure have been suggested including destruction of CD4+ 
cells, CD8+ cell exhaustion and viral mutational and non-mutational CTL escape (Day et al., 
2006; Feeney et al., 2004; Goonetilleke et al., 2009; Goulder et al., 1997; Letvin and Walker, 
2003; Wei et al., 2003).  
 
1.8 Mechanisms of CTL mutational escape  
 
HIV-1 uses two major ways to escape killing by CTL and these are mutations in or proximal 
to an epitope (Klenerman et al., 1994), or by non-mutational mechanisms (Cohen et al., 1999; 
Le Gall et al., 2000). Non-mutational escape of CTL response includes Nef-mediated 













C (Collins et al., 1998; Tomiyama et al., 2002; Yang et al., 2002), which are discussed above 
(Index 1.2.8).  
 
In mutational escape, there are three mechanisms of escape. Firstly, mutations occurring at the 
anchor residue of the epitope may prevent binding of the peptide to the MHC class I molecule 
resulting in the epitope not being presented on the surface of the infected cell (Couillin et al., 
1994; Goulder and Watkins, 2004; Kaufmann et al., 2007), in which case, there can be no 
generation of a de novo mutant specific CTL response. Secondly, a mutation may impair 
recognition by the T cell receptor (TCR) and subsequent CTL activation may be antagonised, 
preventing CTLs that are capable of recognizing wild-type virus (Franco et al., 1995; Price et 
al., 2004; Reid et al., 1996). Thirdly, a mutation may prevent epitope-presentation due to 
interference with intracellular antigen processing in which proteosomes degrade viral proteins 
in forms that are not presentable to MHC-1 or are less recognized by MHC-1 than wild-type 
(Cardinaud et al., 2011; Cascio et al., 2001; Klenerman et al., 1994; Rock et al., 1994; Saric 
et al., 2001; York et al., 2003; Zimbwa et al., 2007) 
 
Other forms of interference with intracellular antigen processing may involve preferential 
binding of oligopeptides to the transporters associated with antigen processing (TAP), and 
their translocation in an unprocessed form through the endoplasmic reticulum (ER) or 
restriction of access of some antigenic peptides to the ER (Draenert et al., 2004; Lauvau et al., 
1999). Furthermore, the amino terminal precursors may not be trimmed (Draenert et al., 2004) 
or trimmed into antigenic peptides of the incorrect length that does not bind to the MHC class 
I molecule (Seifert et al., 2003; Serwold et al., 2001). Often CTL escape mutations occurring 
in amino acid residues outside but within five residues flanking known HLA class I restricted 
epitopes interfere with the processing of optimal peptide antigen (Allen et al., 2004; Draenert 














Figure 1.12: Schematic illustrations of antigen processing and presentation and processes that 
may lead to CTL mutational escape during HIV nd SIV infection (Drawn based on Goulder 
and Watkins, 2004).  
 
1.9 Viral escape from CTL responses  
 
Viral escape offers a survival advantage to the virus as the CTL response generated against 
the wild-type does not recognise the mutant (Price et al., 1997). However, the extent to which 
evasion of CTL responses affects the rate of disease progression remains not well understood. 
Some CTLs that target structurally and/or functionally conserved epitopes may be beneficial 
to the host if escape mutations impose a replicative fitness cost to the virus (Crawford et al., 
2007; Goepfert et al., 2008; Martinez-Picado et al., 2006; Matthews et al., 2008; 
Schneidewind et al., 2007). Conversely, gradual accumulation of CTL escape mutants may 
lead to loss of the critical epitopes associated with effective control of viremia that may offer 
sufficient advantage to viral fitness in vivo (Draenert et al., 2004; Goulder and Watkins, 2004; 
Kawashima et al., 2009). Understanding the nature and impact of CTL selected mutations on 
disease progression remain important for the design of an effective CTL based vaccine. This 













disease progression during the first year of infection in subtype C infected individuals from 
the CAPRISA002 acute infection cohort.  
 
1.10 CTL escape and viral fitness  
 
While viral evasion of CTL response or CTL escape may offer a survival benefit to the virus, 
there is limitation to the plasticity of HIV-1 proteome (Liu et al., 2007). Such lack of 
plasticity is seen in reversions of some mutations, which may be detrimental to the virus, 
when transmitted to individuals lacking the HLA that selected the mutation (Allen and 
Altfeld, 2008; Allen et al., 2005; Leslie et al., 2004; Navis et al., 2008; Seki et al., 2008).   
 
Most of the escape mutations associated with viral fitness cost are in epitopes restricted by 
protective HLA class I alleles, B*57/5801, B*27, B*51 and B*8101/B*3910; these epitopes 
are the TW10 (Gag 240–249, KK10 (Gag 263–272), TI8 (RT 128–135)  and TL9 (Gag 180 – 
188), respectively (Boutwell et al., 2009; Brockman et al., 2010; Frater et al., 2007; 
Kawashima et al., 2009; Rolland et al., 2010; Schneidewind et al., 2008; Schneidewind et al., 
2007; Wright et al., 2010; Wright et al., 2012). Furthermore, most of these deleterious escape 
mutations have been identified in the conserved Gag p24 protein (Martinez-Picado et al., 
2006; Troyer et al., 2009) and are in structurally constrained epitopes. CTL attenuation of 
viruses by HLA-B*57/58:01 and B*39:10/81:01 alleles in Gag p24 through selection of 
mutations in TW10 (Gag 240 – 249) and TL9 (Gag 180 -188) epitopes (Rolland et al., 2010; 
von Schwedler et al., 2003; Wright et al., 2010) are some of the best examples. Both the 
TW10 epitope and the TL9 epitope are positioned at functionally important domains involved 
in triggering viral assembly with common escape mutations at amino acids positions T242 
and T180, located at the interface of the N-capping boxes in the sixth α-helix and the third α-
helix of the capsid respectively (Martinez-Picado et al., 2006; Tang et al., 2002). 
Furthermore, studies have found higher numbers of rare or novel CTL escape mutations 
associated with reduced replication capacities from viruses from elite controllers compare to 
those from non-controllers (Miura et al., 2009). It remains unknown however, if the rare 













infection with a founder virus that already contains the escape mutations (Boutwell et al., 
2010).  
 
Interestingly, while in vitro studies have shown that some CTL mutations selected by HLAs 
associated with viral control cumulatively incur fitness cost to the virus (Boutwell et al., 2010; 
Boutwell et al., 2009; Crawford et al., 2009; Rolland et al., 2010), in vivo sequential 
development of these mutations may result in increased viral loads (Crawford et al., 2009). 
These results emphasize that a complex interplay of factors are involved in determining the 
HIV-1 overall infection outcome. One way to try and differentiate the role of HLA and viral 
factors is in looking at transmission of HLA-attenuated viruses to individuals who do not have 
these so-called beneficial HLAs. Infection in an MHC haplotype 90-120-Ia-negative macaque 
with a crippled SIV carrying five gag mutations resulted in multiple reversions and 
progressions to AIDS (Seki et al., 2008). In contrast to this, studies in humans have associated 
lower viral loads and higher CD4 counts in acute infection in B*57/58:01 HLA negative 
subjects, who acquired putative attenuated viruses from HLA B*57/58:01 positive individuals 
(Chopera et al., 2008; Goepfert et al., 2008; Thobakgale et al., 2009). However, the overall 
impact of transmission of constrained, or even multiple epitope-attenuated viruses to 
individuals who do not have these HLAs remains controversial, since recent reports failed to 
detect advantage to recipients of less fit mutations (Novitsky et al., 2010; Wright et al., 2011).  
 
1.11 Compensatory mutations and viral fitness  
  
HLAs that are associated with slow disease progression often select for mutations in 
structurally and functionally constrained regions (Altfeld and Allen, 2006; Kelleher et al., 
2001; Martinez-Picado et al., 2006; Schneidewind et al., 2008). The virus adapts to such 
deleterious mutations through developing other linked mutations known as compensatory 
mutations that partially or wholly offset the fitness cost the virus incurs due to the deleterious 
mutation (Brockman et al., 2010; Brockman et al., 2007; Crawford et al., 2009; Crawford et 














The best example and well-studied CTL escape mutation with substantial fitness cost to the 
virus has been the mutation at residue 242 (T242N) in the TW10 epitope. Structural 
modelling has shown that this residue is central to a delicate series of interactions, changes in 
which might perturb CypA binding (Brockman et al., 2007; Crawford et al., 2009; Martinez-
Picado et al., 2006; Pereyra et al., 2010). A number of experiments have shown that viral 
escape in TW10 through T242N residue is indeed partially or wholly compensated by Gag 
residues 219, 223 and 228 (mutations H219Q, I223V and M228L respectively) (Brockman et 
al., 2007; Boutwell et al., 2008).  
 
Studies have also shown that sites of compensatory mutations are more likely than expected 
by chance to be near the site of the original deleterious mutation (Salazar-Gonzalez et al., 
2009). Indeed, studies have shown that mutations like I147L and S165N that partially 
compensate for A146P and A163G in the B*5703/5801 restricted ISW9 and KF11 epitopes, 
respectively (Crawford et al., 2007) are quite near the original site of primary escape 
(Crawford et al., 2009; Draenert et al., 2004; Troyer et al., 2009).  
 
Nevertheless, other compensatory mutations have been detected at sites away from the 
original deleterious mutations. For instance, the fitness cost of the CTL escape mutation 
R264K in the B*27 restricted KK10 epitope has been located at S173A (Schneidewind et al., 
2007), although a close compensatory substitution at site L268M has also been detected 
(Kelleher et al., 2001; Schneidewind et al., 2008; Schneidewind et al., 2007; van der Kuyl et 
al., 2009). Interestingly, however, the mutation L268M has been independently shown to 
enhance binding to Immunoglobulin-like transcript 4 (ILT4), a MHC class I receptor 
inhibitor, expressed on monocytes and dendritic cells, causing substantial defects in the 
antigen-presenting properties of these cells (Lichterfeld et al., 2007). Recent findings suggest 
that the virus uses this pathway of immune escape in some HLA-restricted escape (HLA-A11-
, B8- and B7), while it does not in some others like the B57 (Yang et al., 2010).   
  
Overall, in both SIV and HIV, mutations with a net fitness cost have been shown to revert to 













selected them or compensatory mutations partially restored the viral fitness that would delay 
reversion to wild-type (Crawford et al., 2007; Leslie et al., 2004; Schneidewind et al., 2007).  
 
1.12 CTL escape and HIV evolution 
 
Following transmission to HLA-mismatched recipients, some escape mutations may persist 
for years, while others revert to wild-type (Chopera et al., 2008; Friedrich et al., 2004; Leslie 
et al., 2004; Matthews et al., 2008; Wright et al., 2011). Mutations that have occurred at little 
fitness cost to the virus or those that have been compensated may accumulate in populations 
(Crawford et al., 2007; Draenert et al., 2004; Kawashima et al., 2009) resulting in an “HLA 
footprint” on HIV sequences (Moore et al., 2002; Leslie et al., 2005; Klenerman and 
McMichael, 2007; Kawashima et al., 2009; Matthews et al., 2009). HLA footprinting was 
initially reported by Moore et al. (2002), although correcting for founder effects resulted in a 
loss of some of this signal (Bhattacharya et al., 2007). Further studies have suggested that the 
most common HLA in a given population of HIV infected individuals may influence HIV 
evolution in a particular direction as specific HLA-HIV codon associations are determined by 
specific HLA frequency distributions (Avila-Rios et al., 2009). Indeed, a profound effect of 
HLA-B*51:01, which is a dominant HLA allele in Japanese showed that the protective effects 
of the TAFTIPSI (reverse transcriptase residues 128–135) epitope was virtually eliminated 
from the population due to escape through the I135X (Kawashima et al., 2009). This suggests 
that CTL escape may have a fundamental impact on reducing the immunogenicity of viruses 
and that gradually, the so-called beneficial HLA alleles may not retain their advantage 
(Goulder and Watkins, 2008). Furthermore, studies have shown a strong correlation between 
variant frequency of the rapidly reverting T242N mutation in the B*57:03/58:01 restricted 
TW10 epitope with HLA prevalence in populations suggesting that this mutation is 
accumulating over time, which can be explained, either by mutant acquisition exceeding 
reversion rate or by compensatory mutations that completely prevent reversion (Crawford et 
al., 2007; Kawashima et al., 2009).  
 
Studies have also shown that transmission of viruses encoding escape mutants in the critical 













viremia (Crawford et al., 2009; Goepfert et al., 2008; Goulder et al., 2001) suggesting that 
accumulation of these mutations may lead to loss of protection in populations of individuals 
with beneficial HLAs. The longer-term consequences of the accumulation at the population 
level of these escape mutations on the immune control of HIV remain unknown however 
(Goulder and Watkins, 2008).  
 
1.13 Study rationale 
 
The development of a prophylactic HIV vaccine that prevents initial infection remains a 
global priority. However, the major challenge in developing such a vaccine is defining 
correlates of sterilising protection against HIV-1 infection (Koup et al., 2011; McElrath and 
Haynes, 2010).  In the development of vaccine candidates that elicit CTL responses, of 
particular interest is the elucidation of CTL responses associated with control of acute HIV 
infection. CTL responses have been associated with control of viremia in chronic HIV-1 
infection, and these responses contribute to the initial control of peak viremia in acute 
infection (Borrow et al., 1994; Feeney et al., 2004; Goonetilleke et al., 2009; Goulder et al., 
1997; Henn et al., 2012; Kiepiela et al., 2007; Koup et al., 1994).  
 
The study of patterns of immune escape in HIV-1 acute infection provides us with a sensitive 
tool to identify specific viral regions under active immune selection pressure and contribute to 
our understanding of the correlates of immune control of HIV-1-infection. While certain CTL 
responses appear to control HIV replication, escape from these responses does not necessarily 
result in loss of control. This is because some escape may be detrimental to the virus and 
result in lower replication capacity - creating a balance between the benefit of escape to the 
virus and its survival (Crawford et al., 2009; Martinez-Picado et al., 2006; Schneidewind et 
al., 2007; Woo et al., 2010). Furthermore, mapping immune escape and the fitness cost to the 
virus provide information relevant to the selection of candidate immunogens for an HIV-1 
vaccine.   
 
Understanding events in acute HIV-1 subtype C infection are particularly important since 













2007; Novitsky et al., 2009). Several studies have focused on subtype C chronic infection 
(Kiepiela et al., 2004; Kiepiela et al., 2007) with only a few studies on subtype C acute 
infection. This study sought to address the question of the timing, location and impact of CTL 
escape on disease progression in subtype C HIV-1 infection. Furthermore, this study is part of 
the Centre for AIDS Program of Research in South Africa (CAPRISA) 002 study that focuses 
on investigating the role of viral and immunologic factors during acute and early subtype C 
infections. At the time of this study, the cohort had enrolled 62 recently HIV-1 infected 
individuals (within 3 months of infection) from rural and urban regions of Kwazula Natal. 
 
This study focused on the Gag and Nef proteins as these are immunodominant and targeting 
of the Gag is associated with better disease outcome (Kiepiela et al., 2007; Miura et al., 2009; 
Rolland et al., 2008). Furthermore, the majority of deleterious mutations have been found in 
Gag (Martinez-Picado et al., 2006; Schneidewind et al., 2007; Troyer et al., 2009; Wright et 
al., 2012).  
 
The overall aim of this study was to determine if networks of attenuating mutations in viruses 
in acute infection could be responsible for lower viral loads observed in some individuals.  
 
The specific objectives of the project were: 
 
1. To identify mutations associated with CTL escape that emerge during the first 12 
months following HIV-1 subtype C infection; 
2. To quantify both the frequency of CTL escape-mutations in transmitted viruses and 
the timing of their reversion over two years following their transmission to HLA 
mismatched hosts;  
3. To determine the impact on disease progression of CTL escape mutations detected in 
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This study investigated the frequency, timing and pathogenic consequences of early cytotoxic 
T- lymphocyte (CTL) escape on subsequent HIV-1 disease progression. Altogether, 365 and 
289 full-length gag and nef sequences were generated from samples at enrolment (median 1.4 
months post infection), 3, 6, 12 and 24 months post infection from 58 subtypes C infected 
individuals. Putative escape was identified within or flanking known epitopes restricted by the 
participants HLA. Timing of escape was defined as either acute (≤ 3 months), early (> 3 to ≤ 6 
months) or late (> 6 to 12 month).  
 
In participants with single HIV-1 infection, CTL escape was detected in 69% (35/51) and was 
more frequently observed in the acute than in the early/late infection phases (3.8 versus 1.1 
escape/month/100 amino acids; p=0.0231). Participants with viruses escaping CTL responses 
in Gag and/or Nef in acute and early infection had higher CD4+T-cell counts when compared 
to those without viral escape in this time period (p=0.0018 and 0.0542, respectively). 
Although the decline in viral load was similar after 3 months (p=0.998), the initial 
preservation of CD4+ cells resulted in a higher mean CD4+ T-cell counts in individuals 
whose viruses escaped in acute infection compared to those without viral escape at 12 months 
post-infection (p=0.0274). Moreover, a significantly higher number of viral escape mutations  
(72.4%, 42/58) were selected by HLA-B alleles compared to the number of mutations selected 
by HLA-A alleles (17.2%, 10/58) (p=0.0134). There was also a trend for higher CD4+ T-cell 
counts at 12 months in HLA-B restricted escape in Gag and Nef (p= 0.08; median 500 cells/μl 
[IQR=416 - 645] versus 368 cell/μl [IQR=303 - 624]).  
 
The high frequency of escape during peak viremia provides evidence of CTL pressure on the 
virus in very early infection. These results demonstrate that escape occurs predominantly in 
HLA-B restricted epitopes and immune responses selecting escape mutations in acute 














2.1 Introduction   
 
Virus-specific cytotoxic T cell (CTL) responses contribute to the control of viremia in acute 
infection and numerous studies have shown an inverse correlation of CTL responses after 
seroconversion with control of viremia (Borrow et al., 1994; Freel et al., 2012; Goonetilleke 
et al., 2009; Henn et al., 2012; Kim et al., 2010; Koup et al., 1994). However, the precise 
nature of CTL responses associated with successful control of HIV-1 infection is not fully 
understood. Moreover, most of these studies on the early dynamics of the HIV infection have 
predominantly been done in subtype B settings, with the few studies done in subtype C 
suggesting that observations in different subtype populations may not be extrapolated to other 
subtypes (Gray et al., 2009a; Novitsky et al., 2009; Radebe et al., 2011). Understanding CTL 
responses and immune escape in subtype C acute infection cohorts is important as firstly, 
subtype C is the most dominant virus globally;  secondly, acute infection is thought to play a 
disproportional role compared to other stages in infection in influencing disease progression 
(Brenchley et al., 2004; Kelley et al., 2007; Levesque et al., 2009; Veazey et al., 1998); and 
lastly, understanding immunological and viral factors that correlate with control of infection 
during acute infection are critically important for the design of an effective HIV-1 CTL based 
vaccine. 
 
In subtype C chronic infection, studies have shown that Gag responses were associated with 
lower viral loads (Kiepiela et al., 2007). However, although events in acute infection are 
thought to influence subsequent disease progression, a study on the CAPRISA acute infection 
cohort found none of the HIV-1 protein-specific CTL responses in the first three months of 
infection,  including those targeting Gag, were prognostic of set-point viral load at 12 months 
post-infection (Gray et al., 2009a). Furthermore, this group of researchers documented that 
individuals with rapid disease progression were more likely to lose immune responses in the 
first year of infection compared to controllers, suggesting that CTL escape is detrimental to 
the individual (Mlotshwa et al., 2010).  
 
Nonetheless, escape from CTLs targeting structurally or functionally conserved epitopes may 













et al., 2006; Schneidewind et al., 2008; Schneidewind et al., 2007; Smith, 2004). However, 
these mutations have predominantly been found in Gag epitopes restricted by HLA alleles 
associated with relative protection and the majority of these have been again in subtype B 
(Brockman et al., 2010; Crawford et al., 2009; Frater et al., 2007; Martinez-Picado et al., 
2006; Schneidewind et al., 2007) (see Chapter 1.10). There are a few studies in subtype C 
infected cohorts that have investigated the effect of escape in acute infection. These studies 
focused on B*57/58:01 restricted epitopes in Gag (Chopera et al., 2011; Crawford et al., 
2009) and although in vitro studies demonstrated that the accumulation of escape mutations 
reduced viral replicative capacity, there was increase in viral load in vivo in association with 
escape in all three HLA-B*5703–restricted CTL responses (Crawford et al., 2009). 
 
To better understand events in acute infection and subsequent influence on disease 
progression, this study analyzed viruses in recently infected women from the CAPRISA 002 
acute infection cohort. The design of the CAPRISA study was to detect HIV infection at the 
very earliest stage of HIV infection through monthly screening of HIV negative women by 
PCR or women with a reactive HIV antibody test within 3 months of a previously negative 
antibody result (van Loggerenberg et al., 2008). Because viruses rapidly adapt in a new host, 
this cohort attempted to enrol individuals close to the period of infection such that early 
viruses would have had limited time to evolve, making this cohort suitable for studying acute 
infection. This chapter reports on the characterisation of gag and nef sequences from 58 
women recruited during acute HIV infection and followed for at least one year. Seven women 
were found to be either co-infected (n=4) or superinfected (n=3) with two distinct HIV strains. 
The timing of CTL escape and its consequences on HIV-1 disease progression was 
















2.2 Material and Methods  
 
2.2.1 Study subjects 
 
The CAPRISA 002 Acute Infection cohort enrolled subjects within 3 months of infection, and 
followed them until initiation of antiretroviral therapy according to South African National 
Guidelines (defined at that time as CD4+ < 200 cells/μl or AIDS defining illness) (van 
Loggerenberg et al., 2008). Women were enrolled from both the HIV negative cohort, and 
other seroincidence cohorts in Durban, South Africa. HIV-1 infection was identified using 
rapid antibodies assay and PCR, and was confirmed using an enzyme immunoassay (EIA) test 
as previously described (van Loggerenberg et al., 2008). CD4+ T cell counts were assessed 
using a FACSCalibur flow cytometer while viral loads were measured using a COBAS 
AMPLICORTM HIV-1 Monitor Test v1.5 (Roche Diagnostics, Branchburg, New Jersey, 
USA). Samples were collected at enrolment, weekly for three weeks, fortnightly until 3 
months, monthly until a year and quarterly thereafter. Written informed consent was obtained 
from all participants. This study received ethical approval from the University of KwaZulu-
Natal, University of the Witwatersrand and University of Cape Town (REC NO: 025/2004) 
 
2.2.2 HIV-1 Plasma RNA isolation and sequencing 
 
RNA was isolated from plasma samples using either the Magna-Pure Compact Nucleic 
Extractor (Roche) or manually using QIAamp viral RNA extraction mini kit (QIAGEN) for 
samples with plasma viral load of less than 2000 copies per mL. SuperScript lll Reverse 
transcription kit (Invitrogen) and gene specific primers, the Gag D reverse (5′-AAT TCC TCC 
TAT CAT TTT TGG-3’; HXB pos 2382-2402) and Nef OR: (5′-AGG CAA GCT TTA TTG 
AGG-3’; HXB pos 9608-9625) for gag and nef respectively, were used to transcribe cDNA 
from RNA. Gag PCR primers for the first round were the Gag D reverse and Gag D forward 
(5′-TCT CTA GCA GTG GCG CCC G-3’; HXB pos 626–644). Gag A forward (5′-CTC TCG 
ACG CAG GAC TCG GCT T-3’; HXB pos 683–704) and Gag C reverse (5′-TCT TCT AAT 
ACT GTA TCA TCT GC-3’; HXB pos 2334–2356) were the second round primers. Nef PCR 













TCT-3′; HXB pos 8561-8578), while the second round primers were Nef F (5′-CCT AGA 
AGA ATA AGA CAG GGC TT-3′; HXB pos 8754-8776) and Nef R (5′-CCT GGA ACG 
CCC CAG TGG-3′; HXB pos 9443-9461). Gag sequencing primers were Gag A forward, Gag 
A reverse (5′-ACA TGG GTA TCA CTT CTG GGC T-3′; HXB pos 1282–1303), Gag B 
forward (5′-CCA TAT CAC CTA GAA CTT TGA AT-3′; HXB pos 1226–1246), Gag B 
reverse (5′-CTC CCT GAC ATG CTG TCA TCA T-3′; HXB pos 1825–1846), Gag C reverse 
and Gag C forward (5′-CCT TGT TGG TCC AAA ATG CGA-3′; HXB pos 1748–1768). Nef 
sequencing primers were Nef Reverse and Nef forward. Sequences were assembled using 
Chromaspro (Technelysium Pty Ltd) and aligned using the ClustalW in Bioedit (default 
settings, Thompson et al., 1994). 
 
2.2.3 Timing of CTL escape   
 
The timing of CTL escape was estimated as the time of the first appearance (observation) of a 
CTL mutation either in or proximal to a known epitope restricted by the participants’ HLAs. 
Timing was then defined as either acute (0 to 3 months), early (>3 to 6 months) or late (>6 to 
12 month). Time to escape was estimated as a mid-point between the last sequenced time 
point and the timing of the first observation of the escape mutation. 
 
2.2.4 Virus-specific PCR 
 
First strand synthesis was transcribed as above described, but using the unique individual-
specific reverse (R) primer (sequence shown below). Primers below were then used to amplify 
gag sections specific to the individual’s sequence in non-nested 2 rounds. Specific primers 
used were CAP237GagR: (5'- TCA TTA TGT TTG CAT TGC C -3'; patient’s virus sequence 
pos 1115 - 1122); CAP237GagF: (5’- GGT ACA CAA TCC CCT ATC G -3’; HXB2 pos 420 
- 438) CAP281GagR: (5’- CAC ATT GTT TAC CTG GCT CAT -3’; patient’s virus sequence 
pos 1190 - 1110) and CAP281GagF: (5’- AAG TAA TAG AGG AGA AGG C -3’; HXB2 















2.2.5 DNA sequence divergence and phylogenetic analyses  
 
Phylogenetic and molecular evolutionary analyses were conducted using MEGA software 
version 4 (Tamura et al., 2007). Maximum pairwise distances were estimated using Kimura 
Two parameter model (Kimura, 1980). Where maximum likelihood phylogenetic trees were 
constructed, this was implemented in RDP3 (Martin et al., 2005) and edited in MEGA 
(Tamura et al., 2007). Recombination in the dually infected sequences was assessed using 
Genetic Algorithms for Recombination Detection (GARD) implemented in Datamonkey 
(Kosakovsky Pond et al., 2006) and nucleotide transition and transversion plots using the 
highlighter plot tool (www.hiv.lanl.gov). 
 
2.2.6 IFN-γ ELISpot assay 
 
This data was provided by CM. Gray, NICD/UCT; HIV-1-specific T cell responses across the 
entire HIV-1 clade C proteome were quantified by interferon gamma (IFN-γ) enzyme-linked 
immunospot (ELISpot) assay using freshly isolated and prepared PBMCs as previously 
described (Masemola et al., 2004). Peptide pools used were HIV-1 subtype C consensus 
sequences and positive responses at the single-peptide level within the peptide pools were 
confirmed in a second IFN-γ ELISpot assay and monitored longitudinally in participants 
positive in the initial screening.  
 
2.2.7 HLA typing  
 
HLA Data was provided by the C. Gray, NICD/UCT; HLA class I (four digits) genotyping 
was performed on DNA extracted from either PBMCs or granulocytes using Pel-Freez DNA 
isolation Kit (Pel-Freez). Exons 2, 3, and 4 were then sequenced using Atria Allele SEQR kits 
(Abbott Diagnostics) and Assign SBT 3.5 software (Conexio Genomics). Ambiguities were 
















2.2.8 Statistical analyses  
 
Statistical analysis and graphical presentations were implemented in GraphPad Prism 5.0 
(GraphPad Software, Inc.). To control for fluctuations at viral set-points at 12 and 36 months 
post-infection, we calculated viral load and CD4+ T-cell counts as medians of measurements 
taken at three time-points closest to these intervals. To determine if DNA distances fell 
outside of the normal Gaussian distribution, extreme upper outliers were defined as those 
whose DNA distances fell above an exploratory data analysis value (EDA), which was 
calculated from the following box plot formula: ([3 x IQR + [upper quartile - lower quartile 
value]); [John et al., 1983; Iglewicz and Hoaglin, 1993]). Statistical analysis of significance 
was based on Mann-Whitney two-tailed t test or Kruskal-Wallis (Dunn’s test) for multiple 
comparisons. Variations in timing and number of mutations selected by different HLAs were 
compared using analysis of variance (ANOVA - two-way t test) model. Rates of viral load 
and CD4+ count changes over time were estimated using locally weighted regression statistics 
(Loess) (Cleveland et al., 1988)  
 
 
2.3  Results  
 
2.3.1 Cohort characteristics  
 
Sixty two women were enrolled into the CAPRISA 002 acute infection study within a median 
of 6 weeks of infection (IQR = 4-8 weeks) (enrolment visit), of whom one participant, 
CAP259, opted out in early stages, while samples for three were not available for sequencing 
at the time of this study. HIV infection in 58 women was characterised in this thesis.   
 
Laboratory staging of acute infection was available for 52 individuals (generated by R. 
Thebus, IIDMM, UCT). At the time of sampling for sequencing, two individuals were HIV 
RNA positive and enzyme immunoassay (EIA) antibody negative (Fiebig 1-II), two were EIA 
antibody positive but Western blot negative (Fiebig III), seven had an indeterminate Western 













integrase band (Fiebig V), while  22 had positive western blot results and a p31 band present 
(Fiebig VI) (Table 2.1) (Fiebig et al., 2003). The median viral load at the enrolment visit was 
71 900 copies/ml (IQR=12 500 – 399 000).      
 
CD4+ T-cell counts and viral load measurements were taken weekly for three weeks, monthly 
until 12 months and quarterly thereafter. Viral load measurements and CD4+ T cell counts at 
12 months post-infection were used as prognostic of disease progression (Lyles et al., 2000). 
To control for fluctuations in viral loads, set-points at 3, 6 and 12 months were determined as 
medians of three viral load measurements close to these time-points. Median viral loads and 
CD4+ T-cell counts at 3 and 12 months post were 4.60 (IQR = 4.01 – 5.06) and 4.34 (IQR = 
3.46 – 4.82) copies/ml; and 522 (IQR = 393 – 628) and 410 (IQR = 319 – 560) cells/μl, 
respectively. 
 






















CAP008 P1V7 V 23 Single  188000 98400 39300 
CAP030* P2V0 V 35 Single 604000 146000 57400 
CAP037 P1V18 IV 14 Co-infec 39700 34700 104000 
CAP045* P2V0 V 35 Single 9790 <400 556 
CAP061 P2V0 VI 57 Single 4380 21000 418 
CAP063 P1V0 III 34 Single 305000 186000 164500d 
CAP065 P2V0 VI 42 Single 59 500 104000d 122000 
CAP069 P1V12 I/II 14 Single 1390000 673000 1230000 
CAP084 P2V0 VI 22 Co-infec 28500 2090 6530 
CAP085 P2V0 V 23 Single 43400 6450 3030 
CAP088 P2V0 VI 36 Single 38700 45300 38700 
CAP129 P1V15 IV 14 Single 21700 25000 80100 
CAP136 P2V0 V 28 Single 2080 1680 1865 
CAP137 P1V13 IV 14 Co-infec 126000 112000 
 
246000 
 CAP174 P2V0 VI 28 Single 56600 100000 60700 
CAP177 P2V0 III 30 Single 57600 89700 42100 
CAP188* P2V0 IV 26 Single 30900 66900 89600 
CAP200 P2V0 V/IV 42 Single 172000 279000 108000 
CAP206 P2V0 VI 41 Single 140000 138000 252000 
CAP210 P2V0 V 36 Single 34200 132000 376000 
CAP211* P2V0 IV 20 Single 62300 8420 1010 
CAP217 P2V0 VI 67 Single 162000 177000 26700 
CAP220* P2V0 V 23 Single <400 <400 <400 
CAP221 P1V10 I/II 14 Single 1230 16800 53100 
CAP222 P2V0 V 43 Single 33900 1360 448 
CAP224 P2V0 V 43 Single 100000 27200 46300 
CAP225 P2V0 IV 23 Single 64400 47600 21500 













CAP229 P2V0 ND 48 Single 14900 14000 22500 
CAP237 P2V0 IV 28 Super 52500 7750 11900 
CAP239 P2V0 V 48 Single 16100 59700 156000 
CAP244 P2V0 VI 58 Single 39900 26100 14500 
CAP248 P2V0 V 62 Single 79400 40600 64600 
CAP255 P2V0 VI 54 Single 106000 57800 36400 
CAP256 P2V0 VI 42 Super 105000 750000 223000 
CAP257 P2V0 V 49 Single 173000 14900 10000 
CAP258 P2V0 VI 49 Single 268000 228000 122000 
CAP260* P2V0 V 28 Single 6920 3510 3480d 
CAP261 P2V0 VI 62 Single 445000 65000 65400 
CAP262 P2V0 V 48 Single 13600 3260 7160 
CAP264 P2V0 V 83 Single 393000 42300 40500 
CAP265* P2V0 VI 86 Single 1825 517 3380 
CAP266 P2V0 VI 14 Single 76700 1640 2010 
CAP267 P2V0 V 44 Co-infec 12400 19400 19300 
CAP268 P2V0 VI 55 Single 4130 15100 7640 
CAP269* P2V0 VI 25 Single 506 790 980 
CAP270 P2V0 V 54 Single 527000 365000 738000 
CAP271* P2V0 VI 40 Single 1620 9680 10100 
CAP274 P2V0 VI 72 Single 38270 164000 85300 
CAP275* P2V0 VI 60 Single 63400 9700 2830 
CAP277* P2V0 VI 53 Single 6410 2070 483 
CAP278* P2V0 IV 59 Single 870 625 891 
CAP279* P2V0 VI 54 Single 155000 13300 32200 
 CAP280 P2V0 V 87 ND 77050 37400 2430 
CAP281 P2V0 ND 68 Super 2700 1230 400 
CAP282* P2V0 ND 74 Single  10200 28200 1470 
CAP285* P2V0 ND 99 Single 421500 198000 ND 






Viral load value is median of 3 measurements close to the respective time points; Infection date is estimated as a 
midpoint between the last negative and first positive antibody test or as 14 days for antibody negative but PCR 
positive participants; aparticipant’s identification number; bFeibig et al., 2003; cCo-infection classified by 
Woodman (Woodman et al., 2011), and superinfection (super) classified in this study using the gag/nef 
sequences; *These individuals were characterised as single infections (n=16) based on the maximum pairwise 
DNA distances of either clonal sequences at enrolment or longitudinal Gag and Nef sequences; dValue at 9 
months post-infection; ND=Not done. VL <400: Below limit of detection  
 
 
2.3.2 Characterisation of the infecting virus  
 
 
Altogether, a total of 365 and 289 full-length gag and nef sequences were generated from 58 
participants (median 6 gag and 5 nef sequences per participant) over the course of the first 12-
24 months post-infection. A further 192 full-length gag and 204 nef sequences were available 
from 32 participants over the first 6 months of infection (Chopera et al., 2008). All individuals 
were infected with HIV-1 subtype C (Figure 2.2).  
 
The number of infecting strains following transmission had previously been reported in 39 
participants using single genome amplification and sequencing of env amplicons (Abrahams 













(Woodman et al., 2011). These studies identified four individuals (CAP037, CAP084, 
CAP137 and CAP267) as co-infected with two epidemiologically unlinked strains following 
transmission.   
 
To determine if we could identify dual infection through the analysis of longitudinal 
sequences, the pairwise distance between the different individuals’ sequences for all time-
points from enrolment to 12 months post infection was computed (Figure 2.1a and b). We 
expected individuals infected with a single virus infection to have a normal Gaussian 
distribution of maximum pairwise DNA distances within the first year post-infection, whereas 
individuals with dual infection would fall outside of this curve. The group median maximum 
pairwise DNA distances were 0.7% [IQR 0.4 – 1.2%] and 1.0% [IQR 0.5 – 1.75%] in gag and 
nef respectively. Seven individuals fell outside of the normal distribution (≥ extreme outlier 
values of 3.2% and 5.0% in the gag and nef respectively) including the four individuals 
previously identified as dually infected (CAP037, CAP084, CAP137, CAP 267) and a further 
three (CAP237, CAP256, and CAP281) (Table 2.1). This frequency of superinfection in the 
first year of infection (5.2%; 3/58) is in agreement with that reported by Kraft et al. (2012) in 
a Zambian subtype C cohort (6.8%; 3/44) although the main purpose of characterizing 
superinfection in this study was to avoid confusing active CTL escape with superfluous 
















































































































































































































































































































































































































































































































































































































































































































Figure 2.1 Maximum pairwise DNA distance comparison of intrapatient sequences over one year post infection 
in (A) gag and (B) nef. Intrapatient distances were calculated using the MEGA package with the Kimura two-
parameter model of evolution (Kimura, 1980). Extreme outlier pairwise DNA distances are shown in red colour. 
 
Of the seven individuals with high diversity, four of these individuals separated into distinct 
clusters in the full-length gag and/or nef (CAP037, CAP137, CAP256 and CAP281) while a 
further two separated into distinct clusters in p17/p24 (CAP084 and CAP237) (Figure 2.2a, b, 
c and d). Although viral diversity was high in CAP267, these sequences clustered together 
phylogenetically in both the full length nef and gag/partial gag sequences. Nevertheless, 
CAP267 had previously been identified as infected by more than one HIV-1 viral strains at or 
very close to the initial infection (co-infected). Three individuals were identified as putative 
superinfections (SI): CAP256 previously identified by Treurnicht et al. (2008), and a further 
two more individuals, CAP237 and CAP281 were identified in this study. In CAP237, the 
sequence of the second infecting virus differed from the initial infection by 7.2% and 8.6% in 
gag and nef respectively, while in CAP281 the virus differed from the initial infection by 
7.5% and 8% in gag and nef respectively (Table 2.2). Thus looking at diversification over 
time, this study correctly identified four individuals previously classified as co-infected, and 














Sequences were then analyzed for recombination in order to determine if there was evidence 
of superinfection prior to first detection. The first evidence of recombination between the two 
superinfecting strains was detected at 50 weeks for CAP237 with a p17 segment (1-280 
nucleotide-lengths) from the sequence at 6 weeks taken up in the sequence at 50 weeks post 
infection, as estimated using GARD and highlighter plot similarities (Figure 2.3). Similarly, 
the first evidence of recombination in in CAP256 was detected at 30 weeks post-infection 
with significant recombination in later sequences. There was no detectable evidence of 















Figure 2.2a:                                                                Figure 2.2b 
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Figure 2.2c:                                                             Figure 2.2d              
  
                               
Figure 2.2 Neighbour joining trees showing the phylogenetic clustering of sequences generated from enrolment 
to a year post infection. Un-labelled sequences are other subtype C sequences from southern Africa. a) Gag p17 
and b) p24 nucleotide sequences showing clustering of sequences that are putative dual infections; c) Full lengths 
longitudinal HIV-1 gag nucleotide sequences showing the clustering of sequences that are putative dual 
infections; d): Full length longitudinal HIV-1 nef nucleotide sequences showing clustering of sequences that are 
putative dual infections; Green: CAP037; Dark Blue: CAP084; Purple: CAP137; Yellow: CAP237; Pink: 
CAP256; Black: CAP267 and Red: CAP281. Bootstrap values greater than 75% are shown, and scale length of 
0.01 is shown as a bar below each tree.  
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Figure 2.3 Highlighter plot showing longitudinal gag sequence similarities in CAP237, CAP256 and CAP281. 
Later viral sequences for each of the three participants are compared to the individual’s earliest available 
sequence (enrolment); sequences are arranged in a descending order of similarity to the earliest sequence. 
Nucleotide mismatch are shown as coloured tick (A = green, T = red, G = orange, C = light blue, IUPAC = dark 
















2.3.2.1 Confirmation of superinfection  
 
To confirm superinfection and determine the timing of infection with the second strain, 
primers specific to unique short sections of the individuals’ superinfecting viral sequence, 
which could not amplify the initial primary infecting virus, were designed. The timing of re-
infection was defined as the midpoint between the last PCR negative time-point and the first 
time-point of detecting the second sequence.  
 
In CAP237, sequencing identified a second incoming strain at week 15, and was not detected 
at week 4 or 6. Using CAP237 specific primers to the SI virus, there was no amplification 
detected for samples from 4 and 7 weeks, while the superinfecting virus was detected at 
weeks 11, suggesting that re-infection occurred between week 7 and 11. An increase of 1.5 
copies/mL log viral load occurred between 11 and 13 weeks post infection further supporting 
this timing (Figure 2.4).   
 
In CAP256, superinfection was first identified at week 15, and was not detected at week 6 or 
13. Additionally, typical of superinfection, an increase of 1.7 copies/mL log viral load was 
observed from week 12 to 15. These timings were later confirmed using CAP256 specific 
primers by D. Sheward (HIV diversity group of Williamson, IIDMM).   
  
In CAP281, superinfection was first identified at week 46, and was not detected at week 10 or 
42. This individual controlled her viral loads to low levels and virus specific primers were 
designed but were not sensitive enough to detect virus in samples with low viral loads 
(generally below 1000 copies/ml). However, a significant viral load increase (log 1.1 
copies/ml) occurred at 42 weeks post infection, suggesting that superinfection occurred at this 























      Table 2.2 Estimated timing of superinfection in the three participants 
PID Infection Time*1 (Wks PI) Superinfection Time*2  (Wks PI) 
CAP237 2 9 
CAP256 6 14 
CAP281 10 42 
Wks PI Weeks Post-Infection 
     *1 Midpoint between last HIV negative and first HIV positive  










































































































Figure 2.4 Timing of superinfection and impact on disease progression for the superinfected participants, 
CAP237, CAP256 and CAP281, showing viral load and CD4+ T cell counts. The arrow shows the estimated 
timing of the new infecting virus or the midpoint between first detection of superinfection (SI) and last negative 
specific primer PCR for the SI. Characteristic of superinfection, these three individual had a more than one log 

















2.3.3 Identification of CTL escape-mutations emerging during the first year of 
         infection 
 
Gag and Nef proteins were selected as they have been shown to elicit dominant immune 
responses in early infection (Gray et al., 2009a), and as responses to Gag have been shown to 
be associated with lower viral loads (Berger et al., 2011; Kiepiela et al., 2007). Only 
individuals with single infection (n=51) were included in this analysis as it was difficult to 
predict whether changes in epitopes were due to infection with multiple strains or viral 
evolution in individuals with dual infection or superinfection.  
 
Putative CTL escape mutations were defined as changes that persisted over time in (or within 
5 amino acids flanking) known epitopes, defined using the ‘A’ list of epitopes, restricted by 
the participants’ HLA (Llano et al., 2009; www.hiv.lanl.gov). Significant HLA-associated 
mutations defined using a large clade C South African cohort occurring in published epitopes 
were also included in this analysis (Goepfert et al., 2008; Matthews et al., 2008; Rousseau et 
al. 2008). Reversions were defined as changes from low amino acid frequency to high 
frequency or consensus amino acid in epitopes not restricted by the participants HLA. Gag 
and Nef IFN-γ ELISpot data was also available for 28 participants (Mlotshwa et al., 2010) 
(Table 2.3). 
 
2.3.4 Putative escape mutations and CD8+ T-cells recognition of HIV-derived  
         peptides measured by the IFN-γ ELISpot assay  
 
To investigate if mutations associated with immune pressure were accurately predicted, the 
relationship between putative CTL escape and CD8+ IFN-γ responses measured using IFN-γ 
ELISpot assay was assessed in 28 participants, whose data was available (Table 2.3; IFN-γ 
data given by C. Gray: Gray et al., 2009a; Mlotshwa et al., 2010). Individuals’ HLAs 
restricting known epitopes could be mapped out in 94.0% (47/50) of all peptides recognised 
by CD8+ T cells that were measured by this assay, whereas three peptides were positive in 













was seen in 26 (52%) epitopes, while 24 remained conserved for the first 12 months post-
infection.  
 
On an individual level, 64.3% of the 28 individuals (18/28) had escape detected where there 
were concomitant reductions in IFN-γ ELISpot responses in Gag and/or Nef confirming 
immune escape. However, there were no IFN-γ ELISpot responses detected in 17.9% (5/28) 
of these individuals despite the detected CTL escape (HLA-mediated sequence evolution).   
 
Whether the reasons for detecting viral escape with no measureable immune pressure in these 
five individuals could have been due to differences in the infecting viral sequence and the 
reagent used to detect responses was investigated. There was one/two mismatch in five of the 
sequences of the infecting virus and those of the reagent used (n=8) in individuals with escape 
but without responses, suggesting that use of autologous sequence could have increased 
response detection.  
 
 
Taken together, evolution of CTL escape mutations in previously defined Gag and Nef 
epitopes was detected in 69% of individuals (35/51) at one year post infection (Table 2.4). 
Escape in Gag was detected in 43% of individuals (22/51), while escape in Nef was detected 
in 47% individuals (24/51). Escape in both Gag and Nef was observed in 11 (11/51; 22.0%) 






























Table 2.3 Comparison of HLA-mediated sequence evolution in gag and nef and CTL immune responses, as 
measured using IFN-γ ELISpot assay (provided by Gray: Gray et al., 2009a; Mlotshwa et al., 2010), 
commencing in acute infection; Known epitopes are underlined.   
 
PID  RPeak Peptide and Known epitope HLA Escape  
CAP008 
 
Gag pep4 2695 GKKHYMLKHLVWASREL 
 
B*08:01 + 
 Nef pep26/27 2495 IHSKRRQDILDLWVYHTQG Cw7 + 
CAP030 Nef pep20 328 RPMTYKAAFDLSFFL Unknown - 
Nef pep21 298 YKAAFDLSFFLKEKG Unknown - 





Nef pep33/34 2178 PGPGVRYPLTFGWCFKLVP A*23:01*g - 





Gag pep11 420* TGTEELRSLYNTVATLY A*30:02 + 
Nef pep29 1638 KRQEILDL-WVYHTQGYFPDWQNY Cw7 + 
Nef pool2 - EEEPEVGFPVRPQVPPLRPM 
 
B*45:01 +/No responseM 
CAP088 
 
Gag pep49 465 SHKARVLAEAMSQANSA B*45:01 + 
Nef pep30 2677.5 TQGYFPDWQNYTPGP A*29:02 - 
Nef pool2 - EEEPEVGFPVRPQVPPLRPM 
 
B*45:01 +/No responseM 
CAP129 
 
Nef pep17 138 EVGFPVRPQVPLRPM B*81:01 + 
Nef pep26 1775 IHSKRRQDILDLWVY B*18:01 + 
Gag pep40 - GPKEPFRDYVDRFFKTLR B*18:01 +/No response 
Gag pep25 - GATPQDLNTMLNTVGGH B*81:01 +/No responseM 
CAP174 Nef pep19 923 QVPLRPMTYKAAFDL A*03:01 + 
Nef pep26 1365 IHSKRRQDILDLWVY Cw*07:01 + 
CAP206 Nef pep32 243 QNYTPGPGRVYPLTF B*07:02 - 
CAP210 Gag pep40 2068 GPKEPFRDYVDRFFKTLR Cw*03:04 - 
Gag pool2 135 NLQGQMVHQAISPRTLNA B*15:10 + 
CAP217 Gag pep33 2190 SDIAGTTSTLQEQIAWM B*58:01 + 
Nef pep20 2618 RPMTYKAAFDLSFFL B*58:01 + 
CAP221 Nef pep26 543 IHSKRRQDILDLWVY Cw*07:01 + 
CAP222 
 
Gag pep25 1568 GATPQDLNTMLNTVGGH B*81:01 - 
Nef pep18 2838 PVRPQVPLRPMTYKA B*81:01 - 
CAP225 
 
Gag pep25 9077.5 GATPQDLNTMLNTVGGH B*81:01 - 
Nef pep17 1308 EVGFPVRPQVPLRPM B*81:01 - 
Nef pep32 2468 QNYTPGPGRVYPLTF B*42:02 - 
Nef pep41 1248 NNCLLHPMSQHGMED Unknown + 
CAP228 Gag pep23 320 AFSPEVIPMFTALSEGA A26 - 
Nef pep33 2915 PGPGVRYPLTFGWCF A*23:01*g - 
CAP229 Gag pep33 1188 SDIAGTTSTLQEQIAWM B*58:01 + 
Nef pep20 1078 RPMTYKAAFDLSFFL B*58:01 + 
CAP239 Gag pep33 380 SDIAGTTSTLQEQIAWM B*58:01 + 
CAP244 Nef pep33 5735 PGPGVRYPLTFGWCF A*23:01*g - 
CAP255 Nef pep26 4045 IHSKRRQDILDLWVY B*18:01 + 
Nef pep33 2688 PGPGVRYPLTFGWCFFKLVP 
 
B*18:01 + 
CAP257 Gag pep4 413 RLRPG-GKKHYMLKHLVWASREL B42 - 
Nef pep33 4928 PGPGVRYPLTFGWCF A*23:01*g - 
CAP258 Nef pep33 4245 PGPGVRYPLTFGWCF A*23:01*g + 
CAP260 Nef pep30 2640 TQGYPDWQNYTPGP 
 
A29 - 
CAP 261 Nef pep26 300 IHSKRRQDILDLWVY B*13 + 
CAP262 Gag pep25 1335 GATPQDLNTMLNTVGGH B*81:01 - 
Nef pep18 935 PVRPQVPLRPMTYKA B*81:01 + 
CAP264 Nef pep21 1920 YKAAFDLSFFLKEKG Cw8 - 
CAP266 Gag pep11 1220 TGTEELRSLYNTVATLY A*29 + 
Nef pep30 6778 TQGYFPDWQNYTPGP A*29 + 













Nef pep33 3065 PGPGVRYPLTFGWCF A*23:01*g - 
CAP268 Gag pep33 2523 SDIAGTTSTLQEQIAWM B*58:01 - 
Nef pep26 2898 IHSKRRQDILDLWVY Cw7 - 
Nef pep18 - PVRPQVPLRPMTYKA B*07 +/No response 
Gag pep11 - TGTEELRSLYNTVATLY A*02:05 +/No response 
Gag pool 3 - RLHPVHAGPVAPGQMREP B*07 +/No responseM 
CAP270 Nef pep20 2065 RPMTYKAAFDLSFFL B*58:01 + 
Nef pool 1 - RVIGWPAVRERMRRAR B*08:01 +/No responseM 
 +/- Sequence evolved/did not, respectively; *g Goepfert et al., 2008, JEM; MReagent sequence mismatch the 
autologous sequence   
 
 
Table 2.4 Timing, location and HLA restriction of escape mutations and IFN-gamma ELISpot data   
 
PIDa Epitopeb D. E LocationH RP Timing HLAbb 
CAP008 KRQEILDLWVY KY11 Nef (105 - 115) 2495 Acute Cw*07:01 
CAP008 GGKKQYMLK GK9 P17 (Gag 24 - 32) 2695 Acute B*08:01 
CAP030 EEVGFPVRPQV  EV11 Nef (64 - 74) 1990 Acute B*45:01*m 
CAP040 RLRPGGKKHYM  RY10 p17 (Gag 20 - 29) ND Acute B*42:01 
CAP040
** 
YVDRFFKTL YL9 p24 (Gag 296 - 304) ND Acute Cw*03:04 
CAP045 EEVGFPVRPQV  EV11 Nef (64 - 74) 863 Acute B*45:01*m 
CAP063 EEVGFPVRPQV  EV11 Nef (64 - 74) ND Acute B*45:01*m 
CAP063 SLYNTVATL SL9 p17(Gag 77 - 85) ND Late A*02:01 
CAP085 EEVGFPVRPQV  EV11 Nef (64 - 74) NR Acute B*45:01*m 
CAP085 RSLYNTVATLY RY11 p17 (Gag 76 - 86) 420 Late A*30:02 
CAP085 KRQEILDLWVYHTQGY KY11 Nef (64 - 74) 1638 Early Cw*07:01 
CAP088 EEVGFPVRPQV  EV11 Nef (64 - 74) NR Acute B*45:01*m 
CAP088 AEAMSQANS AS9 p7p/p6 (Gag 364-372) 465 Acute B*45:01 
CAP129 KRQEILDLWVH KY11 Nef (105 - 115) 1775 Early B*18:01 
CAP129 RPQVPLRPM RM9 Nef (71 - 77) 155 Late B*81:01*m 
CAP129 FRDYVDRFFK FK10 p24 (Gag 293 - 302) NR Acute B*18:01 
CAP129 TPQDLNTML TL9 P24 (Gag 180 - 188) NR Early  B*81:01 
CAP174 KRRDILDLWVY KY11 Nef (105 - 115) 1365 Acute Cw*07:02 
CAP174 QVPLRPMTYK QK10 Nef (73 - 82) 923 Late A*03:01  
CAP177 EEVGFPVRPQV  EV11 Nef (64 - 74) ND Acute B*45:01*m 
CAP188 RLRPGGRKHY RY10 p17 (Gag 20 - 29) ND Late A*74*r 
CAP188 SLYNTVATL SL9 p17 (Gag 77 - 85) ND Acute A*02:02 
CAP210 HQAISPRTL HL9 p24 (Gag 144 - 152) 135 Late  B*15:10 
CAP211 TSTLQEQIAW TW10 p24 (Gag 240 - 249) ND Acute B*57:03 
CAP211 ISPRTLNAW IW9 p24 (Gag 147 -155) ND Acute B*57:03 
CAP217 KAAFDLSFF KF9  Nef (82 - 90) 3529 Acute B*58:01 
CAP217 TSTLQEQITW TW10 p24 (Gag 240 - 249) 2190 Acute B*58:01 
CAP221 KRQEILDLWVY KY11 Nef (105 - 115) 543 
 
Late Cw*07:01 
CAP224 AAFDLSFFLK AK10 Nef (84 - 92) ND Early A*03:01  
CAP228 KRQEILDLWVY KY11 Nef (105 - 115) NR Acute  Cw*07:01 
CAP229 KAAFDLSFF  KF9  Nef (82 - 90) 1808 Early B*58:01*m 
CAP229 RSLYNTVATLY RY11 p17 (Gag 76 - 86) NR Early  B58 
CAP229 TSTLQEQIAW TW10 p24 (Gag 240 - 249) 1188 Acute B*58:01 
CAP239 TSTLQEQIAW TW10 p24 (Gag 240 - 249) 380 Acute B*58:01 
CAP248 VKVIEEKAF VF9 p24 (Gag 156 - 164) ND Late B*15:03 
CAP255 KRQEILDLWVH KY11 Nef (105 - 115) 4045 Early B*18:01 
CAP255
** 
VRYPLTFGWCY YY9 Nef (135–143) 2688 
 
Acute B*18:01 
CAP258 RYPLTFGW RW8 (Nef 134 – 141) 4245 
 
Early A*23:01 













CAP262 RPQVPLRPM RM9 Nef (71 - 77) 935 Early B*81:01*m 
CAP265
** 
TPGPGVRYPL TL10 Nef (128 - 137) ND Acute  B*42:01 
CAP266 YFPDWQNYT YT9 Nef (120 - 128) 6778 
 
Acute A29 
CAP266 LYNTVATL LL8 p17 (Gag 78 - 85) 1220 
 
Acute A29 
CAP268 RPQVPLRPM RM9 Nef (71 - 77) NR Early B*07*r 
CAP268 SLYNTVATL SL9 p17 (Gag 77 - 85) NR Acute A*02:05 
CAP268 HPVHAGPIA HA9 p24 (Gag 216 -224) NR Late B*07 
CAP269 RPQVPLRPM RM9 Nef (71 - 77) ND Acute B*07:02 
CAP269 SPRTLNAWV SV9 p24 (Gag 148 - 156) ND Acute B*07:02 
CAP270 WPTVRERM WM8 Nef (13 -20) NR Acute 
Late 
B*08:01 





CAP274 KAAFDLSFF KF9  Nef (82 - 90) ND t  B*58:01 
CAP274 TSTLQEQIAW TW10 p24 (Gag 240 - 249) ND Acute B*58:01 
CAP275 RLRPGGKKHY RY10 p17 (Gag 20 - 29) ND Acute B*42:01*m 
CAP277 TPQDLNTML TL9 p24 (Gag 180 -188) ND Late B*81:01 
CAP278 RPQVPLRPM RM9 Nef (71 - 77) ND Late B*39:10 
CAP278
** 
TPQDLNTML TL9 p24 (Gag 180 -188) ND Acute B*39:10 
CAP282 TPQDLNTML TL9 p24 (Gag 180 -188) ND Late B*42:01 
CAP289 TPQDLNTML TL9 p24 (Gag 180 -188) ND Early B*39:10 
  aParticipant identification; bEscape residue in each epitope underlined; Defined epitope (D. E) bbAssociated 
HLA; HDefined epitope with residues based on HXB2 sequences in brackets; RPeak responses (SFU/106 
PBMC); **Escape sequence is present at enrolment (CAP040 – 3 weeks (Wks); CAP255 – 8 Weeks; CAP265 – 
12 Wks; CAP 278 – 9 Wks post-infection); *g Goepfert et al., 2008; *r Rousseau et al., 2008; *m Matthews et 





Table 2.5 Participants with viral escape in Gag and Nef in the first 12 month of infection 
Location Number of individuals with viral escape % 
p17 6 12.0 
p24 12 24.0 
p17+24 3 5.9 
P7p6 1 2.0 
Nef 24 47.1 
Gag+Nef 11 22.0 
 
 
2.2.5 Escape occurs more frequently in the acute/early than in the late phase of 
         infection 
 
Timing of CTL escape was followed up in order to estimate the frequency and pattern of 
escape in the first year of infection. CTL escape mutations were classified according to the 
infection phase of their occurrence as either acute (< 3 months), early (> 3 to ≤ 6 months) or 














The frequency of escape in acute infection was higher than in early infection: out of the 58 
epitopes identified as having putative CTL escape mutations, 34 (59.0%) were identified in 
acute infection, a further 11 evolved in early infection, while 13 evolved in the late phase of 
infection (Table 2.6).  
 
 
Table 2.6 Timing and number of epitopes developing CTL escape mutations in Gag and Nef in the first  
                    12 months post infection 
 
Location Gag Nef  Total 
Acute 17  17 34 
Early  3 8 11 
Late 5 8 13 
Total  25 33 58 
 
Within the first 12 months, the rate of escape was significantly higher in acute when 
compared to the early/late infection-phases (Figure 2.5; 3.8 versus 1.1 escape/month; 
p=0.0231). Furthermore, when corrected for amino acid length and in individuals escaping per 
month, nef escape was more frequent than gag escape although this was not statistically 
significant (Figure 2.5; 2.7 versus 1.1 escapes/month/100 amino acids; p>0.1824). Taken 
together, the high frequency of escape in acute compared to early/late infection suggests that 
CTLs exert considerable pressure on the virus driving early viral diversification during the 
first year of the infection.  
 
The median time to escape in Gag (estimated as a mid-point between the last sequenced time 
point and the timing of the first observation of the escape mutation) was 12 weeks (IQR: 8 – 
33), while it was 10.5 weeks in Nef (IQR: 8.3 – 17) weeks post infections. In the Gag, 
however, while escape/escape intermediate mutations were generally observed between 8 and 
12 weeks post infection in the majority, in some individuals like the B*5801/B*5703-positive 
participants in this study, it was observed as early as 2 weeks (14 days) post-infection. This 
was contrary to escape in the B7 immunodominant TL9 epitope, where escape was generally 
observed later (about 10 months post-infection). These issues will be examined in details in 




























































Figure 2.5 Frequency of escape in Gag and Nef proteins in the first year of HIV-1 subtype C infection 
 
 
2.2.6 Impact of CTL escape on disease progression 
 
2.2.6.1 Acute/early CTL escape associates with higher CD4+ T-cell counts   
 
To determine the impact of CTL escape on disease progression, markers of disease 
progression including viral loads and CD4+ T-cell counts at 3, 6 and 12 months post-infection 
were first compared between individuals with viruses developing at least one escape in either 
Gag or Nef to those individuals where there was no evidence of escape. To explore the effect 
of the timing of escape on disease progression, we stratified participants according to timing 
of escape and compared viral loads and CD4+ T cell counts at different time-points (3, 6 and 
12 months post-infection).  
 
Although the median viral loads were similar between individuals with and without viral 
escape (Table 2.7A), participants infected with viruses that evolved acute and early escape 
had significantly higher CD4+ T-cell counts at 3 and 6 months post-infection (Table 2.7B; 
p=0.0018 and 0.0542 respectively) suggesting at least in acute and early infection that escape 













infection when all individuals with any evidence of viral escape were compared to individuals 
where the virus never escaped.  
 






Median   (IQR) 
Escape 
Median   (IQR) 
     p-
value 
3 Months 4.60 (3.84 – 5.19) 
[n=27] 
4.54 (4.01 – 4.86 
[n=24] 
0.685 
6 Months 4.37 (4.02 – 5.10) 
[n=24] 
4.40 (3.51 – 4.95) 
[n=27] 
0.485 
12 Monthsa 4.29 (3.30 – 4.87) 
[n=16] 








Median   (IQR) 
Escape 
Median   (IQR) 
p-
value 
3 Months 461 (330 - 548) 
[n=27] 
604 (478 - 735) 
[n=24] 
0.0018 
6 Months 415 (330 - 522) 
[n=24] 
522 (389 - 624) 
[n=27] 
0.0542 
12 Monthsa 367 (303 - 624) 
[n=16] 
474 (348 - 569) 
[n=35] 
0.7155 
A) Medians with Interquartile range (IQR) of Log10 viral load consecutively compared at 3, 6 and 12 months 
post-infection between individuals without and with viral escape; B) Median CD4+ T-cell counts and 
Interquartile range (IQR) consecutively compared at 3, 6 and 12 months post-infection between individuals 
without and with viral escape; a the analysis at 12 months post-infection constitute individuals whose viruses 
escape in acute, early and late infection 
 
 
2.2.6.2 Rates of loss of viral load and CD4+ T-cell counts in individuals with and 
            without viral escape  
 
To further investigate the overall effect of escape on markers of disease progression, linear 
mixed models, adjusting for repeated measurements for every participant, were fitted to viral 













post-infection time periods were separately analyzed in order to assess the effect of acute CTL 
escape on viral load and CD4+ count and their changes over time. Viral load was log-
transformed to ensure normality and adjusted for time post infection, CD4+ counts (in the 
viral load model) and viral load (in the CD4 counts model).  
 
There was no significant difference in the rate of change or reduction in viral load between 
participants infected with viruses that escaped CTL responses in either the 0 to 3 or the >3 to 
12 months post infection when compared to participants without viral escape in 12 months 
post-infection in Gag and/or Nef (Table 2.8A; p=0.6029 and p=0.4391, respectively; Figure 
2.6A). Furthermore, there was no significant difference in the overall mean viral load between 
participants infected with viruses that escaped CTL responses in either the 0 to 3  or the >3 to 
12 months when compared with participants without viral escape at 12 months post infection 
(Table 2.8B; p=0.7422 and p=0.8491, respectively). 
 
However, the rate of change of CD4+ T-cell counts in participants infected with viruses that 
escaped CTL responses differed between the two groups (Table 2.8C; p=0.0439; Figure 
2.6B). In the escape group, CD4+ T-cell counts in the first three (0 to 3) months post-infection 
increased at a rate of approximately 37 cells/µl per month, while they were decreasing at a 
rate of 16 cells/µl per month for those with no viral escape. Moreover, although this trend was 
not sustained after acute infection where there was a similar rate of CD4+ decline between 
individuals with and without viral escape in early and late (>3 to 12 months) infection periods 
(p=0.9977), the overall mean CD4+ T-cell counts between participants infected with viruses 
that escaped CTL responses in either the 0 to 3  or the >3 to 12 months were significantly 
different when compared to that of participants without viral escape at 12 months post 
infection (Table 2.8D; p=0.0117 and p=0.0274, respectively).  
These results highlight the importance of the CTL responses that associate with selection of 














Table 2.8 Contemporaneous benefit of acute escape in Gag and/Nef on subsequent disease 















Log10 VL (copies/ml/month 
Rate 
Log10 VL (copies/ml/month 
p-value 
0 -3 months PI 0.16 (SE=0.08) -0.21 (SE=0.09) 0.6029 
>3 to 12 months PI -0.03 (SE=0.01) -0.04 (SE=0.01) 0.4391 
B Mean 
Log10 VL (copies/ml) 
Mean 
Log10 VL (copies/ml) 
 
0 -3 months PI 4.57 (SE=0.17) 4.66 (SE=0.21) 0.7422 




















0 -3 months PI 36.65 (SE=17.43) -16.16 (SE=19.78) 0.0439 
>3 to 12 months PI -6.55 (SE=2.10) -6.54 (SE=2.52) 0.9977 
D Mean (cells/μl) Mean (cells/μl)  
0 -3 months PI 627 (SE=35.75) 478 (SE=43.84) 0.0117 
>3 to 12 months PI 583 (SE=34.03) 460 (SE=41.67) 0.0274 
  
A) Rates of change in viral load (VL); B) The overall mean VL in each time period estimated using the model; 
C) Rates of change in CD4+ T cell counts; D) The overall mean CD4+ T cell counts in each time period 
estimated using the model; Negative (-)/positive (+) signifies decrease/increase of CD4+ T cell counts, 
respectively; PI: post infection; SE: standard error.  
 
 
       A                                                                     B 
   
Figure 2.6 Rate of loss of/reduction in viral load (A) and CD4+ T-cell counts (B) compared in individuals with 















2.2.6.3 Transient correlations of CTL escape in Gag/Gag-Nef with higher CD4+ 
            counts but not with viral load 
 
To determine what CTL responses were impacting on disease progression, viral load and 
CD4+ T-cell counts in participants with and without viral escape in Gag or Nef epitopes were 
separately compared.   
 
There were no significant associations in viral load between individuals with and without viral 
escape in Gag or Nef either at 3, 6 or 12 month post-infection (Figures 2.7A, C, and D). 
However, when compared to those that did not escape, participants infected with viruses that 
developed mutations in Gag had a trend towards higher CD4+ T-cell counts, while those with 
viral escape in both Gag and Nef had significantly higher CD4+ T-cell counts at 3 months 
post-infection (Figure 2.7 B; p=0.0983 and 0.0248, respectively). Although these results were 
not sustained at 12 months post-infection, there was still a trend for higher CD4+ T cell 
counts at 6 months post-infection for participants with viral escape in both Gag and Nef 
(p=0.068), (Figure 2.7 C and F). These results suggest that escape in both Gag and Nef 




























































































































Figure 2.7: Impact of viral escape on markers of disease progression. Figures A, C and E:  Log10 viral load 3, 6 
and 12 months post-infection compared between individuals with and without viral escape in Gag, Nef and both 
Gag-Nef. Figures B, D and F:  CD4+ T-cell counts at 3, 6 and 12 months post-infection compared between 

















2.2.6.4 HLA-B alleles drive early sequence evolution in HIV-1 infection 
 
HLAs differentially contribute to the total HIV-1-specific CTL response with HLA-B-
restricted CTL responses making a stronger contribution and exerting a greater selection 
pressure compared to HLA-A restricted responses (Kiepiela et al., 2004; Altfeld et al., 2006 
Brumme et al., 2008).  
 
Of the 50 Gag and/or Nef reactive peptides identified in the 28 participants with IFN-γ 
production data available, 52% (26/50) were restricted by HLA-B, while 28% (14/50), 14% 
(7/50) and 6% (3/50) were restricted by HLA-A, HLA-Cw and unknown-HLAs, respectively 
(Table 2.3). To determine if differential contribution of HLA-associated polymorphisms could 
be detected in primary infection in this cohort, HLA mediated sequence evolution in epitopes 
in the first 12 months of infection were analyzed.   
 
Of the 28 escape mutations identified in Gag, five, 21 and two were in epitopes restricted by 
HLA-A, HLA-B and HLA-Cw respectively; and of the 30 escape mutations in Nef, 22 were 
located in epitopes restricted by HLA-B, whereas three and five were in epitopes restricted by 
HLA-A and HLA-Cw respectively (Table 2.9).  
 
Table 2.9 Differential contribution of HLAs to mutation-selection in Gag and Nef in the first 12 months of  
              HIV-1 subtype C infection   
 
  
Location HLA-A HLA-B HLA-C 
Gag 5 21 2 
Nef 5 21 4 
Total  10 42 6 
 
The contribution of different HLAs to the number of mutations selected did not significantly 
differ between gag and nef genes (p=0.1922). However, there was a significantly higher 
contribution to the number of mutations selected by HLA-B when compared to other HLAs 













p=0.0134). Overall, HLA differences accounted for 77.04% of the total variance in the 
number of mutations selected in the first year of infection.   
Next, the differential HLA bias towards selecting mutations in different parts of Gag was 
determined since response to this protein is associated with better HIV infection control 
outcome (Kiepiela et al., 2007; Rolland et al., 2008). There was generally no HLA-bias 
towards selection of mutations in p17; however, 94% (16/17) of the epitopes that evolved 
sequences in p24 were HLA-B restricted (Table 2.10). 
  
Table 2.10 Contribution of HLAs to mutation-selection in the different Gag proteins in the 
first 12 
                 months of HIV subtype C infection   
 
Location HLA-A HLA-B HLA-C Total 
p17 5 4 1 10 
p24 0 16 1 17 
p2p7p1p6 0 1 0 1 
Total 5 21 2 28 
 
Studies on South African HIV subtype C infection have found that HLA-B*57/58:01 and 
HLA-B*39:10/81:01 are beneficial, while HLA B*18/08:01 and B*58:02 are deleterious 
(Kiepiela et al., 2004; Leslie et al., 2010). Of the 16 evolving epitopes in p24 that were HLA-
B-mediated, 10 (63%) were driven by these beneficial HLA-B alleles. Participants positive for 
HLA-B*57/58:01 were more likely than others to evolve sequences in acute infection, while 
HLA-B*39:10/81:01-positive participants were more likely to evolve sequences in the B7 
immunodominant TL9 epitope in late/after 6 months of infection (5/7). Escape in the B*58:01 
predominantly occurred in the immunodominant TW10 epitope in p24 in acute/the first 3 
months post-infection, while it occurred in both ISW9 and TW10 in the B*57:03. In the seven 
B*39:10/81:01-positive participants, four evolved late TL9 escape mutations (CAP129, 
CAP225, CAP277 and CAP289). The role of B*81:01 in controlling viral replication will be 
presented in detail in Chapter 3. 
 
HLA-B mediated sequence evolution in nef epitopes was also common (Table 2.9): of the 21 













HLA-B alleles, while 10 (47.6%) were mediated by deleterious HLA B*18/08:01. The 
remaining four (19.1%) were mediated by HLA-B*45:01/42:01/07:02. HLA-mediated 
evolution in Nef was most likely to occur in the B*45:01 restricted EV11 epitope than in any 
other epitope, as all the six participants positive for this allele evolved sequence in acute 
infection.   
 
Overall these results suggest that the association of HLA-B with stronger selection pressure in 
Gag p24 is driven by beneficial HLA alleles and contribute to our understanding as to why 
HLA-B alleles are associated with better infection outcome in the Gag. These results also 
support reports demonstrating a greater selection pressure by HLA-B compared to other HLA 
class 1 alleles (Kiepiela et al., 2004).  
 
2.2.6.5 HLA-B restricted CTL escape in Nef and Gag associate with modestly higher  
         CD4+T-cell counts at 12 months post-infection 
 
Studies reporting the dominant role of HLA-B were done in chronic infection, which may be 
enriched with participants controlling the infection (Kiepiela et al., 2004). The impact of 
HLA-B associated mutations selected in the first year of infection was determined in this 
thesis. Participants additionally selecting mutations with other HLA types other than HLA-B 
(n=5) were excluded in this analysis in order to better refine the role of HLA-B although 
results of this analysis w re not affected when participants that selected mutations with both 
other HLAs and HLA-B were included.  
 
There was no evidence (either in Gag or Nef) to support an association of HLA-B restricted 
escape with viral load at 12 months post infection (Figure 2.8A).  However, there were trends 
for higher CD4+ cell counts for participants with HLA-B restricted escape in both Gag and 
Nef, and for participants with HLA-B restricted escape in both Gag and Nef (Figure 2.8B, 
p=0.076 and 0.08 respectively).   
 
Furthermore, there were no detectable differences in viral load between participants infected 













not (Figure 2.8C). There was however, a trend towards higher CD4+T-cell counts for 
individuals infected with virus that developed escape mutations in p24 at one year post-
infection (Figure 2.8D p=0.2; medians: 500 cells/µl [IQR = 481 – 646] versus 368 cells/µl 
[IQR = 301 – 606]) although this was not significant. 
 











































































































































Figure 2.8: Impact of HLA-B restricted viral escape on markers of disease progression in primary infection. 
Figures A and B: Log10 viral load and CD4+ T-cell counts compared between individuals without escape (n=16) 
and with HLA-B restricted viral escape in Gag, Nef or both. Figures C and D: Log10 viral load and CD4+ T-cell 
counts compared between individuals without and with viral escape in p17, p24 or both -  Individuals with both 



















2.2.6.6 Association of high CD4+ T-cell counts with acute escape is driven by HLA-B 
 
To better understand how escape effected disease progression in the 51 participants with 
single infection in this study, two groups were compared: those with high CD4+ T-cell counts 
(≥ 500 cells/μl at 12 months post infection (n=20)] and those with low CD4+ T-cell counts (< 
350 cells/μl at 12 months post infection (n=16). Fifteen individuals with intermediate CD4+ 
T-cell counts (<500>350 cells/μl) at 12 months post infection were excluded from this 
analysis. Of the 20 with high CD4+ T-cell counts, 14 (70%) were infected with viruses that 
escaped CTL responses in Gag and/or Nef, of which 12 (86%) had acute viral escape, while of 
the 16 individuals with low CD4+ T-cell counts, 8 (50%) were infected with viruses that 
evolved CTL escape mutations in Gag and/or Nef.   
 
In thirteen of the 14 participants with the high CD4+ T cell counts (13/14) group, viral escape 
was restricted by HLA-B alleles, which included 11/12 (92%) participants harbouring viruses 
that evolved acute CTL escape mutations. These included: in Nef, EV11 epitope restricted by 
B*45:01(CAP030; CAP045; CAP085 & CAP088); RM9 restricted by B*07:02/39:10/42:01 
(CAP269, CAP278 & CAP129) and TL10 restricted by B*42:01 (CAP265); and in Gag, 
RY10 (p17) epitope restricted by B*42:01 (CAP275); TL9 (p24) restricted by B*39:10 & 
81:01 (CAP278 & CAP129); SV9 (p24) restricted by B*07:02 (CAP269) and TW10 (p24) 
restricted by B*58:01(CAP229 &CAP239) (Table 2.4).  
 
Interestingly, the EV11 and the RM9 epitopes that overlap each other and restricted by the 
B*45:01 and B7 alleles, respectively contain residues that mediate Nef down regulation of 
MHC and CD4 (Hung et al., 2007), while the RY10 epitope contains the p17 functional basic 























The identification of CTL escape through monitoring sequence evolution associated with the 
individuals’ HLAs provides a sensitive tool to evaluate host immune pressure (Moore et al., 
2002; Brumme et al., 2007; Wang et al., 2009). In this study, viral evolution was monitored in 
58 individuals from close to infection and at least one year post infection. We confirmed the 
identification of four individuals who were co-infected with two strains at the earliest time-
point, and furthermore identified three individuals who were superinfected within the first 
year. These 7 individuals were excluded from further analysis due to difficulties in predicting 
mutations associated with immune escape in individuals with dual infection. This chapter 
reports on viral escape in Nef and Gag in the 51 participants with single infection. 
 
Here, the epitopes were predicted using the well defined list of optimal epitopes (Frahm, 
Linde and Brander, www.hiv.lanl.gov; Llano et al., 2009), and HLA-associated residues that 
were previously identified in published epitopes using a large clade C South African cohort 
(Rousseau et al. 2008; Goepfert et al., 2008; Matthews et al., 2008). These predictions were 
supported by the fact that individuals’ HLA-restricted known epitopes could be mapped out in 
94% of all the positive peptides used in IFN-γ ELISpost assay, and also as the majority of 
participants (64.3%) in this study with predicted escape had concomitant loss/reduction in 
IFN-γ response support the approach used in this study. The detection of viral escape in the 
absence of detectable IFN-γ ELISpot responses could be due to a mismatch in peptides 
reagent and the infecting virus; missed responses due to fluctuation in cellular immune 
responses (Mlotshwa et al., 2010);  or  single cytokine IFN-γ ELISpot assay is not detecting 
all T-cell responses (Boulet et al., 2007).  
 
Despite the increasing breadth and magnitude of responses in the first year of infection (Gray 
et al., 2009a), escape was more frequent in acute when compared to chronic infection. CTL 
responses are crucial to the initial control of viremia in acute infection (Borrow et al., 1994; 
Freel et al., 2012; Goonetilleke et al., 2009; Henn et al., 2012; Kim et al., 2010; Koup et al., 
1994), and here we demonstrate that these early focused responses are a major driver of early 













acute infection was driven by the higher viral loads (increased viral replication), which allow 
increased rates of viral evolution and CTL escape (Mudd et al., 2012), and this together with 
functionally avid CTL responses in acute infection (O'Connor et al., 2002) may both be 
contributing to these rapid evolution of CTL epitopes.      
 
Alleles associated with slow disease progression contribute strongly to the initial CTL 
response to HIV-infection (Altfeld et al., 2006; Wang et al., 2009) and select mutations in 
conserved regions, mainly Gag p24 (Borgans et al., 2007; Kiepiela et al., 2007; Streeck et al., 
2007). Furthermore, HLA-B is more commonly associated with control and has greater 
selective pressure than others (Kiepiela et al., 2004; Leslie et al., 2010; Carson et al., 2012). 
This study has further documented that 72.4% of  the number of mutations selected in the first 
year of infection was attributed to HLA-B alone, with 43% (6/14) of individuals having high 
CD4+ T-cell counts (≥ 500 cell/µl) harbouring viruses with  mutations located in p24 and 
selected by beneficial HLA-B alleles. The result showing that HLA-B and in particular 
beneficial HLAs are biased towards selecting mutations in the conserved p24 strongly 
contribute to our understanding why studies have consistently associated HLA-B with 
reduced HIV-1 infection severity.   
 
This data augment previous finding of Kiepiela et al. (2004), who demonstrated that HLA-B 
was associated with control of viral loads. Together with later findings in the same cohort, it 
was suggested that most of the epitopes associated with viral control were those restricted by 
beneficial HLAs that targeted or selected mutations in the conserved p24 Gag (Kiepiela et al., 
2004; Kiepiela et al., 2007). Other studies have shown that beneficial HLAs associated with 
control select mutations with a fitness cost to the virus (Martinez-Picado et al., 2006; Rolland 
et al., 2010; Schneidewind et al., 2008; Schneidewind et al., 2007; Wright et al., 2010; 
Wright et al., 2012). These mutations are in epitopes like ISW9, TW10 and TL9 restricted by 
beneficial HLAs like the B*57/B*58:01 and HLA-B*81:01/39:10 (Kiepiela et al., 2004; 
Leslie et al., 2010), which will be investigated in details in Chapter 3 and 4.  
 
Nonetheless, a previous study in this cohort found that loss of CTL responses was more 













determine the proportions of viral escape explored in this study that result in complete 
abrogation of immune recognition. In this thesis, there was a CD4+ T cells benefit of escape 
particularly in early infection. However, analysis of viral load trajectory over time showed 
that there was no difference in viral loads between individuals with virus escaping in acute 
infection and those that did not in the first 12 months post-infection in Gag and/Nef. Some 
studies have suggested that the inability of CTLs to resolve viremia during chronic infection 
may be due to the loss of the most potent and effective CTL specificities during the first 
weeks of infection (O'Connor et al., 2002). The initial benefit to the host due to loss of viral 
fitness may be lost through the development of compensatory mutations that restore the viral 
replicative fitness (Brockman et al., 2010; Crawford et al., 2009); these issues will be 
addressed in more detail in chapter 3 and 4.  
 
In conclusion, correlating sequence evolution in CTL epitopes with markers of disease 
progression is inherently complicated by the large HLA diversity of the population and while 
viral evolution is intrinsic to understanding the role of different HLAs, this is only one 
property that may be affecting the host’s ability to control viral replication. This study has 
documented that the major driving force of sequence diversity in Gag and Nef in acute 
infection is the HLA, with HLA-B driving acute than early/late sequence evolution in these 
phases of the HIV-1 infection and more than any other HLAs. Furthermore, the study has 
shown that in Gag, HLA-B preferentially select mutations in p24. Moreover, participants with 
acute viral escape have significantly higher CD4+ T-cell counts than in participants without 
viral escape in the first year of the infection suggesting that viral escape provides some benefit 
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HLA-B*81:01 and B*39:10 alleles have been associated with viremic control in HIV-1 
subtype C infection. Both alleles restrict the TL9 epitope in p24 Gag and cytotoxic T-
lymphocyte (CTL) mediated escape mutations in this epitope have been associated with an in 
vitro fitness cost to the virus. In this study, the timing and impact of mutations in the TL9 
epitope on disease progression in five B*81:01- and two B*39:10-positive subtype C infected 
individuals were investigated.  
 
Whereas both B*39:10 participants sampled at two months post-infection had viruses with 
mutations in the TL9 epitope, in three of the five (3/5) B*81:01 participants, TL9 escape 
mutations were only detected 10 months after infection, taking an additional 10 to 15 month 
to reach fixation. In the two remaining B*81:01  individuals, one carried a TL9 escape variant 
at 2 weeks post-infection, whereas no escape mutations were detected in the virus from the 
other participant up to 33 months post-infection, despite CTL targeting of the epitope. In all 
participants, escape mutations in TL9 were linked to co-evolving residues in the region of 
Gag known to be associated with host tropism. Late escape in TL9, together with co-evolution 
of putative compensatory mutations, coincided with spontaneous increase in viral loads in two 
individuals who were otherwise controlling infection.  
 
These results provide in vivo evidence of the detrimental impact of B*81:01 mediated viral 






















3.1 Introduction  
 
Genome-wide association studies (GWAS) have shown that the major determinant of HIV 
disease progression is the human leukocyte antigen or HLA class I (Fellay et al., 2007; 
Pereyra et al., 2010). However, not all individuals carrying beneficial HLAs progress slowly 
to AIDs defining diseases (Emu et al., 2008). Understanding the relationship between the 
virus and the host, and how HLA differentially influences disease progression, remains a 
central question in HIV research and optimal vaccine immunogen design (McMichael and 
McCutchan, 2010).   
 
CTL responses targeting p24 Gag have been associated with long-term control of HIV-1 
replication (Berger et al., 2011; Borghans et al., 2007; Kiepiela et al., 2007). Indeed, HLA 
alleles associated with control of HIV-1 replication preferentially present p24 Gag epitopes 
(Borghans et al., 2007) in acute infection (Wang et al., 2009). Apart from HLA B*57/58:01, 
there is limited information on the impact of CTL immune escape in individuals controlling 
infection in African cohorts, which may differ from Caucasian cohorts due to differences in 
HLA allelic frequency.  
 
HLA B-7 supertype is very common in Black Africans compared to Caucasians (Gonzalez-
Galarza et al., 2011; Goulder et al., 2000). The HLA-B7 supertype includes HLA-B*07:02, 
HLA-B*39:10, HLA-B*42:01, HLA-B*42:02 and HLA-B*81:01 (Leslie et al., 2006), and 
within this supertype, only HLA-B*81:01 and B*39:10 alleles are consistently associated with 
control of HIV-1 in subtype C chronic infection (Leslie et al., 2010) although all these alleles 
present the immunodominant TL9 (Gag 180 – 188) epitope in p24 (Leslie et al., 2006). 
Moreover, the magnitude of B*81:01 and B*39:10 restricted TL9-specific responses (Leslie et 
al., 2006), and the corresponding polymorphisms in this epitope are significantly higher than 
in B*42:01 restriction suggesting a stronger selective pressure by B*81:01 and B*39:10 
(Geldmacher et al., 2009; Leslie et al., 2006). This difference in recognition and selection 
pressure may be due to differences in HLA specificity (Leslie et al., 2006) that may be caused 














Mutations in residues E177, Q182 and T186, located in or proximal to the TL9 epitope, have 
been associated with immune escape in the B*81:01, B*42:01 and B*39:10 positive 
individuals (Leslie et al., 2006). In vitro studies have shown that the E177D/A and T186S 
mutations incur a fitness cost to the virus (Rolland et al., 2010; von Schwedler et al., 2003; 
Wright et al., 2010), while the Q182S mutation reverts after transmission to HLA-mismatched 
individuals suggesting it is not beneficial to the virus (Matthews et al., 2008).  
 
In this study, a detailed analysis of individuals with alleles belonging to the HLA-B7 
supertype recruited during acute/early infection and followed for three years is presented. The 
timing and frequency of escape in TL9 epitope are reported, and the impact of escape on 
disease progression in HLA-B*81:01 and HLA-B*39:10 positive HIV-1 subtype C infected 
































3.2 Materials and Methods 
 
3.2.1 Study subjects 
 
Samples used in this study were from participants of the CAPRISA 002 acute infection cohort 
(van Loggerenberg et al., 2008), described in details in chapter 2.2.1 of this thesis.  
 
3.2.2 HIV-1 Plasma RNA isolation and Sequencing  
 
As described in chapter 2.2.2, cDNA was synthesized from RNA and viral sequencing was 
done directly on PCR products or was cloned in pGem-T Easy vector according to the 
manufacturer’s instructions (Promega, USA). Where only p24 gag sequences were generated, 
the sequencing primers were only the Gag B forward and Gag B reverse.  
 
3.2.3 IFN-γ ELISPOT assay 
 
This data was provided by C. Gray, UCT and described in detail in chapter 2.2.5.  
 
3.2.4 HLA typing  
 
HLA data was provided by C. Gray, NICD, which was a high resolution (four digits) typing 
and performed as described in chapter 2.2.6  
 
3.2.5 Statistical analyses  
 
Statistical analysis and graphical presentations were implemented in GraphPad Prism 5.0 
(GraphPad Software, Inc.). To control for fluctuations in viral loads and CD4 counts, the 12 
month and 36 month set points of these parameters were calculated by taking the median of 
measurements at 3 time-points closest to 12 and 36 months, respectively. Statistical analysis 
of significance was based on Mann-Whitney two-tailed t test. To identify networks of 













models in Spidermonkey (Poon et al., 2008) were used (available at www.datamonkey.org). 
Repeated inference with ancestral states sampled from the posterior distribution were used to 
evaluate robustness (Delport et al., 2010) in identifying networks of interacting sites in an 
alignment using Bayesian network techniques, which assumes that co-evolving sites will tend 
to acquire mutations along the same set of branches (Poon et al., 2008).  
 
3.3 Results  
 
Of the 62 women recruited into the CAPRISA 002 acute infection study, five were HLA-
B*81:01-positive, and two were B*39:10-positive (Table 3.1). To evaluate gag evolution and 
the timing of escape in the B*81:01 and B*39:10 restricted TL9 epitope, sequencing was 
performed on samples collected at the earliest time-point and every three months post 
infection until 3 years or initiation of antiretroviral (ARV) therapy according to national 
guidelines (Chapter 2.2.1). Samples from additional time-points were sequenced to further 
refine timing of escape.   
 
Table 3.1 HLA Type 1 for the five B*81:01 and two B*39:10 individuals in this study (data 
                 provided by C. Gray, UCT) 
 
   
                                 PIDa                          Allele pair 
                        
                      HLA - A             HLA - B               HLA - C 
 
CAP0129      26:01, 80:01        18:01, 81:01      02:02, 04:01 
CAP0222      30:01, 33:03        53:01, 81:01      04:01, 04:01 
CAP0225      01:01, 30:01        42:02, 81:01      17:01, 18:01 
CAP0262      01:01, 66:02        42:01, 81:01      17:01, 18:01 
CAP0277      30:09, 43:01        58:02, 81:01      04:01, 04:01 
CAP0278      30:01, 43:01        39:10, 42:02      12:03, 17:01 
CAP0289      30:02, 68:01        39:10, 58:02      06:02, 12:03 
 


















3.3.1 The influence of HLA-B*81:01 and B*39:10 on early and chronic disease 
         progression   
 
The trajectory of viral loads and CD4+ T-cell counts over a three-year post-infection period 
was analyzed in order to understand disease progression in HLA-B*81:01/B*39:10 positive  
participants (Figure 3.1). Two of the B*81:01 (CAP129 and CAP225) were typical 
progressors with viral load set-points ranging from 80,100 to 21,500 copies/ml. Furthermore, 
one B*39:10-positive participant (CAP289) maintained high viral loads from the first year of 
infection (>500,000 copies/ml). There were two controllers with viral loads below 2,000 
copies/ml, one B*39:10-positive participant (CAP278) who controlled viral loads from the 
start of infection, and one B*81:01 positive participant (CAP262) who only controlled her 
viral load after 18 months of infection. Conversely, two B*81:01-positive participants who 
controlled viral replication below 2,000 copies/ml for the first 18-24 months of infection had 
viral loads that  increased by one log over a 6 month period and thereafter (CAP222 and 
CAP277). CD4+ T cell counts were relatively stable except in three participants who had 
declining CD4+ T cell counts: the one B*39:10-positive participant (CAP289) who had high 
viral loads; and the two B*81:10-positive participants (CAP222 and CAP277) who had 

























































Figure 3.1 Figure 1: (A) Viral load and (B) CD4+ T cell count trajectories for the first 48 months of infection for 
the five HLA-B*81:01-positive participants (CAP129, CAP222, CAP225, CAP262 and CAP277; represented by 
squares) and two B*39:10-positive participants (CAP278 and CAP289; represented by triangles). CAP289 had 
not reached 48 months postinfection by the time of this study. The trajectory of median viral loads and median 
CD4+ T-cell count of all other CAPRISA participants (OTHERS) excluding the B*39:10/81:01 and B*57/58:01 
are shown as dotted red lines. The broken black line is viral load level 2,000 copies/mL, defining controllers. 
Viral loads and CD4+ T-cell counts were smoothed at each time point (medians of measurements taken at three 
time-points closest to intervals 3, 6, 9, 12, 15, etc up to 48 months post-infection).  
 
 
The influence of HLA-B*81:01 and B*39:10 on viral load set-point and CD4+ T-cell counts 













analyzed separately as these “protective” alleles are often associated with better control of 
HIV-1 replication (Migueles et al., 2000; Miura et al., 2009).  
 
There was a trend for lower viral load in B*81:01-positive participants when compared to 
those with non-protective alleles (i.e. B*81:01/57/58:01/39:10 negative participants) at set-
point (12 months post-infection) although this was not significant (p = 0.2) (Figure 3.2A; 
median 3.57 log10 copies/ml [IQR = 2.7 – 4.6] versus 4.46 log10 copies/ml [IQR = 3.49 – 
4.8]). There were however, significantly higher CD4+ T-cell counts for the B*81:01 positive 
participants compared to individuals with non-protective alleles at one year post-infection 
(p=0.049) (Figure 3.2B; median 597 cell/ul [IQR = 467 – 644] versus 369 cell/ul [IQR = 305 
– 525]). To determine whether these HLA alleles affected disease progression in chronic 
infection, both viral loads and CD4+ T-cell counts at 3 years p st-infection were analyzed. By 
three years post-infection, 12 participants had initiated ARV therapy and to not bias the 
analysis towards controllers, the last available viral load and CD4 count data on these subjects 
prior to commencing ARV therapy was used. There was no significant difference in either 
viral load or CD4+ T-cell counts at 36 month post-infection in B*81:01 positive participants 
compared to those with non-protective alleles suggesting that this potential benefit detected at 
12 months was not sustained in chronic infection. 
 
Whether B*81:01 positive participants controlled infection better than B*57/58:01 positive 
participants was also investigated. Although the CD4+ T-cell counts tended to be higher and 
viral loads lower in B*81:01 positive, when compared to B*57/58:01-positive participants at 
12 months, this difference was not significant, and this trend was not sustained at 36 months 
(Figure 3.2 C and D).   
 
Of the two B*39:10-positive participants, one was a controller (CAP278), whereas the other 
was a typical disease progressor (CAP289) (Figure 3.1). The controller had a viral load at 12 
months of 2.95 log10 copies/ml compared to 5.72 log10 copies/ml for the progressor, while 






















































Figure 3.2 Association between viral load (VL) and CD4+ T cell counts prognostic markers and HLA-B*81:01 
and B*39:10 alleles at 12 and 36 months post-infection.  (A and C) Log10 VL compared between individuals 
without and with HLA-B*81:01, B*39:10 or B*57:03/58:01 alleles at 12 and 36 months post infection; (B and 
D) CD4+ T cell counts compared between individuals without and with HLA-B*81:01, B*39:10 or B*57/58:01 
alleles at 12 and 36 months post infection respectively. In red are B*81:01 participants positive for the Cw*04:01 
allele. Both B*39:10-positive participants are also positive for the Cw*12:03 allele. Viral load and CD4+ T cell 
counts are calculated as medians of measurements taken at three time-points closest to these intervals. To not 
enrich for slow progressors, we included the last attained median values for viral load and CD4+ T cell counts 
before initiation of ARV therapy for individuals who had received treatment prior to 12 (n=1) or 36 months 













































































































































































































































3.3.2 Linkage to HLA-Cw alleles did not impact disease progression  
 
In subtype C infection, a good clinical outcome in individuals positive for B*81:01 and 
B*39:10 alleles has been linked to an additive impact of Cw*04:01 and Cw*12:03 alleles, 
respectively (Leslie et al., 2010). Of the five B*81:01-positive participants, three participants 
were positive for the Cw*04:01 allele of which two were controllers (CAP222 & CAP277) 
and the third a typical progressor (CAP129). However, of the two B*81:01-positive 
participants who did not carry the Cw*04:01 allele, one was a typical progressor (CAP225), 
while the other was a controller (CAP262). Although both of the B*39:10-positive 
participants were also positive for the Cw*12:03 allele (Table 3.1), one was a progressor 
(CAP289) and the other a controller (CAP278) (Figure 3.1). These results suggest that the 
differential disease progression in B*81:01- or B*39:10-positive participants was not simply 
due to the HLA-Cw allelic combinations.  
 
3.3.3 Kinetics of p24-Gag-TL9 escape in B*39:10 and B*81:01 participants  
 
Substitutions in positions E177, Q182 and T186 Gag residues that are located within or 
proximal to the TL9 epitope (Gag180 -188) result in loss of immune recognition in 
B*81:01/B*39:10-positive individuals, with the predominant polymorphisms associated with 
HLA mediated TL9 restriction in vivo being the E177D, Q182S and T186S (Frater et al., 
2007; Leslie et al., 2006; Matthews et al., 2008; Rolland et al., 2010). 
    
In B*81:01-positive participants, mutations in TL9 generally emerged later in infection (Table 
3.2). The first mutation to emerge was at position 182. In three participants who selected this 
mutation post-infection, the Q182X (where X=S/T/A/H) was detected between 70 and 83 
weeks post-infection in CAP222; 50 and 61 weeks in CAP225; and 48 and 50 weeks in 
CAP277. In two of the three participants (CAP222 and 277), additional escape mutations 
were detected within 6 to 12 months following the emergence of the escape mutation at 
position 182, and reached fixation only 10 to 15 months later (Table 3.2). The T186S 
mutation emerged either alone as in CAP277, or concurrently with E177D as in CAP222. In 













Q182T mutation was already present. The mutation remained stable for up to 28 weeks; 
however, by 32 weeks the Q182S mutation emerged. As the Q182X mutation in the TL9 
epitope was detected in the earliest sample sequenced from three of the 37 CAPRISA 
participants who were negative for HLA-B7 supertype alleles, it is possible that this mutation 
was present in the transmitted virus. This is supported by the fact that there was no evidence 
of an immune response to this epitope in acute infection (Table 3.3). There was no sequence 
evolution in the TL9 epitope in the fifth B*81:01 participant (CAP262).  
 
The viruses from the two B*39:10-positive participants had a different pattern of escape. In 
one B*39:10 participant (CAP278), all three mutations (E177D, Q182S and T186S) were 
already present in the earliest sequences available at 9 weeks post-infection, with no further 
evolution within the epitope during 22 months of follow-up. In the second B*39:10 
participant (CAP289), the Q182A mutation was present at 8 weeks post-infection and evolved 
to Q182G at 28 weeks post-infection.  
 
To evaluate the likelihood of the HLA B*39:10-associated mutations in residues E177, Q182 
and T186 being present on the transmitted virus in CAP278, we estimated the frequency of 
TL9 mutations in participants negative for HLA-B7 supertype and Cw*08:02 alleles that 
recognise this epitope (Llano et al., 2009) in the CAPRISA 002 cohort. We found no 
sequences from either acute or chronic infection with either the two (Q182S with T186S) or 
the three (E177D, Q182S and T186S) concurrent mutations. Furthermore, the triple mutation 
was not present in any of the sequences analyzed from 507 HIV-1 subtype C infected adults in 
Durban, KwaZulu-Natal, South Africa (Kiepiela et al., 2004; Rousseau et al., 2008).   
 
Together, these results show that the TL9 escape in B*81:01 generally occurs later and can 
take approximately one year from the first mutations for escape in this epitope to reach 
fixation. Furthermore, we show that the three concurrent E177D, Q182S and T186S site 
mutations are rare and might have arisen due to early escape in one of the two B*39:10-
positive participants although it cannot be ruled out completely that this was a transmitted 













Table 3.2: HLA-B*81:01, B*39:10 and other B7 allelic restricted sequence variations in and proximal to 
the TL9 epitope, and putative compensatory mutations. The commonly evolving amino acid residues are in 
italics in the peptide 176-SeGATPqDLNtML-188. 
PIDa W. PI  TL9 Mutations Others 
  E177 T180 Q182 T186 L188 T190 H219 I223 A248 M250 I256 
CAP129 2 - - T - - - - H T - - 
B*81:01 23 - - T - - - - H T - - 
 32 - - S - - - - H T - - 
 37 - - S - - - - H T - - 
 42 - - S - - - - H T - - 
 54 - - S - - - - H T - - 
 106 - - S - - - - H T - - 
CAP222 56 - - - - - - - A - - - 
B*81:01 70 - - - - - - - A - - - 
 83 - - S (6/9) - - - - A - - V 
 95 - - S (1/6) - - - - A - - V 
 108 - - S (3/11) - - - - A - - V (3/11) 
 108 [D A S S] 1/11 - - - A - - - 
 108 [D - S S] 7/11 - - - V (2/7) - - - 
 122 [D - S S]13/13 - - - V 13/13 - - - 
 133 [D - S S - - - V] 13/13 - - - 
 148 D - S S - - - V - - - 
 161 D - S S - - - V - - - 
 174 [D - S S - - - V] 13/13 - - - 
 190 D - S S - - - V - - - 
CAP225 50 - - - - - - - - - - - 
B*81:01 61 - - S (10/15) - - - - - - - V (10/15) 
 74 - - S - - - - - - - V 
 85 - - S (3/15) - - - - - - - V (3/15) 
 98 - - S - - - - - - - V 
 117 - - S - - - - - - - V 
 130 - - S - - - - - - - V 
 145 - - S - - - - - - - V 
 158 - - S - - - - - - - V 
 171 - - S - - - - - - - V 
 183 - - S - - - - - - - V 
CAP277 16 - - - - - - - - - I - 
B*81:01 41 - - - - - - - - - I - 
 46 - - - - - - - - - I - 
 50 - - H - - - - - - I - 
 54 - - T - - - - - - I - 
 58 - - T - - - - - - I - 
 71 - - A - - - - - - I - 
 84 - - S - - - - - - I - 
 97 - - S (3/13) - - - - - - I (3/13) - 
 97 - - S S (6/13) - - - - - - (6/13) - 
 97 - - - - - - - - - - (4/13) - 
 110 - - S S - - - - T - - 
 123 - - S S - - - - T - - 
 137 - - S S - - - - T - - 
CAP262 70 - - - - - - - - - - - 
B*81:01 84 - - - - - - - - - - - 
B*42:01 95 - - - - - - - - - - - 
 109 - - - - - - - - - - - 
 122 - - - - - - - - - - - 
 136 - - - - - - - - - - - 
CAP278 9 D - S S - - - V - - - 
B*39:10 54 D - S S - - - V - - - 
 85 D - S S - - Q V - - - 
CAP289 8 - - A - - - - V - - V 
B*39:10 24 - - A - - - - V - - V 
 28 - - G - - - - V - - V 
 41 - - G - - - - V - - V 
CAP061 14 - - - - - - Q V - - - 
B*42:01 33 - - - - - - Q V - - - 
C*08:02 51 - - - - - - Q V - - - 
 76 - - - - F - Q V - I - 
 127 - - - - - - - V - - - 
CAP282 11 - - - - - - - - - - V 
B*42:01 35 - - - - - - - - - - V 
 53 - - - - - - - - - - V 
 60 ND ND ND ND - ND ND ND ND ND ND 
-  : No residue substitution or else the incoming residue is indicated; ND: Not done/not 
















Table 3.3: Temporal Pattern of TL9 specific IFN-γ ELIspot responses in B7 positive participants.  HLAs known to restrict TL9 are in 
bold/underlined.  




Timing of last wild-type (WT) and first 
TL9 mutation  
CAP129 A*26:01,80:01; B*18:01, 81:01; Cw*02:02, 04:01 2 Neg  Q182T 
  4 Neg  
  6 Neg  
  13 Neg   
  23 Neg Q182T 
  32 ND  Q182S 
CAP222 A*30:01,33:03;B*53:01, 81:01; Cw*04:01, 04:01 6 245  
  8 103  
  9 1568  
  11 368*  
  15 168  
  17 243  
  70 ND WT 
  83 ND WT/Q182S (mixed pop.) 
  108 1233 Q182S/and E177D with T186S (mixed 
pop)   
  122 ND E177D, Q182S, T186S (fixed)    
CAP225 A*01:01,30:01;B*81:01, 42:02; Cw*17:01,18:01 3 9078  
  4 888  
  5 475  
  7 1288  
  9 1058  
  14 203  
  18 3328  
  21 1513  
  24 1463  
  29 2080  
  33 818  
  37 468  
  50 1710 WT 
  61 ND WT/Q182S (mixed) 
  85 Neg WT/Q182S (mixed) 
  145 1221 Q182S (fixed) 
CAP262 A*01:01,66:02;B*42:01, 81:01; Cw*17:01, 18:01 7 365  
  14 Neg  
  16 215  
  18 250  
  26 105  
  136 ND WT 
CAP277 A*30:09,43:01; B*58:02, 81:01; Cw*04:01, 04:01 37 6147  
  46 ND WT 
  50 ND Q182H  
  97 193 WT / Q182S / T186S (mixed pop) 
CAP278 A*30:01,43:01;B*39:10, 42:02; Cw*12:03, 17:01 8 117 ND 
   9 ND E177D, Q182S & T186S  
  10 Neg  
CAP289 A*30:02,68:01;B*39:10, 58:02; Cw*06:02; 12:03 8 ND Q182A  
  9 Neg  
  28 ND Q182G  
CAP037 A*23:01,24:02;B*07:02, 53:01; Cw*17:01, 17:01 122 273 WT  
CAP040  A*30:01,30:02; B*15:10, 42:01; Cw*03:04, 17:01 106 293 WT  
CAP220  A*30:04,74:01;B*42:01; 42:01;Cw*17:01, 17:01 68 373 WT  
CAP239  A*01:23,29:02;B*42:01, 58:01; Cw*06:02, 17:01 67 258 WT 
CAP269  A*02:05,68:02;B*07:02, 58:02; Cw*06, 07;  120 Neg WT 
CAP282  A*30:01,66:01;B*42:01, 58:02; Cw*: ND 23 129  
  35 ND WT 
  53 ND Q182T first observed at 12month post-
infection 
  60 Neg  
PI: Post-Infection; ND: Not done; Neg: Negative; SFU:  spot forming units; mixed populations: more than one viral variant identified; fixed: 


















3.3.4 HLA-B*81:01 and B*39:10 exert more selection pressure on TL9 than B*42 
         and B*07:02 
 
Previous studies have shown that the selection strength of immune responses targeting the 
TL9 epitope differ according to the HLAs belonging to HLA-B7 supertype with HLA-
B*81:01 having a stronger selective capacity than B*4201 (Geldmacher et al., 2009; Leslie et 
al., 2006). Since three participants in this study were also positive for the HLA-B42 allele, we 
wished to know the frequency of HLA mediated sequence evolution in the TL9 epitope in 
participants carrying HLA-B7 supertype (n=17), excluding the B*81:01/39:10 positive 
participants. Analysis of sequences at 18 months post-infection revealed that only two, of the 
fourteen B*42:01 participants (including CAP262 who was positive for both 
B*42:01/B*81:01), developed polymorphisms in the epitope, while no mutations were 
detected in the four B*07:02-positive participants (Table 3.4). In one of the two B*42:01 
participants who selected mutations in the TL9 epitope, an escape mutation L188F emerged 
between 51 and 76 weeks (CAP061), however, this mutation was not fixed as it was not 
detected at 102 weeks post-infection (Table 3.2). In the second B*42:01 participant in this 
study, the Q182T mutation was selected between 48 and 53 weeks post infection (CAP282), 
while four of the five B*81:01 positive individuals selected for 182S. A recent study 
employing 2126 chronically HIV-1 subtype C-infected, antiretroviral naïve adults showed that 
unlike the B*81:01 allele that select against the Q182T mutation, the B*42:01 allele select for 
Q182T (Carlson et al., 2012). Thus, the difference in escape at residue 182 provides further 
support that B*81:01 allelic restriction is responsible for the changes observed in the TL9 
epitopes.  
 
These results also support the findings, which demonstrated that B*81:01 allele select for 
mutations in the TL9 epitope over the HLA-B*42:01 allele (Geldmacher et al., 2009; Leslie et 
al., 2006). Overall, these findings emphasise the differential role of closely related HLA in the 














Table 3.4: Differences in the rate of escape in participants positive for the HLA- B7 














Enrolment  1 & 1b 0  0 0 0 
<3 months 0 0 0 0 0 
3-6 0 0 0 0 0 
6-12 1b  1* 0 1 & 1b  0 
12-18 0 1** 0 2 0 
 
a The timing corresponds to the first mutation observed in TL9 epitope in the CAPRISA 
(AI02) cohort; b Participants with mutation at enrollment but with later further evolution of 
the mutations; c Number included one participant (CAP262) who never evolved TL9 
mutation in the follow-up period and positive for both HLA-B*42:01 and B*81:01; *: 
Mutation Q182T; * *: Mutation L188F was transient; PI : Post-Infection   
 
 
3.3.5 Late sequence evolution in TL9 is not due to lack of CTL responses in acute  
         Infection 
 
A lack of CTL pressure in acute infection has been suggested to partly explain why some 
epitopes remain invariant through acute infection and only evolve late in infection (Goulder 
and Watkins, 2004). Of the five B*81:01-positive participants, four (CAP222, CAP225, 
CAP262 and CAP277) targeted the TL9 epitope with responses detected in acute infection for 
three participants (CAP222, CAP225 and CAP262) and at 9 months for one participant 
(CAP277) (earliest sample tested) (Table 3.3). Only one participant (CAP129) who harboured 
an escape mutant at two weeks post infection showed no response to the TL9 epitope in acute 
infection (<3 months post-infection). In two of the three B*81:01-positive participants who 
recognized the TL9 epitope, escape only occurred 10 to 12 month after detectable responses. 
The lack of TL9 variation in CAP262 was unlikely due to lack of immune targeting since 
responses to this epitope occurred in acute infection, albeit at a low magnitude. Moreover, 
there were no TL9 associated mutations in this participant during the 33 months of follow-up 
(Table 3.2). Only one of the B*39:10-positive participants had detectable responses to TL9 
during acute infection (CAP278). The peptide used to detect responses corresponded to the 
wild-type sequence, and it is possible that responses in individuals harboring TL9 escape 
viruses in very early infection could be missed due to differences in the viral mutant and the 













Other than the B*81:01/39:10-positive participants, immune responses at later time points 
(>12 months postinfection) were generated for six of the 19 participants positive for other 
HLA-B7 supertype and Cw*08:02 alleles known to target the TL9 epitope. Low-magnitude 
responses (129 to 273 SFU/106 cells) were detected in five of the six participants tested; 
however, only one of these participants (CAP282) developed an escape mutant (Q182T). 
 
 
3.3.6 Sequence evolution in the TL9 epitope is associated with co-varying sites outside 
        of the epitope  
 
Studies have found significant associations between mutations in TL9 epitope and highly 
variable residues (Gag residues 138, 228, 248, 252, and 256) located in or flanking the three 
tropism-determining loops of p24 involved in host restriction factor recognition (loops 1 to 3 
located at Gag residues 137-147; 214-225; and 248-254 respectively) (Carlson et al., 2008; 
Crawford et al., 2011; Hatziioannou et al., 2004; Rolland et al., 2010). Whether mutations in 
these tropism determining loops that were co-selected with TL9 associated mutations could be 
detected was investigated. Variations in five residues were identified at positions 219, 223, 
248, 250 and 256, with the residues 219 and 223 located in the second loop, which contains 
the cyclophilin A binding sites, and residues 248, 250 and 256 located in or proximal to the 
third loop (Table 3.2).    
 
Using 463 longitudinal population sequences including over 120 clonal sequences from four 
B*81:01 participa ts, co-selection was then investigated using approaches that couple 
phylogenetic and Bayesian network models in Spidermonkey (Poon et al., 2008; www.data-
monkey.org). Significant correlations were found between sites, 186S with 177D, 182S with 
256V, and 186S with 250M (posterior probability>0.5) (Table 3.5). In the longitudinal 
analysis in CAP277, the emergence of T186S mutation was accompanied with evolution of 
sites, 248 and 250 (Table 3.2). Interestingly, every sequence carrying the TL9 double 
mutations (Q182S and T186S) was associated with reversion of the M250I mutation, 
suggesting a selective reversion to accommodate the double TL9 mutations. Similarly, the 
fixation of the triple mutations E177D, Q182S and T186S at around 122 weeks in CAP222 













compensatory site V223A (Table 3.2) (p=0.0035), suggesting that evolution of mutation 
V223A was under selective reversion (Delport et al., 2008). Furthermore, in CAP222, as well 
as in CAP225, evolution of the single Q182S mutation in the TL9 epitope was accompanied 
with emergence of Gag I256V mutation (Table 3.2). In three other participants, CAP129, 
CAP278 and CAP289, a combination of mutations Q182T/A248T, 
E177D/Q182S/T186S/I223V and Q182A/I223V/I256V, respectively, were present in the first 
sample analyzed.   
 
Sequence evolution at site 190 has been shown to compensate for escape in TL9 epitope 
through the T186S mutation (Wright et al., 2010; Wright et al., 2012). There was no sequence 
evolution or transmitted mutations in either any of the B7 positive individuals or any other 
participant investigated in this study at this residue (T190) in this cohort (Table 3.2).   
 
  
Table 3.5 Sites co-varying with each other in 3 of the 4 individuals who evolved sequences 
                 in the B*81:01 restricted TL9 epitope   
 
PID HXB2 Position Site 1 HXB2 Position Site 2 Posterior probability 
CAP222 186S 177D 0.73 
CAP222 182S 256V  0.73 
CAP225 182S 256V  0.73 




3.3.7 Timing of sequence evolution influenced the differential disease progression 
         among the B*81:01 and B*39:10 positive participants  
 
In vitro studies have demonstrated that substitution in the TL9 epitope residue T186 alone 
(Wright et al., 2010; Wright et al., 2012) or in both T186 and E177 (Rolland et al., 2010) 
incurs a fitness cost to the virus.  Mutation at residue Q182 reverts to consensus following 
transmission to HLA mismatched recipients (Matthews et al., 2008) and a recent study of 
Wright et al. (2012) demonstrated in a subtype C Gag backbone that Q182S incurs a fitness 













In order to understand CTL mediated escape and its impact on disease progression in vivo, the 
temporal relationship between sequence evolution in TL9 epitope and, viral loads and CD4+ 
T-cell counts were investigated in the B*81:01 and B*39:10 participants (Figure 3.3A). No 
escape was detected in virus from CAP262, who elicited immune responses to TL9 in early 
infection and gradually controlled viral load to levels below 2000 copies/ml after 24 months 
post-infection. Evolution of a single site, Q182 in the TL9 epitope in tandem with putative 
compensatory mutations A248T or I256V, did not affect viral loads or CD4+ T-cell counts in 
the three typical progressors, CAP129, CAP225 and CAP289 at least for the first 24 months 
following escape. These participants maintained consistently high viral loads for at least the 
first three years post-infection. Interestingly, characteristic of complete escape from a 
dominant response (Crawford et al., 2009; Feeney et al., 2004; Goulder et al., 1997), the 
spontaneous increase in viral load and reduction in CD4+ T-cell counts in two individuals 
controlling viraemia, CAP222 and CAP277, coincided with late sequence evolution in three 
(E177D, Q182S, T186S) and two (Q182S with T186S) sites respectively, together with 
reversion of putative compensatory mutations I/V223A and M250I, respectively. However, 
when viral loads in these participants, were compared to those who evolved single site escape 
mutation, and to the rest of the cohort (Figure 3.1), it was found that CAP277 maintained 
lower viral loads, while CAP222 had fluctuating viral loads that were similar to the median of 
the cohort and generally lower than individuals infected with viruses with single site escape 
mutations. Viral loads were measured quarterly and the cost of escape in these two 
participants was estimated by comparing the median viral load measurements for 9 months 
before escape and 9 months later. Multiple residue escape was associated with a one log10 
increase in viral load (Figure 3.3B). This higher viral load was sustained for approximately 9 
months post escape, after which it subsided, although to a level higher than before escape 
(Figure 3.3B). Interestingly, the B*39:10-positive participant (CAP278), who had the same 
mutations in acute infection maintained low viral loads below 2,000 copies/ml over the three 



























































CAP225 - Typical Progressor








CAP262 - Typical Progressor to Controller

















































CAP277 - Controller to Typical Progressor















































































Figure 3.3 (A) Viral load trajectories for the first 156 weeks (36 months) in B*81:01- (CAP129, CAP225, 
CAP222, CAP262 and CAP277) and B*39:10- (CAP278 and CAP289) positive participants, illustrating the 
timing of TL9 associated escape. Broken blue line illustrates the limit of detection of the assay (400copies/mL or 
2.6 log10). Putative compensatory mutations are shown in red italics. (B) Cost of multiple sequence evolution in 
or flanking the TL9 epitope in individuals who were controlling the infection as measured by the change in viral 
load and longer follow up showing reduction in maximum viral load but to levels higher than before escape. 
Four values of log10 viral loads over 9 months were used to calculate the median viral load before multiple 


















The B-7 HLA restriction alleles, including HLA-B*07:02, HLA-B*39:10, HLA-B*42:01, 
HLA-B*42:02 and HLA-B*81:01, are common in Black Africans and were found at a 
frequency of 40% (25/62) in the CAPRISA cohort. The TL9 epitope, located in p24 Gag, is an 
immunodominant epitope restricted by this HLA supertype. These HLAs are less common in 
Caucasians and the differential CTL targeting of Gag in Caucasians compared to Black South 
Africans is largely due to differences in frequency of TL9 recognition (Goulder et al., 2000). 
The significance of evaluating this epitope is further emphasized by the accumulating 
evidence showing that HLA-B*39:10 and -B*81:01 alleles are associated with better infection 
outcome in subtype C infection in southern Africa (Kiepiela et al., 2004; Leslie et al., 2010). 
Aside from well characterised epitopes associated with viral control such as the B*57/58:01 
restricted TW10, there is little known about the influence of epitope escape on HIV infection 
of Africans. Here we report on a longitudinal study of subtype C infected women from 
Kwazulu-Natal South Africa, from acute to chronic infection. This study provided opportunity 
to determine the timing of escape in TL9, identify co-evolving sites, and provided insights 
into the impact of these mutations on disease progression.   
 
Previous studies have shown that individuals carrying any of the closely related HLA‑B7 
supertype alleles can mount a CD8+ T cell response that targets the TL9 epitope  (Leslie et 
al., 2006), with the most dominant being HLA-B*81:01, followed by B*39:10, and then 
B*42:01 (Leslie et al., 2006). While the B42 alleles may have contributed to the selection of 
mutations in TL9 in each of the three participants positive for B*81:01 or B*39:10 in 
combination with B42 allele (Table 3.1), there were far fewer polymorphisms in viruses in 
individuals positive for only B*42:01/42:02 alleles, at least for the first 18 months post-
infection confirming previous observations that B*81:01 and B*39:10 exert the greatest 
selective pressure on the virus  (Leslie et al., 2006) (Table 3.4).  
 
The emergence of known B*81:01 escape mutations (E177D, Q182S and T186S) (Leslie et 
al., 2006) is documented and a common pattern of evolution with the Q182S mutation 













escape, which usually occur rapidly and during acute and early infection (Chopera et al., 
2008; Crawford et al., 2009; Martinez-Picado et al., 2006), escape in women with a B*81:01 
background was usually late and took nearly a year to reach fixation. In late infection, slow 
escape has been postulated to be due to a number of factors including low selection pressure, 
increased diversity of specific responses, and raised viral fitness cost (Ganusov et al., 2011; 
Loh et al., 2008; Schneidewind et al., 2008). Indeed, in vitro studies have demonstrated that 
T186S mutation alone, or in combination with E177D, incurs a fitness cost to the virus 
(Rolland et al., 2010; Wright et al., 2010; Wright et al., 2012). Interestingly, late evolution of 
T186S either alone, or in combination with E177D, coincided with an increase in viral load 
and although viral replication was subsequently brought under control, it returned to a level 
higher than before escape. This reflects the complex balance between the host and the virus, 
where immune escape results in loss of control and is thus detrimental to the host; however, 
the impact of the mutation on viral replication capacity provides some benefit.  
   
While escape mutations that reduce viral fitness often select for variants that affect structural 
and/or reduced function (Schneidewind et al., 2008; Schneidewind et al., 2007), the 
development of mutations that compensate for the fitness cost in the TL9 epitope are not well 
described. The analysis of Wright et al. (2010) found that individuals carrying both Q182S 
and T186S had higher viral loads than individuals carrying single T186S. However, although 
assays for their recent in vitro studies for the Q182S mutation alone yielded discordant 
replication results, in vitro experiments in a subtype C Gag backbone found that Q182S incurs 
a fitness cost to the virus and same level of replication for either T186S alone or both T186S 
and Q182S (Wright et al., 2012). A recent cross-sectional study on sequences from 662 
individuals infected with HIV-1 subtype C found that polymorphism at I256 was significantly 
associated with the B*81:01 restricted Q182 and T186 sites (Crawford et al., 2011). Here we 
find concomitant evolution of I256V in each sequence carrying the Q182X mutation 
providing further support that this mutation compensates for the fitness cost due to sequence 
evolution at site 182. However, the replication cost for this site mutation with the co-evolving 














In vitro studies have demonstrated that mutations in residues H219, I223, M228 compensate 
for the fitness cost due to the T242N escape mutation in B*57/58:01 restricted TW10, while 
A248T and M250I have been associated with TW10 escape (Brockman et al., 2007; Crawford 
et al., 2011; Martinez-Picado et al., 2006). This study has found an overlap in sites associated 
with B*81:01/39:10 restricted TL9. The development of both Q182S and T186S mutations in 
TL9 was associated with reversion to M250.  Similarly, the fixation of the three escape 
residues at two years post-infection in CAP222 was associated with selective reversion of the 
transmitted mutation I/V223A in the cyclophilin binding loop, while the H219Q mutation in 
Gag subsequently developed 17 months post-infection in one of the controllers (CAP278). 
These common evolutionary pathways associated with TW10/TL9 restriction may be due to 
functional and structural interactions between the region harbouring these epitopes (Martinez-
Picado et al., 2006; Tang et al., 2002). These results support the model proposed by Crawford 
et al. (2011), in which exposed capsid variable-residues generically compensate for fitness 
cost due to selection in structurally and functionally conserved capsid residues. The findings 
in this study also support common compensatory pathways of viral evolution in variable 
domains associated with host tropism.    
 
In conclusion, this study expands our understanding on why some individuals with so-called 
beneficial alleles do not control viral replication. This study also provides evidence that late 
escape at multiple sites in/and proximal to TL9 epitope was associated with increased 
viraemia in subtype C HIV-1 infected individuals. This study expands our knowledge of Gag 
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This study aimed to determine the impact of HLA mediated viral polymorphisms transmitted 
to HLA-mismatched individuals on disease progression. Although some studies have shown 
that infection with viruses carrying beneficial HLA-mediated escape mutations provide 
survival benefit, this finding remains controversial.  
 
Gag was sequenced from 56 participants with acute HIV infection and HLA associated 
mutations known to impact on replication capacity were mapped. Specific amino acid sites 
that were associated with low viral loads and high CD4+ counts at 12 months post-infection 
were also analyzed. For the newly identified mutation (Q65H), replication of wild-type and 
mutant viruses in PBMCs was compared.  
 
In HLA-B*57/58:01-negative participants, 51% (25/49) were infected with viruses carrying at 
least one of the B*57/58:01 attenuating escape mutations in ISW9 (A146P:19/49), KF11 
(A163G: 10/49) or TW10 (T242N/S: 11/49) epitope. In HLA-B7 negative participants, only 
9.4% (3/32) had viruses carrying mutations in the HLA-B7 immunodominant TL9 epitope. A 
novel mutation in Gag p17, Q65H was identified, which in PBMCs assays reduced replication 
by 22% compared to wild-type. This mutation, thought to be restricted by HLA-B7 and A*30, 
was in 5.5% (2/37) of B7 and A*30 negative participants. Unlike a previous study in this 
cohort which analysed a subset of 21 individuals, infection with viruses carrying mutations in 
HLA-B*57/58:01 restricted epitopes alone did not impact on viral load setpoint in HLA-
mismatched participants, although CD4 counts at 3 months post infection were higher in 
participants with greater than any 2 of these mutations (p=0.031). However, HLA-
mismatched participants infected with viruses carrying 3 or more of any of the B*57/58:01 or 
B*39:10/81:01 attenuating escape mutations had significantly lower viral load and higher 
CD4 counts at 3 months (p=0.017 and p=0.041) and at 12 months (p=0.008 and 0.091) post-
infection, respectively. These results suggest that multiple mutations generated when viruses 
are passaged through individuals with beneficial HLAs are needed to attenuate the virus, 














4.1 Introduction  
 
It has long been known that infection with viruses containing deleterious mutations, such as 
deletions in nef, can result in delayed disease progression (Deacon et al., 1995; Michael et al., 
1995). Recently, a study of Alizon et al. (2010), who investigated the relationship between 
viral genotype and viral load set-point in 1100 MSM (men who have sex with men) infected 
with phylogenetically linked viruses, demonstrated that more than a half of variations in viral 
load at set point are due to inheritable HIV pathogenic traits (virulence). Furthermore, studies 
of transmission pairs ranging from 24 to 112 heterosexual couples found that there was a 
correlation between HIV-1 viral load levels within couples (Hecht et al., 2010; Hollingsworth 
et al., 2010).These studies support the idea that shared characteristics of the transmitted virus 
are important determinants of HIV-1 disease progression; however, the identity and 
contribution of some of these viral factors on differential disease outcome remain poorly 
defined. Studying HLA associated escape mutations in viruses following their transmission to 
HLA-mismatched hosts may further provide insights into viral determinants affecting disease 
progression. 
 
Studies have shown that transmission of viruses carrying attenuating CTL escape mutations to 
individuals lacking the HLA that selected the attenuating mutations (HLA mismatched 
individuals) is beneficial to recipients (Chopera et al., 2008; Goepfert et al., 2008; 
Thobakgale et al., 2009; Prado et al., 2010).These mutations were shown to affect viral loads 
up to 12 months post infection (Chopera et al., 2008), and this may be a possible mechanism 
that explains why viral load is an inheritable trait. However, the role of transmitted escape 
mutations on viral load remains controversial as some studies could not find any advantage of 
infection with viruses containing CTL-associated attenuated mutations (Novitsky et al., 2010; 
Wright et al., 2011).In an attempt to resolve the conflict in the field, this chapter reports on an 
extension of an earlier study by Chopera et al. 2008. Here, 56 individuals were analyzed, 
including the 21 reported by Chopera et al., (2008). Furthermore the impact on disease 
progression of other transmitted CTL escape mutations, including a novel mutation in p17 














4.2 Material and Methods  
 
4.2.1 Study subjects 
 
Participants in this study were those of the CAPRISA 002acute infection cohort, investigating 
the role of viral and immunological factors in acute and early HIV-1infections (van 
Loggerenberg et al., 2008), described in detail in chapter 2.2.1 of this thesis.  
 
4.2.2 Viral sequencing 
 
As described in chapter 2, cDNA was synthesized from RNA and viral sequencing was done 
directly on PCR products or was cloned in pGem-T Easy vector according to the 
manufacturer’s instructions (Promega, USA).  
 
4.2.3 HLA typing 
 
HLA data was provided by C. Gray, NICD, which was high resolution (four digits) typing and 
performed as described in Chapter 2.  
 
4.2.4 Site-directed mutagenesis for generation of infectious molecular clones  
 
The HIV-1 subtype C infectious molecular clone, pBR246-F10 was used as the backbone. 
The vector component of the original plasmid was digested with XhoI enzyme to delete the 
XhoI restriction site and this was followed by blunting with Klenow and blunt-end ligation. 
Cloning sites BssHIIand XhoI (by silent mutations) were then inserted in the backbone by site 
directed mutagenesis using the QuickChangeII site-directed mutagenesis kit (Stratagene). The 
BssHIIsite was inserted at the beginning of the gag gene (second and third amino acids) using 
primers Gag-BssHII F and Gag-BssHII R, while an XhoI site was inserted just at the end, at 
~60 nucleotides downstream of the gag stop codon using primers Gag-XhoIF and Gag-XhoI 














The p17 65H mutation was introduced into a consensus subtype C full length gag by PCRsite 
directed mutagenesis using Gag-BssHIIF and Q65HR, generating two fragments ~200-300bp 
and~1200-1800pb, respectively. Ligation of these two fragments was done using the Gag-
BssHII Fand Gag CRM primers. This product was then cloned into the pGEM-T Easy vector 
(Promega, USA) and the mutation was confirmed by sequencing using Gag Af and Ar primers 
(Primers described in chapter 2).  
 
Both the wide-type (65Q) and mutant (65H) full length gag clones were each ligated into the 
subtype C backbone and propagated in  transformed E. coli OneShot Stable 3 (Invitrogen) 
cells, generating full-length chimeric plasmids pBR246-F10_WT and  pBR246-F10_MT 
clones respectively, stocks of which were purified using a Qiagen Plasmid Midi Kit (Qiagen, 
Valencia, CA). 
 
Sequences of the primers used in this chapter were: Gag-XhoIF (HXB2 position 2338– 2369; 
5’ATG ATA CAG TAC TCG AGG ACA TAA ATT TGC CA); Gag-XhoIR(HXB2 position 
2338 – 2369; 5’TGG CAA ATT TAT GTC CTC GAG TAC TGTATCAT), Gag-BssHIIF 
(HXB2 position 778– 810;  5’-AGA AGG AGA GAG ATG GGCGCGCCA ACT CGAGGA-
3’);Gag-BssHIIR (HXB2 position 778–810;  5’-TCC TCG 
AGTTGGCGCGCCCATCTCTCTCCTTCT-3’);Q65HR (HXB2 position 974–996; 5’-
CTGAAGAGCTGGGTGTAGCTGTT-3’); Q65HF (HXB2 position974–996; 5’-
AACAGCTACACCCAGCTCTTCAG-3’); Gag CRM (HXB2 position 2334–2353; 5’- TCC 
TCG AGT ACT GTA TCA TCT GC-3’).  
 
4.2.5 Viral stocks 
 
HEK293T cells were transfected with 7.5 μg of plasmid DNA in Dulbecco modified Eagle 
medium (Gibco) supplemented with 10% fetal bovine serum (Atlantic Biologicals) using 
PolyFect(Qiagen, Valencia, CA). Supernatants were harvested after 72 hours and aliquots 
were stored at -80°C. Virus titration was performed in quadruplicate in TZM-bl cells. Eleven 
serial four-fold dilutions of viral stocks were assayed. After 48 hours of incubation at 37°C 













galactosidase-luciferase activity and viral titres were expressed as tissue culture infective dose 
(TCID), calculated using Reed and Muench,(1938) method (Excel sheet).  
 
4.2.6 Viral replication assays 
 
CD8+ T cells were depleted from PBMCs isolated from 3 healthy HIV-negative 
donorsaccording to the kit manufacturer’s instructions (Dynal, Invitrogen). The PBMCs were 
then stimulated in RPMI 1640 supplemented with 20% FBS, 5 ug/mL of phytohemagglutinin 
(Sigma, St. Louis, Mo.,USA), 1%PenS and 20 U/mL of IL-2 (Becton Dickinson Labware) for 
72 h at 37°C with 5% CO2 and were then washed with PBS 1X (without Ca++/Mg++) 
supplemented with 1% (vol/vol) FBS (Wash media). In order to compare the replication 
between the two viruses (wild-type and mutant), the stimulated PBMCs were inoculated with 
viral stocks (MOI = 0.001) in independent experiments (parallel infections) in RPMI 1640 
supplemented with 20% FBS, 1%PenS and 20 U of interleukin-2 (Growth media) and after 24 
hours, the media (inocula) were removed, cells washed (with wash media) and replaced with 
fresh growth media (1mL). Sampling was done on days 3, 5, 7, 10, 12 and 14 with 
replacement of an equal volume of growth medium. Fresh PBMCs were added on day 7. 
Growth was followed up as increases in the concentrations of p24 as measured using the p24 
ELISA kit (Perkin Elmer; GibcoBRL Life technologies) and following the manufacturer’s 
instruction.  
 
4.2.7 Statistical analyses 
 
Amino acid sites encoded by the earliest gag sequences associated with low viral loads and 
high CD4+ counts at 12 months post infection were identify using Wilcoxon rank-sum T-tests 
and significance of p values was evaluated for multiple comparisons using the Bonferroni-
corrected alpha values for each site (Marasuilo & McSweeney, 1977). To calculate relative 
viral fitness, the mean p24 concentration of wild type virus at each sampling interval was 
divided by the mean p24 concentration of mutant virus at a coincident time point post-
infection [relative viral fitness = (Mean of triplicate p24 concentration of MT/mean of 













seriously affected by variations in virus input (Dykes and Demeter, 2007), the exponential 
growth constant q for each virus in parallel cultures was estimated from the ratio of the 
concentration of p24 produced at each sampling time (p24t) and the peak concentration 
(p24max) of the virus produced – this method is adopted from Resch et al. (2002). Statistical 
analysis and graphical presentations were implemented in GraphPad Prism 5.0 (GraphPad 
Software, Inc.). To control for fluctuations of viral set-points at 12 and 36 months post-
infection, we calculated viral load and CD4+ T-cell counts as medians of measurements taken 
at three time-points closest to these intervals. Statistical analysis of significance was based on 




Virus adaptations in the donor, including those mediated by the donor HLAs, will be 
contained in the sequence of the transmitted virus. This study aimed to determine the impact 
on disease progression of HLA mediated polymorphisms on the virus transmitted to HLA-
mismatched individuals. Previously, Chopera et al. (2008) detected a survival advantage in 
nine out of 21 HLA-B*57/58:01 negative CAPRISA individuals infected with viral strains at 
enrolment, carrying the T242N mutation in the TW10 and/or the A146X processing mutation 
in the ISW9 epitope. These individuals had significantly lower viral load and higher CD4 
counts at 3 months and 12 month post-infection (p=0.0077 and p=0.0129;and p=0.0275 and 
p=0.0172; for viral load and CD4 count differences at 3 and 12 months, respectively) 
(Chopera et al., 2008). In a more detailed analysis, the study was expanded to include 56 
individuals and to investigate the role of other HLAs that are associated with replication 
fitness cost to the virus in Gag. Furthermore, this study screened for novel mutations that 
impacted on viral loads and CD4 counts.   
 
4.3.1 Identification of mutations that affect viral replication capacity 
 
To assess the frequency of these attenuating mutations, and possibly an additive contribution 
of mutations on disease progression, HLA associated Gag mutations known to incur 













sequences were available and longitudinally followed for at least 24 months post-infection or 
initiation of antiretroviral therapy (ART)  (Table 4.1).To ensure that we were evaluating 
mutations that evolved in the previous host(s), transmitted escape mutations were defined as 
changes in or near epitopes not restricted by the HLAs of the recipient (HLA-mismatched 
individuals). These changes were mapped onto the earliest available sequence (median of 42 
days post infection, IQR = 28 -56).   
 
Mutations were in epitopes restricted by HLA B*57/B*58:01, HLA-B*81:01/39:10 and HLA-
B*13 and included mutations in or proximal to ISW9, KF11 and TW10 (restricted by HLA 
B*57/B*58:01); TL9 (restricted by B*81:01/39:10); and RI9 (restricted by HLA-B*13). 
Mutations proven with in vitro experiments to reduce viral fitness including A146Pproximal 
to the ISW9 (Gag 146-AISPRTLNAW-155), A163G in the KF11 (Gag 162- 
KAFSPEVIPMF-172), E177D, T186S proximal and in TL9 (Gag 176-SEGATPQDLNTML-
188), respectively, T242N in the TW10 (Gag 240-TSTLQEQIAW-249) and I437L/M in the 
RI9 (Gag 429-RQANFLGKI-437) epitopes (Table 4.1) (Martinez-Picado et al., 2006; 
Boutwell et al. 2008; Crawford et al., 2009; Prado et al., 2009; Troyer et al., 2009; Rolland et 






































Table 4.1 Identification of transmitted escape mutations associated with a replicative fitness cost to the virus and 
participants’ clinical data (See Appendix 3). Shown are mutations in the HLAs -B*57/58:01 restricted epitopes, 
ISW9, KF11 and TW10; the B*39:10/81:01restricted epitopeTL9; and the B*13 restricted epitope RI9. 
Participants infected with viruses carrying a novel putative CTL escape mutation in p17 affecting viral 
replication capacity are also included. 
 
 
Blank cell (s): the specified mutation(s) is/are absent; Individuals who are positive for HLAs - B*57/58:01are 
shown in red PID numbers; X: change away from HIV-1 C clade consensus; aParticipant has HLA-B*1510 or 
HLA-B*13 associated with ISW9 residues A146X/I147X (Honeyborne et al., 2007); Participants Jnegative 
(n=11)  and gpositive (n=9) for T242N/X in the TW10 and/or A142P/X in the ISW9 epitope included in the 
study (n=21) of Chopera et al. (2008); hThough previously thought to compensate for fitness cost due to escape 
through A146X, Crawford et al. (2009) showed that I147L, together with A146P mutation incur fitness cost to 
the virus; *Gag p17 mutation at HXB2 position 65; **Participant infected with virus that developed the mutation 
at HXB2 position 65 in Gag p17 or else was there at transmission –in purple colour: the polymorphism is present 
in virus in participants positive for HLA-B7 supertype or A*30 alleles that may be linked to formation of the 
polymorphism.  *** Mutation reverted to subtype C consensus residue; Mutations in the cyclophilin binding 




PID ISW9 (147-155) KF11 (162-172) TL9 (180-188) TW10 (240-249) and associated mutations RI9 (429-437) p17* 
A146P I147Lh A163X S165X  T242X A248X M250X H219Q I223V M228   
CAP008J   A163G S165N   A248G       
CAP030J     T180I     I223V M228L   
CAP037 A146S I147L        I223V  K436RI437L  
CAP040      T242S    I223V M228L   
CAP045a, g A146P I147M   L188F   M250I H219Q     
CAP061g A146P I147L    T242N   H219Q I223V M228I  Q65H 
CAP063 A146N I147L A163G S165N   A248G       
CAP065a,g A146S I147L            
CAP069J       A248T    M228I   
CAP085g A146P I147L    T242N     M228L  Q65H 
CAP084J             Q65H*** 
CAP088g A146P  A163G  Q182H, P181S T242N    I223N    
CAP129 A146P      A248T    M228L   
CAP137      T242S        
CAP174 J        M250I      
CAP177a  I147L     A248T       
CAP188  I147L            
CAP200a, g A146P I147L    T242N    I223N    
CAP206J         H219P I223P M228L   
CAP220             Q65H 
CAP221 A146P I147L A163N   T242N    I223V    
CAP224 A146P I147L            
CAP225g A146P I147L    T242N        
CAP228g A146P I147L A163S   T242N    I223V M228I   
CAP244J       A248N       
CAP255g A146P I147L A163S     M250I     Q65H 
CAP257  I147L           Q65H** 
CAP258J  I147L     A248N      Q65H 
CAP260       A248T       
CAP261a  I147L A163G S165N    M250I      
CAP264a       A248T       
CAP265   A163G S165N    M250I      
CAP266  I147L         M228L   
CAP267 A146P  A163G S165N  T242N    I223P    
CAP269 A146P            Q65H 
CAP271 A146S I147L           Q65H 
CAP275  I147L            
CAP277 A146P I147L      M250I     Q65H 
CAP278  I147L           Q65H** 
CAP279 A146P     T242N A248Q  H219Q  M228I   
CAP281  I147L A163N     M250I      
CAP136              
CAP210J              
CAP222              
CAP237              
CAP248J              
CAP256J              
CAP262              
CAP282              
CAP211             Q65H 
CAP217              
CAP229              
CAP239              
CAP268              
CAP270              













4.3.2 The frequency of mutations associated with replicative fitness cost in HLA 
         mismatched participants    
 
4.3.2.1 Frequency of HLA B*57/58:01 associated escape mutations in HLA 
            mismatched participants   
 
HLA B*57 and B*58:01 restricted responses select mutations in the ISW9, KF11 and TW10 
epitopes in p24 in acute or early HIV-1 infection (Martinez-Picado et al., 2006; Crawford et 
al., 2009). Of the 56 participants, 49 were negative for the B*57/58:01 alleles. The frequency 
of the ISW9 processing mutation A146P, and the KF11 epitope mutation A163G was 39% 
(19/49) and 20% (10/49) respectively, while the frequency of the T242N in the TW10 epitope 
was 23% (11/49) (Table 4.2). Taken together, a high percentage of individuals were infected 
with viruses carrying the HLA B*57 and B*58:01 associated escape mutations: 43% (21/49) 
participants were infected with virus carrying either the T242N and/or the A146X processing 
mutation in the ISW9 epitope, while 51% (25/49) were infected with at least one of the 
A146P/T242X/163X HLA B*57/B*58:01associated mutations. 
 
Furthermore, a study of Martinez-Picado et al. (2006) describing escape in TW10 epitope 
suggested that escape through T242N mutation is rare if there is either M250I or S252N 
mutation downstream of the TW10. In addition, the M250I mutation has been shown to affect 
viral replication capacity (Chopera et al., unpublished). In agreement with this finding, none 
of the B*57/58:01-negative participants who were infected with T242N variants had the 
M250I mutation, suggesting that co-existence of T242N and M250I might indeed be under 
constraint. The S252X (X=N/H) mutation was present in five participants infected with the 
T242N variants – thus, suggesting that the two mutations can co-exist. There was co-variation 
of sites M250 and S252, where six of the seven (6/7) participants with variation at site M250 
also had variation at site S252. The frequency of M250I and S252X mutation was 14 % (7/49) 



















4.3.2.2 Frequency of HLA-B7 supertype allele-associated mutations in HLA  
           mismatched participants  
 
Of the 32 participants negative for the HLA-B7supertype alleles (HLAs B*81:01, B*42:01, 
B*39:10, B*07:02) and Cw*08:02 capable of selecting mutations in the TL9 epitope (Leslie 
et al., 2006; Llano et al., 2009), none were infected with viruses containing the well described 
E177D/A and T186S mutations associated with reduction in viral fitness (Von Schwedler et 
al., 2003; Rolland et al., 2010; Wright et al., 2012). Furthermore, only 9.4% (3/32) 
participants had mutations (T180I, P181S, Q182X and L188F) in the TL9 epitope. However, 
although no study in vitro has been done to prove the fitness cost incurred to the virus due to 
mutations T180I, P181S and L188F, these reverted in vivo between 1.5 and 2.5, 6 and 10.6, 
and 31 and 46 months post-infection, respectively suggesting a fitness cost of these mutations 
(Appendix 4). 
 
These results suggest that mutations in the B*39:10/81:01 TL9 epitope known to incur 
replicative fitness cost to the virus, unlike HLA B*57/58:01 associated mutations, are not 
common in viruses transmitted to HLA mismatched participants, despite the high frequency 
of HLAs that are capable of selecting mutations in the epitope in HIV-1, subtype C population 
(Goulder et al., 2000; Gonzalez-Galarza et al., 2011) and in this cohort (40%; 25/62).  
 
4.3.2.3 Frequency of HLA B*13 associated mutations in HLA mismatched  
           participants 
 
Although HLA- B*13 is not always significantly associated with slow disease progression in 
HIV-1 subtype C infection, in a study of 578 infected individuals from Durban, Honeyborne 
et al. (2007) found that individuals with CTL responses to the RI9 epitope and who select for 
CTL escape mutations I437L/M had lower viral loads than others. Furthermore, mutations in 
this residue were associated with replicative fitness cost in vitro (Prado et al., 2009). In this 
study, it was found that these mutations were rare and were present in only 2% (1/55) of the 
individuals who did not have the HLA-B*13 allele. The low occurrence of this mutation is 
probably due to the low frequency of B*13 allele in black African populations as only 3.2% 













study of Honeyborne et al. (2007), who found that the phenotypic frequency of this allele in 
1212 participants was 3.9%.  
 
Table 4.2: Summary of frequencies of mutations in Gag due to HLAs known to restrict dominant CTL epitopes 



















7 49 A146Pf/X 5 10.2 






7 49 A163Gf/X 5 10.2 









7 49 T242Nf/X 10 20.4 
T242Nf/X, H219Qk 
and A248Qd   
1 2.0 
eM250I 1 2.0 
M250I and S252N 2 4.1 
M250I and S252G 4 8.2 
S252N 5 10.2 
TL9 
B*81:01/42:01/39:10/07
:02 or Cw*08 
24 32 E177Df 0 0 
T186Sf 0 0 
T180A/X 1 3.1 
P181S/X 1 3.1 
L188F 1 3.1 
RI9 
HLA-B*13 





29 37 Q65Hg 2 5.5 
 
bNumber of HLA positive participants; cNumber of HLA mismatched participants; ***Number of individuals 
with mutation; X: change away from HIV-1 clade C consensus; dT242N + G248A in subtype B completely 
abrogates recognition at low peptide concentrations (Leslie et al., 2004); eIncluded as a study of Martinez-Picado 
et al. (2006) associated this mutation with lack of variation in TW10 epitope and also associated with in vitro 
fitness cost (Chopera et al., Unpublished); fProven in-vitro to incur fitness cost to the virus; gStatistically 
associated with lower viral loads; exact HLA associations remain controversial (B*81: Wright et al., 2010; 

















4.3.3 Screening for novel mutations 
 
Specific amino acid sites that are associated with low viral loads and high CD4+ counts at 12 
months post-infection were analyzed in the earliest sequences using Wilcoxon rank-sum tests. 
This method compared independently the median viral loads and CD4+ counts between 
groups of viruses with and without the consensus amino acid at each site. Data for participants 
positive for the B*57/58:01 alleles were initially excluded as these “protective” alleles are 
often associated with better control of HIV-1 replication (Migueles et al., 2000; Miura et al., 
2009). When corrected for multiple comparison a significant association was detected for a 
mutation at site 65 (n=10) in p17 with lower viral load (p=0.0033) and a trend towards higher 
CD4+ cell counts at 12 months post-infection (p=0.1758) although this trend for higher CD4 
counts was lost when individuals positive for the B*57/58:01 alleles were included in this 
analysis (section 4.3.4.5). At this site, glutamine (Q) is mutated to histidine (H). The Q65H 
mutation was not located in a known epitope; however, longitudinal analysis of sequences 
demonstrated that this site evolved in two participants. In CAP278 (HLA-A*30:01,43:01; 
B*39:10, 42:02; Cw*12:03, 17:01), a viral load controller, the mutation Q65H was first 
observed between 54 and 85 weeks, while it was formed between 50-107 weeks post infection 
in CAP257 (HLA-A*23:01, 29:02; B*42:02, 44:03; Cw*17:01,17:01), an intermediate 
disease progressor.  
 
A recent study of Huang et al. (2011) in a cohort of 1053 black South Africans from 
Bloemfontein and Durban, associated this Q65H polymorphism with HLA-A*30. However, 
of the two individuals in the CAPRISA cohort with viruses that evolved this polymorphism, 
one was negative for HLA-A30 suggesting that this is either not the restricting allele or both 
alleles are associated with this residue. Interestingly, however, 11 of the 16 HLA-A30 
participants in this study were also positive for an HLA-B7 supertype allele, suggesting an 
over representation of A*30 allele in participants positive for B7 alleles. Furthermore, both 
individuals were positive for the HLA-Cw*17:01 and HLA-B7 supertype alleles (HLA- 
B*42:02 and B*39:10) suggesting that these may be the restricting alleles. The hypothesis that 
this polymorphism is associated with HLA-B7 supertype is further supported by a study of 













association between this residue and escape in TL9, a dominant B7 epitope. Nevertheless, 
further analysis using bioinformatic tools that predict binding of peptides to any known MHC 
molecule using artificial neural networks (ANNs) (Hoof et al., 2009; available at: 
www.cbs.dtu.dk/services/NetMHCpan) suggested that both B7 supetype and A30 alleles bind 
the epitope (60-IMKQLQPAL-68) harbouring the Q65H mutation.  
 
4.3.3.1 Frequency of Q65H mutation in participants negative for HLA-B7 supertype and 
A*30 alleles 
 
Sequences were further analyzed to determine the frequency of the p17 mutation Q65H in the 
cohort and 18% (10/56) participants were found to be infected with viruses carrying the 
mutation. However, of the 37 participants negative for B7 and A30 alleles, only two were 
infected with virus carrying the polymorphism suggesting that in this cohort, the frequency of 






























4.3.3.2 Polymorphism at p17 Gag Q65H affects viral replication 
 
Studies in vivo showed the Q65H mutation to be associated with lower viral loads. 
Furthermore, this residue is situated in the fourth α-helix of p17, where mutations in this helix 
are known to affect envelope incorporation, dimerization and, therefore, viral assembly 
(Dorfman et al., 1994; Morikawa et al., 1998). In vitro studies were performed to determine 
the impact of the p17 Gag Q65H mutation on viral replication. The Q65H mutation was 
introduced into a consensus subtype C gag, and both the wide-type (65Q) and mutant (65H) 
full length gag were each ligated into a subtype C backbone, pBR246-F10 forming chimeric 
pBR246-F10_WT and  pBR246-F10_MT infectious molecular clones, respectively.   
 
Infective viral stocks were successfully generated for both the wide-type and the mutants. 
Results of this study on the growth kinetics of viruses generated in parallel infections in 
PBMCs demonstrated that there was increasing concentrations for both mutant and wide-type 
over the entire 3 to 10 days of follow-up suggesting that the mutation Q65H did not abrogate 
virus formation (Figure 4.1A and B). However, p24 concentrations of these viruses in PBMCs 
suggested that the mutant virus replicated slower that the wide-type virus. Moreover, when an 
exponential growth model (Resch et al., 2002) was fitted to the data from each culture (Figure 
4.1C), the net growth rate (q) suggested that the mutant virus was less fit (q=2.1±0.4 day-1; 
doubling time: 3.34 days) than the wild-type virus (q=2.5±0.6 day-1; doubling time: 2.81 days) 
although the differences were small. This analysis was confined to replication titres between 
day 3 and 7 as the growth kinetics of this study demonstrated that exponential increase 
levelled off after day 7. The net growth rate (q) for the mutant was also lower (4.19±0.7 day-1; 
doubling time: 1.7 days) than that of the wild-type (5.43±1.3 day-1; doubling time: 1.3 days) 
when the exponential growth curve was fitted between day 3 and day 5. Taken together, it was 
found that the mutant replicated 78% of the wild-type (22% less than the wild-type) (Figure 
4.1D). This polymorphism was thus included in the analysis of mutations associated with 


































































































Figure 4.1 Impact of the polymorphism at p17 Gag Q65H on viral replication. Replication kinetics of chimeric 
wild-type (pBR246-F10_WT) and mutant (pBR246-F10_MT) viruses carrying the Gag p17 65Q and 65H 
mutations, showing changes in p24 concentrations over the first 10 days (3 repeats) (A) and fold increases (B), 
respectively; Mean values of triplicates and standard deviation at each sampling point time post-infection are 
shown; (C): Viral spread is normalized/measured as ratio of concentrations of p24 at time t (p24t) to the 
maximum (peak) p24 (p24max) produced. The exponential growth curves for the wild-type is in black, while that 
of the mutants is in red colour (D): Relative replication of the mutant, pBR246-F10_MT viruses compared to that 
of the wide-type pBR246-F10_WT viruses. Relative replication is calculated as percentage of mean ratio of 

























4.3.4 Impact of transmitted CTL escape mutations on disease progression 
 
4.3.4.1 Impact of HLA-B*57/58:01 footprints in HLA mismatched participants on  
            disease progression   
 
Firstly, the analysis of Chopera et al. (2008) was repeated where, in this study in 21 HLA-
B*57/58:01-negative individuals from the CAPRISA 002 cohort, they had found that nine 
were infected with viruses containing either the T242N or A146P, or both mutations and these 
were significantly associated with lower viral load and higher CD4 counts at both 3 and 12 
months post infection. In the current study in 56 participants (including the initial 21), 43% of 
the HLA-B*57/58:01 negative participants (21/49) were infected with viruses carrying either 
the T242N and/or the A146X processing mutation in the ISW9 epitope at enrolment (Table 
4.1). However with this increased sample size, and unlike the Chopera et al. (2008), there 
were no significant differences in either viral load or CD4counts between those infected at 
enrolment with and without virus carrying the T242N and/or the A146X mutations, either at 3 
or 12 months post-infection. At 3 months post infection, the medians for viral load and CD4 
counts for individuals infected with and without viruses carrying the mutations were 4.59 
log10 copies/ml (IQR= 3.72 – 5.01) versus 4.74 copies/ml [IQR= 4.01 - 5.22] for viral loads, 
respectively (Figure 4.2A; p=0.28); and 535 cells/ul [IQR = 448-691] versus 467 cells/ul 
[IQR=358-612] for CD4 counts, respectively (Figure 4.2B; p= 0.24). Similarly, at 12 months 
post infection, the medians for viral load and CD4 counts for individuals infected with and 
without viruses carrying the mutations were 4.51 log10 copies/ml (IQR= 3.33 – 4.82) versus 
4.12 copies/ml [IQR= 3.34-4.82] for viral load, respectively (Figure 4.2C; p=0.96); and 402 
cells/ul [330-566] versus 425 cells/ul [IQR=301-572] for CD4 counts, respectively (Figure 
4.2D; p=0.95).  
 
Thus, using expanded numbers, it was not possible to reproduce the findings that individuals 
infected with virus carrying the T242N and/or the A146X mutations in HLA-B*57/58:01 
mismatched participants affected viral loads or CD4 counts.    
 
To further understand this result, it was investigated if the selective pressure of the 













in the ISW9 epitopes may be selected by HLA-B*13 and B*15:10 (Honeyborne et al., 2007), 
viruses were defined as carrying B*57/58:01 signature mutations (Table 4.3) only if 
individuals were infected with viruses containing either the T242N/S mutation in the TW10 
epitope (as this mutation is unique to B*57/58:01); or if either of the two additional HLA-
B*57/58:01 restricted mutations in epitopes ISW9 (A146X/I147X), KF11 (A163G) and 
M250I mutation upstream of the TW10 were present. 
 














































































Figure 4.2 Impact of infection with viruses carrying the T242X (X=N/S) and/or A146X (X=P/S) mutations on 
viral load and CD4 counts. Viral load (A and C) and CD4 counts (B and D) at 3 and 12 months post-infection for 
the B*57/B58:01 negative individuals (n=49) compared between participants infected with viral strains carrying 
either both or any of the TW10 escape mutation and the ISW9 processing escape mutation (n = 21) and those 
that did not (n = 28).  
 
 
Thirty-eight % (18/49) of the cohort were grouped as infected with viruses carrying the 
B*57/B*58:01 signature, with 61% of these (11/18) infected with viruses carrying the 













viruses carrying B*57/58:01 signature mutations had lower viral loads and higher CD4 
counts, these markers of disease progression were compared between participants infected 
with viruses with (n=18) and without the B*57/58:01 signature mutations (n=31) at 
enrolment. There were no significant differences in viral load between participants infected 
with and without virus carrying the B*57/58:01 signature mutations, either at 3, 6 or 12 
months post-infection (Figure 4.3A, C and E). However, individuals infected at enrolment 
with virus carrying three of any of the signature mutations had higher CD4 counts at 3 months 
post-infection (p=0.031; Figure 4.3B). Nonetheless, this trend was not sustained either at 6 
months or at one year post-infection (Figure 4.3D and F) suggesting that the potential benefit 
derived from B*57/58:01 associated mutations was limited to the early phase of the infection.  
 
 
Table 4.3 HLA-B*57/58:01 negative participants infected with viruses carrying HLA-B*57/58:01 signature 
mutations  
 
PID ISW9 (147-155) KF11 (162-172) TW10 (240-249) and associated mutations 
 A146P I147L A163X S165X T242X A248X M250X H219Qa I223Vb M228Xd 
CAP040y     T242S    I223V M228L 
CAP045 A146P I147M     M250I H219Qc   
CAP061 A146P I147L   T242N   H219Qc I223V M228I 
CAP063 A146N I147L A163G S165N  A248Gc     
CAP085 A146P I147L   T242N     M228L 
CAP088 A146P  A163G  T242N    I223N  
CAP137y     T242S      
CAP200 A146P I147L   T242N    I223N  
CAP221 A146P I147L A163N  T242N    I223V  
CAP225 A146P I147L   T242N      
CAP228 A146P I147L A163S  T242N    I223V M228I 
CAP255 A146P I147L A163S    M250I    
CAP261*  I147L A163G S165N   M250I    
CAP265*   A163G S165N   M250I    
CAP267 A146P  A163G S165N T242N    I223P  
CAP277 A146P I147L     M250I    
CAP279 A146P    T242N A248Qc  H219Qc  M228I 
CAP281*  I147L A163N    M250I    
 
a,b,d :Known (approved in vitro) B57/5801 compensatory mutations ; yParticipant carrying T242S variant 
associated with minimal fitness cost to the virus in vitro (Boutwell et al., 2008); cMutations that independently 
increase infectivity (Martinez-Picado et al., 2006; Boutwell et al., 2008). *Participant not fitting the Chopera et 










































































































































































































































































































































Figure 4.3 Impact of B*57/58:01 footprints in HLA mismatched participants on disease progression- viral load 
and CD4 counts were grouped according to presence or absence of B*57/58:01 signature mutations (having 
T242N/S in the TW10 epitope or else, two mutations from any two of the different HLA-B*57/58:01 restricted 
epitopes ISW9 (A146X/I147X), KF11 (A163G) and M250I upstream of the TW10). Viral load (A, C and E) and 
CD4 counts (B, D and F) compared at 3, 6 and 12 months post-infection between individuals with and without 
the B*57/58:01 signature mutations. Colour codes Green, Red and Blue are participants infected with viruses 
carrying H219Q, T242S and A248T variants, respectively independently associated with wide-type level of 














4.3.4.2 No defined influence of transmitted B*57/58:01 compensatory mutations on 
            the course of disease progression  
 
Gag mutations known to compensate for the replicative fitness cost incurred due to escape 
through the T242N mutation are H219Q, I223V and M228L (Brockman et al., 2007; 
Crawford et al., 2007), with mutations I223V and M228L reported to partly compensate for 
the replicative fitness cost, whereas the H219Q mutation alone is able to restore wild-type 
fitness to the T242N mutation in vitro (Boutwell et al., 2009). 
 
Sequences were analyzed for compensatory mutations in order to answer the question that the 
extended data might have had more compensatory mutations than there were in the data of 
Chopera et al. (2008) resulting in a loss of signal. The frequency of transmitted compensatory 
mutations was generally high in these participants. Of the 11 participants infected with viruses 
carrying the T242X, viruses in 64% (7/11) carried the I223X (X=V/N/P) mutation while 
viruses in 46% (5/11) had the M228X (X=L/I). Furthermore, 27% (3/11) of these participants 
were infected with viruses carrying both I223X and M228X mutations together. Viruses in 
two participants 18% (2/11) had the H219Q mutation. Nevertheless, when the numbers of 
mutations compensating escape through T242N/S in TW10 epitope present in the dataset of 
Chopera et al. (2008) were compared with those in the expanded dataset, there were no 
significant variations in either the number or the location of compensatory mutations (Figure 
4.4).   
 
Furthermore, data was investigated to determine if grouping participants according to number 
of compensatory mutations could affect viral load or CD4 counts (Table 4.4). However, there 
was no evidence suggesting that the number of compensatory mutations in the infecting virus 
had an influence on either viral load or CD4 counts. 
 
Overall, this study found limited influence of the transmitted B*57/58:01 compensatory 



















Table 4.4 Participants infected with viruses carrying the T242X mutation grouped according to the number of 










0 137e 246000 338 
 225c 21500 597 
1 85c 3030 519 
 88c 38700 510 
 200c 108000 367 
 221e 53100 435 
 267e 19300 341 
2 40e 11000 321 
 228c 1520 811 
 279e 32200 368 
3 61c 418 402 
aNumber of compensatory mutations; bfViral loadand CD4 counts are median of 3 values around 12 months, 







































Figure 4.4 Comparison of frequency of mutations compensating for the fitness cost incurred due to escape 
















4.3.4.3 Protective HLA (B*57/B*58:01 or B*81:01/39:10) associated mutations revert  
            to consensus in HLA mismatched participants    
 
Next, the timing of reversion was analyzed in mutations conferring escape in protective HLA-
positive individuals that were present in mismatched recipients in order to understand the 
constraint associated with these mutations and to determine if their reversion over time could 
have had a measurable impact on markers of disease progression. Reversion was defined as 
change from a low to high frequency amino acid in an epitope not restricted by the HLA of 
the host i.e. change towards the subtype C consensus (most common) residue.   
 
Reversion of mutations at residues T242N, M250I and T180I/P181S generally occurred 
earlier in infection and at: 11 [IQR = 7 – 16]; 11 [5 – 20] and 1.2-2.5/6-10.6 months post-
infection respectively, while it occurred later at residues A146P or A146P/I147L: 30 [16 – 34] 
and L188F (31 - 46) months post-infection (Table 4.5).In one of the 3 participant negative for 
HLA-B7 alleles, reversion occurred at the Q65H novel mutation in the p17 between 3.7 and 
5.3 months post infection. There was no reversion in residues, A163G conferring escape in 
KF11 epitope observed over 36 months of follow-up. 
 
Interestingly, however, there was reversion occurring within 1.5 years post-infection in 82% 
(9/11) of participants infected with virus carrying the T242N/X mutation, while only 57% 
(4/7) of those with M250I mutation had shown reversion. In participants infected with viruses 
carrying the A146P or A146P/I147L mutations, only 6% (1/15) of those investigated had 
reverted within 1.5 years post-infection, while only 33% (5/15) participants had the mutation 
reverting by 46 months post infection. On the other hand, there was reversion occurring 
within 1.5 years post-infection in 66.7% (2/3) of HLA-mismatched participants infected with 
virus carrying the TL9 mutation (T180I/P181S), while L188F reverted later (31-46months 



















Table 4.5: Summary of timing of reversion of B*57/58:01 associated mutations over 36 months period.  
Mutation  Median 




A147P/I147L 30 [16 – 34] 33 (5/15) 
A163Gb -      0 (0/10) 
T242N 11 [7 – 16] 82 (9/11) 
M250I 11 [5 – 20] 57 (4/7) 
T180I/Xc 1.2 – 2.5 100 (1) 
P181S/Xd 6 – 10.6 100 (1) 
Q182Hd - 0 (0/1) 
L188Fe 31 - 46 100 (1) 
p17Q65Hf 3.7 – 5.3 22f (1/3) 
 
aPercentage of (No. of individuals with mutations reverting/Total No. of those with the mutation) individuals 
with viral mutation reverting to consensus within the median time; bNo reversion observed over the 36 months 
period; c-eOnly one participant had the mutation (three participants altogether) and thus too few to estimate the 
median timing of reversion; however, these mutations reverted in vivo; fThere was reversion in one participant – 
































Of interest in this study, 9/18 participants that were defined as carrying B*57/58:01 signature 
mutations associated with fitness cost to the virus (Table 4.3) had either 1 or 2 mutations 
reverting to consensus before one year post-infection (Table 4.6). Furthermore, viruses 
carrying the T242N mutation had reverted to consensus in 6/11 participants by 12 months post 
infection, which suggested that the sequential loss of impact of higher CD4 counts due to 
B*57/58:01 signature mutations, observed at 3 months post-infection probably were at least in 
part, due to reversion.  
 
 
Table 4.6 Summary of participants infected with HLA associated viral mutations in the HLA mismatched 
participants and changes in viral load and CD4 counts accompanying reversions over one-year time post-
infection    
 
PID bNo. Timing of reversion of mutation in month post infection & ΔVLc/ΔCD4d 
<3 >3 - 6 ΔVLc/ΔCD4d >6 – 12 ΔVLc/ΔCD4d 
CAP085 2  T242N +0.83/-211   
CAP088 5  T180I +0.07/-24 T242N, P181S -0.07/-193 
CAP137 1  T242S -0.051/-46   
CAP200 2    T242N -0.41/-47 
CAP221 3    T242N +0.50/-160 
CAP255 4 M250I     
CAP261 2    M250I 0.00/-4 
CAP267 3  A146P +0.19/-112 T242N 0.00/-90 
CAP281 2    M250I -0.133/+4 
 
bNumber of mismatched HLA associated viral mutations present at enrolment ; c/d: Change in log10 viral load 

































4.3.4.4 Modest impact of early reversion of protective HLA (B*57/B*58:01 or  
            B*81:01/39:10) associated mutations on disease progression  
 
Studies have shown that reversion of escape mutations to consensus amino acid residues in 
viruses transmitted to individuals lacking the selecting HLA is a measure of the fitness cost 
the mutant virus incurred due to donor HLA mediated escape (Liu et al., 2007; Novitsky et 
al., 2011; Henn et al., 2012).  
 
To better quantify the overall impact of reversion of some of the protective HLAs 
(B*57/B*58:01 or B*81:01/39:10) transmitted mutations on viral load and CD4+ counts, we 
compared changes in log10 viral load and CD4+ counts between individuals infected with 
viruses carrying these mutations  that reverted and those in whom mutations did not revert 
before the first 12 months post-infection. Since reversion occurring before one year would be 
expected to raise viral load or lower CD4 counts at 12 months set-point, we calculated change 
as a difference in viral load/CD4 counts at 12 months and viral load/CD4 counts at 6 months. 
 
There was no evidence to support the idea that reversion of B*57/58:01 signature mutations in 
viruses infecting these participants resulted in an increase in viral load (Figure 4.5A). 
Although there was a net negative median change in CD4 counts for individuals infected with 
viruses carrying the B*57/58:01 signature mutations that reverted before 1 year post-infection 
(suggesting that reversion influenced the decrease in CD4 counts), this was not significant 






























































Figure 4.5 Impact of early reversion of protective HLA B*57/58:01 and B*39:10/81:01 mutations on disease 
progression. Figures A and B: Comparison of change (Δ) in log10 viral load (A) and CD4 counts (B) between 
individuals infected with viruses carrying the protective HLAs signature mutations that reverted (n=9) and those 
in which mutations did not revert (n=9) before the first 12 months post-infection. (Δ) = Viral load/CD4 counts at 
12 months - Viral load/CD4 counts at 6 months, respectively.  
 
 
4.3.4.5 Polymorphism at p17 Gag Q65H associates with lower viral load  
 
In order to estimate the impact of this mutation in this cohort, participants infected with 
viruses that evolved sequence at site 65 (n=2) were excluded and viral load and CD4+ counts 
were compared between participants with (n=10) and without (n=44) the Q65H mutation, 
irrespective of their HLAs. There was lower viral load at set point for participants infected 
with viruses carrying the Q65H mutation (Figure 4.6A; p=0.0056), while CD4+ counts did 
not significantly differ b tween participants infected with and without viruses carrying the 
polymorphism (Figure 4.6B; p>0.05).  
     
It was not possible to compare viral load and CD4+ counts in vivo in HLA-mismatched 
individuals between participants negative and those positive for the Q65H mutation due to the 
small number of participants who were negative for HLA-A*30 and B7 supertype alleles and 
infected with this mutation (n=2) (Figure 4.6 C and D; open squares). However, when we 
compared viral load and CD4+ counts at set point between participants negative for supertype 
-B7 alleles (n=32) infected with viruses carrying the wild-type Q65 (n=28) and with those 
infected with the polymorphisms H65 (n=4), there was lower viral load at set point for 













CD4+ counts did not significantly differ between participants infected with and without 
viruses carrying the polymorphism in these participants (Figure 4.6D; p>0.05). However, 
these findings were supported by those of Huang et al. (2011), who demonstrated that 
participants infected with viruses carrying the Q65H mutation have significantly higher CD4+ 
counts in two chronic cohorts totalling 1053 individuals.   
 















































































Figure 4.6 Associatio  of the amino acid Histidine at position 65 in p17 Gag with lower viral load. Viral load 
(A) and CD4 counts (B) compared at 12 months post infection for individuals infected with viral strains with and 
without the polymorphism – individuals infected with virus that evolved this polymorphism  (n=2) were 
excluded from this analysis; Viral load (C) and CD4+ counts (D) at 12 months post infection compared between 
participants negative for supertypeHLA-B7 alleles (n=32) infected with viruses carrying the wide-type Q65 
(n=28) and with the variant H65 (n=4). Participants in Red colour carry the B*57/58:01 alleles known for their 
associations with better infection outcome in southern African subtype C clade. Open squares are participants 





















4.3.4.6 CTL imprints due to protective HLAs additively attenuate the virus 
 
A study of Boutwell et al. (2008) demonstrated that the replication capacity in vitro due to the 
three B*57/58:01 footprint mutations was in the order A146P<A163G<T242N (less to 
greatest) and multiple mutations had an additively negative effect on viral replication 
capacity.  
 
A list of participants infected with viruses carrying three or more mutations associated with 
fitness cost to the virus was then compiled (Table 4.7) and viral loads and CD4 counts for 
HLA-mismatched participants infected with viruses carrying 3 or more cumulative mutations 
of HLAs associated with survival benefits were compared in order to determine if these 
mutations had any impact on disease progression. Thus, all participants with protective HLA-
B57/58:01 or HLA-B7supertype alleles (B*81:01, B*42 and B*39:10 and B*07:02) were 
excluded from this analysis as individuals in this cohort were associated with selection of the 
Gag, p17 mutation Q65H included in this analysis and also mutations in the B7 
immunodominant TL9 epitope (Table 4.7).    
 
HLA-mismatched participants infected with viruses carrying three or more replicative fitness 
cost-associated mutations had significantly lower viral load at 3 and 12 months post-infection 
(p=0.0147 and p=0.0241, respectively; Figure 4.6 A and C). There were also significantly 
higher CD4 counts for participants infected with these viruses at 3 months and 12 months 
post-infection (p=0.0004 and 0.0438, respectively; Figure 4.6 B and D). Of interest was that 
none of the individuals included in this analysis (CAP045, CAP085, CAP088, CAP221, 
CAP255 and CAP267) carried any protective HLAs as all HLAs associated with protection 
(HLA-B*81:01, B*58:01/57 and B*39:10) in HIV-1, subtype C (Kiepiela et al., 2004; Leslie 
et al., 2010) were excluded from this analysis. These results suggest that viruses passaged 
through participants carrying beneficial HLAs may additively attenuate these viruses, with 























































































Figure 4.7Analysis of individuals with non-beneficial HLAs comparing the effect of at least three mutations on 
viral and CD4 counts. Additive impact of three or more HLA mediated mutations associated with fitness cost to 
the virus in non-beneficial HLA participants on disease progression- viral load and CD4 counts were grouped 
according to presence or absence in mismatched recipients at enrolment of three or more associated mutations, 
ISW9 (A146X), KF11 (A163X), M250I/T242X, TL9 associated mutations (E177D, T180X, P181S/X, D184X, 
T186S, L188F) and Q65H in p17, due to B*57, B*58:01, B*81:01, B*42:01, B*39:10, B*07:02 and Cw*08:02. 























Next, a critical review of the list of participants infected with viruses carrying cumulative 
mutations associated with fitness cost to the virus was undertaken in relation to mutations 
mediated by HLA-B*57/58:01 in order to understand the results of the additive influence of 
mutations mediated by other beneficial HLAs.  
 
By comparison, of the 9 participants previously described by the study of Chopera et al. 
(2008) – CAP045, CAP061, CAP065, CAP085, CAP088, CAP200, CAP225, CAP228 and 
CAP255, five carried additional mutations due to other HLAs. The HLA-B7 allele-restricted 
TL9 epitope anchor (L188F) and rare (P181S) residues respectively, were present at 
enrolment in CAP045 and CAP088, while in CAP061, CAP085 and CAP255, the p17 
mutation associated with lower viral loads and higher CD4 counts, both in this cohort and 
other cohorts (Huang et al., 2011) were present at enrolment (Table 4.7).      
 
Table 4.7 Participants with viruses carrying three or more mutations due to mismatched HLA at enrolment 
(transmitted mutations) and are associated with fitness cost  
 
PID A146Pa A163Xa TL9a Epitope   
Gag (180-188) 
T242Xa M250Xa p17a 
CAP045 A146P  L188F  M250I  
CAP061b A146P   T242N  Q65H 
CAP085b A146P   T242N  Q65H 
CAP088 A146P A163G P181S Q182H T242N   
CAP221 A146P A163N  T242N   
CAP228 A146P A163S  T242N   
CAP255 A146P A163S   M250I Q65H 
CAP267 A146P A163G  T242N   
CAP277b A146P    M250I Q65H 
a: Mutation associated with reduced viral replication capacity either in vitro or in vivo/both; bParticipants 






















Here we have shown that the frequency of HLA-B*57/58:01-associated signatures are far 
greater than mutations associated with other HLAs that are associated with beneficial outcome 
in HIV-1 subtype C infection: in HLA-mismatched participants, HLA-B*57/58:01 associated 
escape mutations occur at a higher frequency than HLA-B7 mediated escape mutations 
despite the fact that HLA-B7 has a much higher frequency in this cohort (40%; 25/62), 
compared to HLA-B57/58:01 (13%; 8/62). This result may be due to B*57/58:01 alleles 
selecting for escape mutations in Gag in early infection when chances of viral transmission 
are very high due to the high acute phase viral loads (Dyer et al., 1998; Wawer et al., 2005; 
Cohen et al., 2010). In contrast, the HLA-B7 alleles normally select late mutations, a period 
when the risk of transmission is relatively lower.  
 
This difference in frequency of HLA-B*57/58:01 associated mutations when compared to 
those of B7 mutations is unlikely to be due to rapid reversions as most reversions tend to be 
fixed only after acute (90 – 100 days post-infection) infection (Leslie et al., 2004; Henn et al., 
2012; Chopera et al., 2008) and viral sequences in this study were mainly from acute infection 
[42 days (IQR: 28-56) days post-infection]. Moreover, reversion of the B*57/58:01 associated 
mutations in and proximal to the TW10 (residues T242N and M250I) [IQR = 5 – 20] in this 
study occurred no later than reversions in the B7 restricted TL9 at T180I/P181S (around 1.2-
2.5/6-10.6 months) post-infection. However, there were too few participants infected with 
viruses carrying the TL9 or associated mutations to accurately estimate the timing of their 
reversion (Table 4.5).  
 
This study identified a novel putative escape mutation in Gag p17, Q65H, found in 
longitudinal viral sequences from two participants with two similar HLA class1 alleles, HLA-
B*42:02 and Cw*1701. These findings harmonise with those of Wright et al.(2010), who 
associated this mutation with escape in individuals positive for B*81 alleles and those of 
Huang et al. (2011), who associated the mutation with the A*30 allele. This study has 
extended previous HLA association of the evolution of the Q65H mutation in p17 Gag and 













providing opportunities to map out and further study the virological and immunological 
implication of evolution in this epitope.   
 
People infected with viruses carrying the mutation Q65H generally had lower viral loads [first 
reported in a keystone symposium on HIV Pathogenesis (X6) in Santa Fe, January 12 - 17, 
2010, Ntale et al., abstract number 307]. Analyzing over 1000 participants, a study of Huang 
et al. (2011) also found that this mutation was associated with higher CD4 counts. This 
residue is located in the fourth α-helix of p17, in which mutations (residue 54 to 68) that form 
part of a finger-like projection from one side of the molecule abolish dimerization (Chazal et 
al., 1995; Morikawa et al., 1995). Furthermore, MA amino acids between 41 and 68, which 
include (Q65), were found to be critical for soluble Gag secretion and Env-incorporation 
(Chazal et al., 1994; Dorfman et al., 1994, Morikawa et al., 1995). 
 
In vitro assays demonstrated for the first time that viruses carrying the mutation (65H) 
replicate 22% slower than viruses carrying wild-type residue (65Q) in parallel infections in 
PBMCs, in a subtype C infectious molecular clone. Studies have demonstrated that parallel 
infections are insensitive to small replication differences and are much more seriously 
affected by variations in the starting concentrations of the viruses than competition infections 
(Quiñones-Mateu and Arts, 2001; Dykes and Demeter, 2007). The effects of variations in the 
starting concentrations were reduced by normalising the concentration of p24 produced at 
each sampling time (p24t) to the peak concentration (p24max) of the virus produced as had 
been previously done by Resch et al. (2002). Interestingly, a  recent study of Wright et al. 
(2012) associating this mutation with compensation of viral escape through residue T186S in 
TL9 found that viruses carrying T186S/Q65H mutation could not replicate in the GXR cell 
line, and suggested that 65H mutation does not compensate for the fitness cost of T186S.   
 
This study documented that HLA-mismatched participants infected with viruses carrying 3 or 
more HLA footprints associated with fitness cost in Gag had significantly lower viral load and 
higher CD4 counts at 3 and 12 months post-infection. Unlike a previous study in this cohort, 
infection with viruses carrying mutations in HLA-B*57/58:01 restricted epitopes, ISW9 













mismatched participants. However, the majority (5/9) of the participants in the dataset of the 
study of Chopera et al. (2008) carried mutations due to other HLAs that are associated with 
viral replication in vivo. This result suggested that although HLA-B*57/58:01 is the major 
driver of the process, the advantage previously detected by the study was due to an additive 
influence, together with other beneficial HLAs, other than HLA-B*57/58:01 alone.   
 
Taken together, these results support the idea that individuals infected with attenuated viruses 
have better viral control than those without these viral factors; however this benefit it is likely 



































CHAPTER 5: SUMMARY AND CONCLUSION 
 
Defining correlates of protection against HIV-1 infection is the major challenge in developing 
a prophylactic HIV vaccine that will prevent infection (Koup et al., 2011; McElrath and 
Haynes, 2010). However, while it remains generally accepted that an effective vaccine should 
elicit both broadly cross-neutralizing antibodies and CTL responses (Koup et al., 2011; 
Richman et al., 2009; Richman et al., 2003), the nature of the CTL response associated with 
control of viremia remains elusive (Koup et al., 2011).  
 
Studying patterns of immune escape in HIV-1 acute infection provides a sensitive tool to 
identify specific viral regions under active immune selection pressure and contribute to our 
understanding of the correlates of immune control of HIV-1-infection. Escape that is 
detrimental to the virus will result in lower replication capacity - creating a balance between 
the benefit of escape to the virus and its survival (Crawford et al., 2009; Martinez-Picado et 
al., 2006; Schneidewind et al., 2007; Woo et al., 2010).  
 
This study sought to determine the frequency, timing and location of CTL escape, and to 
address the question of how CTL escape impacts on disease progression in subtype C HIV-1 
infection. Most studies to date have focused on the characterization of acute infection in 
subtype B viruses, and a few studies have investigated CTL escape in acute infection in 
subtype C (Crawford et al., 2009; Gray et al., 2009; Radebe et al., 2011). Studies of different 
subtypes, together with differences in HLA frequencies between populations have exposed 
differences in characteristics of these viruses suggesting that observations in subtype B 
infections may not be directly extrapolated to subtype C infections.  
 
 
This study found that Gag and/or Nef escape occur in the majority of people (69%) in the first 
year of infection and is predominantly driven by HLA-B alleles targeting p24.  Escape occurs 
most frequently in the acute infection phase, a period when viremia is at its highest level. 
High viral load turnover, together with early responses that control replication may both 













escape with individuals with acute escape having increasing CD4+ T cell counts in the first 3 
months compared to individuals without viral escape at 12 months. Although this trend was 
not sustained after 3 months, this early preservation of CD4+ T cell counts appeared to 
provide a survival benefit within the first year of infection.  
 
Furthermore, whereas there is a lot of information on the role of HLA-B*57/58:01 associated 
mutations and disease progression (Brockman et al., 2010; Chopera et al., 2011; Crawford et 
al., 2009; Migueles et al., 2000; Miura et al., 2009), there is limited information on B*81:01, 
an allele that has been associated with control of replication in southern Africa. Although 
CTL mediated escape mutations in the B*8101 restricted p24, TL9 epitope had been 
associated with in vitro fitness cost to the virus, the impact on disease progression in vivo had 
never been investigated.  
 
 
This study documented the kinetics and emergence of known B*81:01 escape mutations 
(E177D, Q182S and T186S) and identified a common pattern of evolution with the Q182S 
mutation generally emerging prior to T186S. Escape was linked to co-evolving residues in the 
region of Gag known to be associated with host tropism and these residues were identified as 
putative compensatory mutations. Furthermore, unlike the B*57/58:01-restricted TW10 
escape, which usually occurs rapidly and during acute and early infection (Chopera et al., 
2011; Crawford et al., 2009; Martinez-Picado et al., 2006), escape in individuals positive for 
the B*81:01 allele was often late and took nearly a year to reach fixation. Moreover, while in 
vitro studies demonstrated that the T186S mutation alone, or in combination with E177D 
incurs a fitness cost to the virus (Rolland et al., 2010; Wright et al., 2010), late evolution of 
T186S either alone, or in combination with E177D/and Q182S, coincided with an increase in 
viral load and although viral replication was subsequently brought under control, it returned to 
a level higher than before escape. These results provided not only in vivo evidence of the 
detrimental impact of late B*81:01 mediated viral evolution in a single Gag p24 epitope on 
control of viremia, but also the impact of the response targeting this epitope and consequently 
highlighting the complexity of immune escape that need to be considered in developing an 














Furthermore, in an attempt to resolve the conflict in the field over the impact of transmitted 
CTL escape mutations on disease progression, viral load and CD4 counts were compared in 
participants infected with viruses carrying polymorphisms associated with beneficial HLA- 
B*57/58:01 and B*39:10/81:01 selective pressure in HLA mismatched participants.  
 
This study further documented that HLA-mismatched participants infected with viruses 
carrying 3 or more HLA footprints associated with fitness cost in Gag had significantly lower 
viral load and higher CD4 counts at 3 and 12 months post-infection. Unlike a previous study 
in this cohort (Chopera et al., 2008), infection with viruses carrying mutations in HLA-
B*57/58:01 restricted epitopes, ISW9 (A146P) and TW10 (T242N/S) alone did not impact on 
viral load set-point in HLA-mismatched participants. However, majority (5/9) of the 
participants in the dataset of the study of Chopera et al. (2008) carried mutations due to other 
HLAs that are associated with viral replication in vivo. This result suggested that although 
HLA-B*57/58:01 is the major driver of the process, the advantage previously detected by the 
study was due to an additive influence of beneficial HLAs, and not HLA-B*57/58:01 alone.    
 
In conclusion, this study has elucidated the kinetics of CTL escape and has shown that escape 
occurs predominantly in HLA-B restricted epitopes and in acute infection.  It finds that escape 
in acute infection provides a survival benefit in the first year of infection. This study has also 
provided in vivo evidence that some escape is detrimental, with late B*81:01 mediated viral 
evolution, in a single Gag p24 epitope, significantly influencing control of viremia. Moreover, 
results of this study suggest that multiple mutations generated when viruses are passaged 
through individuals with beneficial HLAs are needed to attenuate the virus. Overall, these 
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Appendix 1 Table of evidence of CTL escape in Gag and Nef; in individuals (n=18) with yellow highlights,
                                                                                                                                                      escape was confirmed with IFN-γ ELISpot assay 
PID Wks PI EPITOPE SFU/10
6  
PBMC FREQUENCY HLA Location 
CAP008 2 RPGGKKQYMLKHL 918 M→K; 80.2-5.1% B*0801 p17 Gag 
3 ............. 2220





2 YSKKRQEILDLWVYHTQ 0 Y-H; (71.33-11.6)
3 ................. 70 K-Q; (83.45-8.36) Cw*0701 Nef
6 ................. 280
10 ................. 555 Escape confirmed 
13 H.Q.............. 2495 K-R; (82.94-8.19%)
25 H.Q.............. 2118
56 ...R..............
CAP030 5 EGEDVGFPVKPQVP - (E - 68.6%)
11 ..DE.....R.... 155 (D - 6.83%) B*4501 Nef
29 ..DE.......... 90
54 ..DE.......... Escape confirmed 
CAP040 4 KIRLRPGGKKHYMLK NOT DONE M→R; 80.2-11.4%









CAP045 2 EEEEVGFPVRPQVPVRP Escape confirmed B*4501 Nef





CAP063 2 EEEVGFPVRPQVPLRPM B*4501 Nef
4 .................
5 ..G..............
11 ..G.............. E→G; (86.5-4.6%)
29 ..D..............
37 ..D..............






CAP085 5 EEEKEVGFPVRPQVPL NO RESPONSE  
13 ...ED........... E→D; (86.5-7.17%)
29 ...ED........... B*4501 Nef 
39 ...EG...........
55 ...GD...........
5 KRQEILDLWVYHTQGY 350 Y-F (44.57-54.4%)
13 ................ 1322.5












5 ELRSLYNTVATLY 0 L-I;(93.22-5.57%)
13 ............. 180 A*3002 p17 Gag 
29 ............. 110
39 ............. Escape confirmed 
55 .I...........
CAP088 5 EEEKEVGFPVRPQVPVR NO RESPONSE B*4501 Nef
13 ...K............. E→K; (86.5-0.34%)
54 ...K.............
5 VLAEAMSQANSANIM B*4501 p7/p6 Gag
6 ............... 465 A-V; (19.37-7.02%)
13 ...........V... 138
26 ...........V... 0
46 ...........T... 0 Escape confirmed 
54 ...........T... 0
CAP129 2 YSKKRQEILDLWVHHTQG 1775 B*1801 Nef
13 .............Y.... 120 E→D; (59.56.39.93%)
26 ......D......Y.... 0
54 ......D......Y.... Escape confirmed 
2 PVRPQVPVRPMTYK 155 V→I; (98.63-0.17%) B*8101 Nef 
13 .............. 137.5




Q/T-S (91.53/6-3.63%) B*8101 p24 Gag 
4 ............. 0











CAP174 2 RPQVPLRPMTYKAA 405 A*0301 Nef 
11 .............. 135 V→A; (98.63-0%)
24 .............. 172.5 Escape confirmed 
40 ...A.......... 67.5
53 ...A..........
2 KKRRDILDLWVYN Cw*0702 Nef 
4 .E........... 717.5 K-E (82.94 - 0.17)
11 ...........H. 295
13 ...........H. 257.5 N: 0.51%
17 .N.........H. 197.5 Escape confirmed 
40 .N...........
53 .N...........





CAP188 4  SLYNTVATLY NOT DONE A*0202 p17 Gag 
13  ..X.A..... Y-H; (55.55-2.6)%
















CAP210 5 HQAISPRTL 0 A-S (71.19-6.54%) B*1510 p24 Gag 
12 ......... 70 Escape confirmed 
22 ......... 135
50 ..S......
CAP211 3 AISPRTLNAW NOT DONE A-L (71.19-27.12%) B*57 p24 Gag 




3 TSTLQEQITW NOT DONE B*57 p24 Gag 
10 ....H.....
23 ..N....... T-N (84.75-10.41)
27 ..N.......
66 ..N.......
CAP217 9 TYKAAFDLSFFLKE 1238 A-E; (47.6-0.17%) B*5801 Nef 
12 ...E.......... 1030
31 ...E.......... Escape confirmed 
60 ...E..........
9 TTSTLQEQIAWM 217 T-N (84.75-10.41) B*5801 p24 Gag 
12 ............ 2190




CAP221 5 YSKKRQEILDLWVYN 70 L-M;(99.15-0.55%) Cw7 Nef
12 ............... 217.5
24 ..........M.... 475 Escape confirmed 
46 ...R..D........




CAP228 8 IIWSKRRQDILDLWVYNT NO RESPONSE
11 L.............I... V-I; (97.78-0.85%) Cw7 Nef
47 L.............I...
147 L.............I...
CAP229 7 TGTEELRSLYNTVTLY 0 R-K;(51.82-45.76%) B58 p17 Gag 
8 ................ 0
21 ................ 0
25 ......K......... NO RESPONSE 
80 ......K.........
7 TTSTLQEQIAWM 1188
8 ...N.....T.. 105 T-N (84.75-10.41) B*5801 p24 Gag 
9 ...N.....T.. 340
21 ...N.....T.. Escape confirmed 
25 ...N.....T..
CAP239 2 TTSTLQEQVAWM
2 ....I....T.. T-N (84.75-10.41) B*5801 p24 Gag 

















CAP255 8 KKRQEILDLWVHNT 1250 Escape confirmed B*1801 Nef 
13 ...R.......Y.. 1070 Q-R (95.9-0%)
36 ....D......Y.. E→D; (59.56.39.93%)
47 E..K.......Y..
8 GIRYPLTFGWCYKLV 100 V-I; (83.96-8.01%) B*1801 Nef 
13 ............... 0
36 ............... Escape confirmed 
47 ............... 990
CAP258 7 RYPLTFGWCFK 2273 F-Y; (97.27-0.85%) A*2301 Nef 
24 .....Y..... 627.5
40 .....Y..... Escape confirmed 
CAP261 9 SKQRQEILDLWVYN 275 B*1302
12 .RK........... 115 K-R; (83.45-5.63%) Nef 
26 .RK........... 148 Escape confirmed 
CAP262 7 VGFPVRPQVPLRPMT 925 R-K; (87.88-8.53%) B*8101
12 ............... 760 Escape confirmed Nef 
16 .....K......... 290
26 .....K.........




12 ......I....... 1155 V-I (93.7-5.8%)
32 ......T....... 1063 T (0%) A*2901  p17 Gag 
49 ......T.......




12 .....F........ 5043 Y-F; (54.44-44.37%) A*2901  Nef 
32 .....F........ Escape confirmed 
49 .....F........
124 .....F........
CAP268 8 LHPVHAGPIAP 0 I-V (47.7-42.6) B*07 p24 Gag 
24 ........... 73




8 RSLFNTMATLYCVH NO RESPONSE M (0%) A*0205 p17 Gag 





8 PVRPQVPLRPMT NO RESPONSE B*0702 Nef 
15 ............ R-K; (87.88-8.53%)
24 ..K.........
CAP269 4 PVRPQVPLRPMT NOT DONE













4 HQPISPRTLNAWV-154 B*0702 p24 Gag 





CAP270 8 WPNVRERMRRAE NOT DONE N-D (5.8-7.5) B*0801 Nef 
29 ..D...K...T. R-K (93.17-3.4%)
58 ..E.......T.
8 KAAFDLSFFLK 2065 S-G (76.28-23.21%) B*5801 Nef 
29 ........... 335 Escape confirmed 
58 ......G....
CAP274 10 KGAVDLGFFLK NOT DONE G (46.76%) Nef
22 .G.V..G.... V (10.76) B*5801
60 .G.V..G.... G (23.21)
10 TTSNLQEQVQWM T-N (84.75-10.41)
22 ...N....VQ.. B*5801 p24 Gag 
60 ...N....VQ..
CAP275 8 KIMLRPGGK NOT DONE A*7401 p17 Gag 





CAP277 8 TPQDLNTML NOT DONE B*8101 p24 Gag 







CAP278 9 SDGTPSDLNSML NOT DONE B*3910 p24 Gag 
12 ............ E-D (98.3-1.45%)
23 ............ Q-S (91.53-3.63%)
54 ............ T-S (96-2.66%)
85 ............
89 ............








CAP289 8 SEGATPADLNTML NOT DONE B*3910 p24 Gag 
















APPENDIX 2 HLA Data for the CAPRISA participants in this study   
SAMPLE A A B B Cw Cw 
CAP008 2301  2301  0801 1510 0701  1601 
CAP030 0201  3402 4403 4501 0401  1601 
CAP037 2301 2402 0702 5301 1701 1701 
CAP040 3001 3002 1510 4201 0304 1701 
CAP045 2301 2902 1510 4501 0602 1601 
CAP061 6602 6802 1401 4201 0802 1701 
CAP063 0201 2301 4501 4501 0401 1601 
CAP065 2301 6802  1510 5802 0804  0602  
CAP069 0301   2301  1503  5802  0210 0602 
CAP084 2902 7401 1503 4403 0210 0701  
CAP085 3002 3002 0801 4501 0701  1601 
CAP088 2902 6601  4501  5802  0602 0602 
CAP129 2601 8001 1801 8101 0202  0401 
CAP136 3004 7401 4201 4201 1701 1701 
CAP137 2902 6801 4101 5802 0602 1701 
CAP174 0301 7401 4901 5802 0602 0701  
CAP177 0301 3002 1510 4501 0401  1601 
CAP188 0202 7401 1503  1516 0210 1402  
CAP200 0205 4301 1510 4101 0401  1701 
CAP206 0301 3201  0702  4403  0210 0702 
CAP210 6802 6802 1510 1510 0304 0304 
CAP211 0205 3002 5703 5703 1801  1701 
CAP217 0202 2901 1503 5801  0210 0602 
CAP220 3004 7401  4201 4201 1701 1701 
CAP221 6802 6802 4403 4403 0701  0701  
CAP222 3001 3303 5301 8101 0401  0401 
CAP224 0301 6602 4201 5802 0602 1701 
CAP225 0101 3001 4202 8101  1701 1801  
CAP228 2301  2638 4403 5101  0303  0701  
CAP229 0123 0123 5801 5801 0602 0602 
CAP237 6602 6802 4201 4201 1701 1701 
CAP239 0123 2902 4201  5801  0602 1701 
CAP244 2301 3004 4403 5802  0401  0602 
CAP248 0205 2902 1401  1503  0210  0804  
CAP255 0301 8001 0801  1801  0202  0702 
CAP256 2901 6601 1503  5802  0401  0602 
CAP257 2301  2902  4202 4403 1701 1701 
CAP258 2301  2902  4101 4201 1701 1701 
CAP259 0202 6601 1401 3910 08 12 
CAP260 2902 4301 1503 4403   18 
CAP261 2911 4301 1302  1503  0602 0602 
CAP262 0101  6602 4201 8101  1701 1801 
CAP264 3601 6802 1510  5301  0401  0804  
CAP265 0201  3001 4201 4507 1601 1701 
CAP266 2901 6601 1503 5802  0401 0602 
CAP267 0301  2301  1401 5802 0210 0602 
CAP268 0205  2601  0705  5801  0701 0702  
CAP269 0205 6802 0702  5802 06 07 
CAP270 0301  3002  0801 5801 0701  0701  
CAP271 0205  2301  1401 4403 0303  0804 
CAP274 0201  3001  4201  5801 0302 1701 












CAP276 0201 2301 1510 5801 06 08 
CAP277 3009 4301 5802 8101 0401  0401  
CAP278 3001 4301 3910 4202 1203 1701  
CAP279 2902 6801 5802 5802 0602 0602 
CAP280 2902 7401  1503  1510 0210 0804  
CAP281 02 30 4201 4403     
CAP282 3001 6601 4201 5802     
CAP285 0301  2402 0702 5802 0602  0702  
CAP289 3002 6801 3910 5802 0602 1203 



















APPENDIX 3 Identification of transmitted escape mutations associated with a replicative fitness cost to the virus and participants’ clinical data. Shown are mutations in the 
HLAs - B*57/58:01 restricted epitopes, ISW9, KF11 and TW10; the B*39:10/81:01 restricted epitope TL9; and the B*13 restricted epitope RI9. Participants infected with 
viruses carrying a novel putative CTL escape mutation in p17 affecting viral replication capacity are also included.  
PID ISW9 (147-155) KF11 (162-172) TL9 (180-
188) 
TW10 (240-249) and associated mutations RI9 (429-
437) 
p17* NViral 

















h A163X S165X  T242X A248X M250X H219Q I223V M228   
CAP008J   A163G S165N   A248G       4.59 299 5.27 445 
CAP030J     T180I     I223V M228L   4.76 573 5.78 607 
CAP037 A146S I147L        I223V  K436RI437L  5.02 311 4.60 434 
CAP040      T242S    I223V M228L   4.04 321 4.07 334 
CAP045a, g A146P I147M   L188F   M250I H219Q     2.75 1093 3.99 888 
CAP061g A146P I147L    T242N   H219Q I223V M228I  Q65H 2.62 402 3.64 490 
CAP063 A146N I147L A163G S165N   A248G       5.20 243 5.48 531 
CAP065a,g A146S I147L            4.71 194 4.78 243 
CAP069J       A248T    M228I   6.09 202 6.14 297 
CAP085g A146P I147L    T242N     M228L  Q65H 3.82 510 4.46 613 
CAP084J             Q65H*** 3.48 519 4.64 524 
CAP088g A146P  A163G  Q182H, 
P181S 
T242N    I223N    4.59 509.5 4.59 726 
CAP129 A146P      A248T    M228L   4.90 634 4.34 727 
CAP137      T242S        5.10 535 5.39 338 
CAP174 J        M250I      4.75 345 4.78 348 
CAP177a  I147L     A248T       4.76 465 4.62 370 
CAP188  I147L            4.49 585 4.95 375 
CAP200a, g A146P I147L    T242N    I223N    5.24 539 5.03 367 
CAP206J         H219P I223P M228L   5.15 292 5.40 297 
CAP220             Q65H 2.60 400 2.60 656 
CAP221 A146P I147L A163N   T242N    I223V    3.09 716 4.73 435 
CAP224 A146P I147L            5 330 4.60 168 
CAP225g A146P I147L    T242N        4.33 597 4.81 461 
CAP228g A146P I147L A163S   T242N    I223V M228I   3.18 811 3.12 1002 
CAP244J       A248N       4.16 303 4.60 469 
CAP255g A146P I147L A163S     M250I     Q65H 4.56 342 5.03 624 
CAP257  I147L           Q65H** 4.00 634 5.24 591 
CAP258J  I147L     A248N      Q65H 5.08 231 5.43 300 
CAP260       A248T       3.54 303 3.84 330 
CAP261a  I147L A163G S165N    M250I      4.82 418 5.65 359 
CAP264a       A248T       5.59 256 4.40 318 
CAP265   A163G S165N    M250I      3.26 944 3.53 989 
CAP266  I147L         M228L   4.89 434 3.30 527 
CAP267 A146P  A163G S165N  T242N    I223P    4.09 543 4.29 341 
















Blank cell (s): the specified mutation(s) is/are absent; X: change away from HIV-1 C clade consensus; Individuals who are positive for HLAs - B*57/58:01 are shown in red PID numbers;  
 aParticipant has HLA-B*1510 or HLA-B*13 associated with ISW9 residues A146X/I147X (Honeyborne et al., 2007); Participants Jnegative (n=11)  and gpositive (n=9) for 
T242N/X in the TW10 and/or A142P/X in the ISW9 epitope included in the study (n=21) of Chopera et al. (2008); hThough previously thought to compensate for fitness cost 
due to escape through A146X, Crawford et al. (2009) showed that I147L, together with A146P mutation incur fitness cost to the virus;NLog10Viral load (copies/mL) and 
CD4+ T-cell counts (cells/µL) are medians of measurements taken at three time-points closest to these intervals.*Gag p17 mutation at HXB2 position 65; **Participant 
infected with virus that developed the mutation at HXB2 position 65 in Gag p17 or else was there at transmission –in purple colour: the polymorphism is present in virus in 
participants positive for HLA-B7 supertype or A*30 alleles that may be linked to formation of the polymorphism.  *** Mutation reverted to subtype C consensus residue; 
Mutations in the cyclophilin binding loop known to compensate for escape in TW10 (T242X) are highlighted in Green. 
 
CAP271 A146S I147L           Q65H 3.21 595 4.00 534 
CAP275  I147L            4.80 737 3.45 528 
CAP277 A146P I147L      M250I     Q65H 3.81 513 2.68 502 
CAP278  I147L           Q65H** 2.94 661 2.95 568 
CAP279 A146P     T242N A248Q  H219Q  M228I   5.19 326 4.51 368 
CAP281  I147L A163N     M250I      3.44 707 2.98 702 
CAP136              3.32 785 3.06 748 
CAP210J              4.53 534 5.58 288 
CAP222              4.53 632 2.65 654 
CAP237              4.72 522 4.08 339 
CAP248J              4.90 358 4.81 432 
CAP256J              5.02 475 5.35 355 
CAP262              4.13 386 3.57 432 
CAP282              4.01 446 3.17 497 
CAP211             Q65H 4.90 592 3.00 360 
CAP217              5.21 515 4.43 498 
CAP229              4.17 601 4.35 696 
CAP239              4.21 1158 5.19 793 
CAP268              3.62 656 3.88 474 
CAP270              5.72 436 5.87 268 












Appendix 4 Timing of reversion of protective HLA associated mutations in mismatched participants  
 
PID Mutation Sample sequenced  
latest time-point 
Timing (Wks)  
of reversion 
CAP030 T180I  5 - 11 
CAP040 242X 93 N 
CAP045 A146X 199 133-199 
 I147X  133-199 
 F188L  133-199 
 M250I 199 N 
CAP061 A146X 122 76-122 
 I147X  76-122 
 242X  58-76 
CAP063 A146X 37 N 
 I147X  N 
 F163X  N 
 F165X  N 
CAP085 A146X 107 N 
 I147X  N 
 242X  13-29wks 
CAP088 A146X 108 N 
 A163X  N 
 T242X  46-54 
 P181S  26-46 
 Q182H  N 
CAP137 242X 52 12-23 
CAP174 M250I 53 N 
CAP200 A146X 106 N 
 I147X  N 
 242X  25-50 
CAP221 A146X 46 N 
 I147X  N 
 F163X  N 
 242X  20-46 
CAP225 A146X 183 130-145 
 I147X  N 
 242X  61-74 
CAP228 A146X 203 N 
 I147X  N 
 F163X  N 
 242X  96-147 
CAP255 A146X 51 N 
 I147X  N 
 A163X  N 
 M250I  10-13wKS 
CAP261 I147X 48 N 
 A163X  N 
 S165X  N 
 M250I  26-49 
CAP265 A163X 75 N 
 S165X  N 
 M250I  N 
CAP267 A146X 58 12-26WKS 
 A163X  N 
 S165X  N 
 M242X  26-48 
CAP277 A146X 137 58-71 
 I147X  123-137 
 M250X  84-97 
CAP279 A146X 50 N 
 T242X  N 
CAP281 I147X  N 
 A163X  N 
 M250X  42-46 
N=Not yet reverted by the latest time-point sequenced.   
 
 
 
